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Summary 
 
Approximately one in ten pregnant women will have their blood pressure 
recorded above normal at some point during their pregnancy. Pre-eclampsia, the 
most common hypertensive disorder of pregnancy, affects around 5% of all first 
time mothers, and is an important cause of foetal and maternal morbidity and 
mortality worldwide. Efforts to diagnose the condition have been hampered by 
inability to predict which women are likely to be affected. Multiple pathways 
are known to be involved in its pathogenesis, and several screening tests have 
been suggested for its early prediction. None, however, have been sensitive or 
specific enough to have come into routine medical practice.  
The work contained in this thesis describes a study which was designed to detect 
biochemical and clinical markers that could improve ability to predict pre-
eclampsia. Over 3900 women were recruited in early pregnancy at four 
maternity clinics across the West of Scotland; baseline characteristics and 
information on past medical and obstetric history were obtained. Women were 
followed up throughout their pregnancy, and information on deliveries obtained 
from hospital databases. One-hundred and eighty of these women, who had 
multiple risk factors for pre-eclampsia, attended for further sampling and 
vascular assessment at gestational weeks 16 and 28.  
The primary aim of the overall study was to examine whether a proteomic 
strategy could be used to identify patterns of peptides in urine that detect pre-
eclampsia in the first and second trimesters. Using samples from healthy 
pregnant and non-pregnant women I was able to describe the normal human 
urinary proteome in pregnancy. By comparing these pregnancy-associated 
peptides between women who went on to develop pre-eclampsia and matched 
controls, I was able to identify a pattern of peptides, characterised by collagen 
fragments, fibrinogen and uromodulin that accurately predicted pre-eclampsia 
at week 28. No such markers were identified in the first trimester samples.  
A further aim of the overall study was to identify early pregnancy plasma 
markers that could help to identify women destined to develop pre-eclampsia. 
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By examining samples from early pregnancy I was able to demonstrate that the 
angiogenic markers soluble endoglin and placental growth factor are already 
altered at week 12-16 in women who go on to develop pre-eclampsia. Using a 
multi-marker approach, I also showed that E-Selectin, an adhesion molecule 
expressed on endothelial cells which controls interaction between circulating 
leukocytes and the endothelium, is higher at week 12-16 in women who go on to 
develop pre-eclampsia. Experiments using samples from later pregnancy, 
alternative analysis techniques and samples from an independent study 
population all helped to confirm these novel findings.  
Endothelial dysfunction is known to play a key role in the development of pre-
eclampsia, contributing to the hypertension, proteinuria and oedema seen in 
affected women. In the risk factor cohort I used vascular function studies to 
examine whether they supplied additional information to aid in risk 
stratification. Peripheral arterial tonometry, a novel non-invasive tool for the 
assessment of microcirculatory endothelial function, was examined in 180 
women at gestational weeks 16 and 28. Reactive hyperaemia index (RHI), a 
measure of endothelial dysfunction calculated from vascular response to arm 
blood-flow occlusion, did not correlate with maternal factors such as age, BMI 
and blood pressure. Further, RHI did not help to identify which women would go 
on to develop pre-eclampsia, when examined at either week 16 or 28. I found 
that PAT score was negatively correlated with baseline digital pulse amplitude, 
suggesting that in later pregnancy, when women are more vasodilated, PAT and 
other techniques which rely on flow-mediated dilatation are less likely to be 
reliable.  
I used pulse wave analysis, a well-established method for measuring arterial 
stiffness and central pressures, to determine whether it supplied additional 
information about pre-eclampsia risk. This technique has been previously 
reported to predict pre-eclampsia in early pregnancy. In this cohort of high risk 
women, no difference was seen at either week 16 or 28 between those who 
would go on to develop pre-eclampsia and those who would have normotensive 
pregnancies.  
Although blood pressure and proteinuria return to normal after pre-eclampsia, 
evidence has emerged the condition has long-lasting implications; women with a 
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history of pre-eclampsia have an increased risk of cardiovascular disease later in 
life, suffering stroke or myocardial infarction more frequently than women who 
had a healthy pregnancy. Conventional risk factors are thought to contribute, 
but do not fully explain this increased risk. I carried out further vascular 
function studies in women after pre-eclamptic pregnancy, to examine whether 
they had ongoing detectable endothelial dysfunction and arterial stiffness. At 6-
9 months post-natally, affected women had lower baseline digital pulse 
amplitude but no other evidence of persistent vascular dysfunction.   
Taken together, these data provide information about a number of markers that 
may improve understanding of the pathophysiological mechanisms underlying 
pre-eclampsia. As well as potentially improving the early prediction of disease, 
this work represents a highly topical area for further studies. While vascular 
function analysis does not appear to provide additional information on top of risk 
factors, these studies also provide useful information on vascular physiology in 
high-risk pregnancies. 
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1.  Introduction 
 
1.1 Introduction 
The French physician François Boissier de Sauvages de Lacroix in 1739 was the 
first to coin the term eclampsia, which he described as an acute form of 
convulsion, and contrasted with the chronic condition now known as epilepsy 
(1). He is credited with establishing the first methodical nosology for disease, 
and described several species of the genus eclampsia, one of which was 
eclampsia parturientum. Given the dramatic nature of the condition, it is 
perhaps surprising that more is not written in historic literature about 
eclampsia. This may be explained by the fact that delivery was historically the 
domain of the midwife: doctors, who in those days were exclusively men, were 
excluded from the scene.    
Proteinuria in the context of eclamptic seizures was first described in 1840, and 
high blood pressure as recorded by sphygmographic tracings shortly after. By 
1894 it was reported that high blood pressure and proteinuria could occur in 
pregnant women, without eclamptic seizures, and the term pre-eclampsia was 
born (2).  
Approximately 10% of pregnant women will have their blood pressure recorded 
above normal at some point during pregnancy. Pre-eclampsia, which is now 
known to be a multi-system disorder of pregnancy, complicates 2-8% of 
pregnancies in the Western world and 5% of first time mothers (3). Although an 
important issue in the developed world, the effect of pre-eclampsia and 
eclampsia in the developing world is staggering; 10-15% of maternal deaths are 
attributed to pre-eclampsia, of which 99% occur in the developing world (4). The 
number of maternal deaths from pre-eclampsia is equivalent to the loss of 170 
jumbo jets full of pregnant women each year. 
The cardinal features of pre-eclampsia are hypertension and proteinuria 
occurring after 20 weeks’ gestation in women who were not previously known to 
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be hypertensive. Most women with the condition are symptom free, a fact that 
contributes to the difficult and often delayed diagnosis. Women with more 
severe forms of pre-eclampsia often complain of headache, abdominal pain and 
visual disturbance, and can suffer complications to virtually all the body’s 
systems, as summarised in table 1.1. The disease does not just affect the 
mother; a third of babies born to women with pre-eclampsia will be born 
premature, and a quarter will be growth restricted.  
 
System Complication 
Central nervous system Eclampsia (seizures)                                                   
Cerebral haemorrhage 
Cerebral oedema 
Retinal oedema 
Cortical blindness 
Renal system Renal tubular necrosis 
Renal cortical necrosis 
Respiratory system Pulmonary oedema 
Laryngeal oedema 
Hepatic system Disseminated intravascular coagulation 
Haemolysis 
Liver Haemolysis, elevated liver enzymes, low platelets 
(HELLP) syndrome 
Jaundice 
Placenta Placental abruption 
Placental infarction 
Baby Growth restriction 
Preterm delivery 
Death 
Table 1-1 Complications of pre-eclampsia. Adapted from Duley et al. (4) 
 
Even with all the advances in modern medicine, the exact cause of pre-
eclampsia remains unknown, and the only cure is delivery of the foetus and 
placenta. In addition, clinicians have no effective way of predicting which 
women are likely to develop the condition. Identifying high risk women is an 
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important aim; modern obstetric care places emphasis upon the primary care 
setting for expectant women, a marker which identified high risk women would 
allow for closer supervision, most likely in the secondary care setting. Such a 
marker would also facilitate recruitment for trials of potential therapeutic 
agents, for accurate diagnosis and for timely intervention whenever problems 
develop.  
In this chapter I will examine the pathophysiology of pre-eclampsia, potential 
roles for its prediction, and I will discuss long-term consequences associated 
with the condition.  
1.1.1 Diagnostic Criteria  
One of the pitfalls in pre-eclampsia research over the years has been differences 
in diagnostic criteria used worldwide. A number of different terms and systems 
are used; some are more detailed than others, some are more inclusive than 
others, and in some cases the same term has been used to describe different 
disorders by different authors. To combat this, a working group of the 
International Society for the Study of Hypertension in Pregnancy (ISSHP) 
published a Consensus statement in 2000, which is now the most commonly used 
set of criteria in the literature (5).   
In brief, in the consensus statement hypertension in pregnancy is split into 4 
main categories; gestational hypertension, pre-eclampsia, chronic hypertension 
(essential or secondary) and pre-eclampsia superimposed on chronic 
hypertension. Gestational hypertension is defined as de novo arterial 
hypertension (systolic BP ≥ 140 mmHg and / or diastolic BP ≥ 90 mmHg on 2 
occasions > 6 hours apart) occurring after gestational week 20, which returns to 
normal post-partum. Pre-eclampsia is defined as gestational hypertension plus 
proteinuria, in turn defined as ≥300 mg/24 hrs, protein: creatinine ratio ≥ 30 
mg/mmol or if neither are available dipstick analysis of ≥ + (which “is often but 
not always associated with 300 mg/24 hrs”).   Chronic hypertension is 
hypertension diagnosed before the 20th gestational week or de novo 
hypertension which fails to settle post-partum. Pre-eclampsia superimposed on 
chronic hypertension is defined as the appearance of de novo proteinuria 
starting after gestational week 20. A sudden increase in blood pressure or 
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proteinuria, or the appearance of thrombocytopenia or deranged transaminases 
are said to be suggestive but not diagnostic of superimposed pre-eclampsia.   
Despite this general agreement, many questions remain about how the disease 
should be classified. Some classifications define pre-eclampsia as pregnancy-
induced hypertension in association with evidence of multi-organ dysfunction; 
proteinuria, or other complications such as renal insufficiency, liver disease, 
neurological problems, haematological disturbance, or intra-uterine growth 
restriction (3). Further definitions separate  proteinuric from non-proteinuric 
pre-eclampsia; proteinuric pre-eclampsia is reported to carry a worse prognosis 
than non-proteinuric pre-eclampsia, which is in turn reported to carry a worse 
prognosis than gestational hypertension alone (6).  
Further questions remain over whether “early onset” (usually defined as that 
occurring before 34 weeks’ gestation) and “late onset” variants of pre-eclampsia 
are the same disease, or whether they have completely different pathological 
mechanisms. How to define “severe” and “mild” pre-eclampsia is another 
matter for debate. A further complicating factor is that the association of pre-
eclampsia with preterm delivery, small for gestational age (SGA) babies, or both, 
appear to have different consequences, particularly for the mother’s future 
cardiovascular health (7).  
For the purposes of this thesis, the diagnostic criteria defined by the ISSHP, but 
requiring at least ++ proteinuria on Dipstick analysis will be used throughout. 
1.1.2 Pathogenesis of pre-eclampsia 
Although the cause of pre-eclampsia remains largely unknown, the pathogenesis 
is thought to occur in two main phases. The first phase begins in the placenta, 
while the second stage is characterised by an abnormal maternal endothelial 
response, resulting in the hypertension, proteinuria and oedema that 
characterise the condition.  
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1.1.2.1 Placental phase 
The placenta is well recognised as having a key role in the development of pre-
eclampsia. This is known to be the case since pre-eclampsia occurs only during 
pregnancy, it resolves after delivery of the placenta, and it can occur in the 
absence of a viable foetus, for example in molar pregnancies. Blood supply to 
the placenta is via the spiral arteries, branches of the uterine arteries; placental 
development is a closely regulated process which is essential for normal foetal 
development.  
The spiral arteries are remodelled in pregnancy in several stages, beginning at 
around the time of implantation. Remodelling transforms the arteries from low-
flow, highly resistant vessels into the high-flow, low resistance vessels which are 
vital for normal placental development (Figure 1.1). Impaired remodelling of the 
spiral arteries is considered to be a key factor in the pathogenesis of pre-
eclampsia (8). In pre-eclampsia, disturbance of spiral artery remodelling may 
occur as early as the time of implantation, offering a potential explanation for 
the fact that women with a history of sub-fertility or early miscarriage are at 
increased risk of the condition (8).  
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Figure 1-1 Cytotrophoblasts invading the maternal spiral arteries transforming them from 
high-flow, low-resistance vessels in normal pregnancy (top) and impaired remodelling in 
pre-eclampsia (bottom). From Powe et al. (9) 
 
Intervillous flow, characterised by the appearance of connecting channels 
between the spiral arteries and the blastocyst, begins at 7-8 weeks’ gestation. 
Following this, the cytotrophoblastic cells of the developing placenta invade the 
decidual segments of the spiral arteries at around 10-12 weeks’ gestation, and 
then the myometrial segments, at around 15-16 weeks’ gestation. The 
trophoblast then invades both the endothelium and the highly muscular tunica 
media of the maternal spiral arteries.  
In pre-eclampsia the cytotrophoblast invades the decidual portion of the spiral 
arteries, but invasion of the myometrial segments is impaired; the spiral arteries 
remain narrow, and blood supply to the foetus is restricted. The effects of this 
on the foetus become more significant as pregnancy progresses, since the 
uterine vasculature is unable to keep up with the increased amount of blood and 
nutrients necessary for foetal development.  
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What causes the impaired development of the uteroplacental circulation in pre-
eclampsia remains unknown, and is a subject of much debate. Vascular, 
environmental and genetic factors all appear to play a role (10). Maternal 
natural killer (NK) cells are now thought to have an important role in these early 
stages of disease development. NK cells are the main maternal immune cells in 
the endometrium prior to implantation, and are have their main role in 
regulation of placental development. Interaction between maternal NK cells and 
foetal major histocompatibility complex (MHC) antigens may represent an initial 
step. Particular combinations of maternal NK cells and foetal MHC-C genotypes 
are linked to impaired placental development, and are reported to be associated 
with an increased risk of miscarriage and pre-eclampsia (11). Ongoing studies 
examining the interaction between NK cells and foetal gene expression may help 
to improve understanding of the vital initial stages in pre-eclampsia 
development.  
Reduced perfusion of the placenta from the abnormal remodelling of the spiral 
arteries appears to be related to impaired placental development. In keeping 
with this theory, conditions associated with vascular insufficiency, including 
hypertension, diabetes, systemic lupus erythematosis (SLE) and renal disease all 
increase the risk of abnormal placentation and pre-eclampsia (12). 
Hypoperfusion of the developing placenta results in placental ischaemia; 
placental pathological findings indicative of ischaemia include atherosis, 
fibrinoid necrosis, thrombosis and placental infarction. The typical placental 
pathological appearances are not seen in all women with pre-eclampsia, but 
their presence does appear to correlate with disease severity (13). 
The interface between the placental and maternal components of pre-eclampsia 
development is thought to occur when the under-perfused, ischaemic placenta 
releases a variety of factors into the maternal circulation (14).  
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1.1.2.2 Maternal response 
The second phase of pre-eclampsia development is characterised by exaggerated 
maternal endothelial activation and a pro-inflammatory state compared to 
normal pregnancy (15). Placental hypoxia leads to oxidative stress, destruction 
of syncitial architecture, and release of components from the intervillous space 
into the maternal circulation. The trophoblastic debris in the maternal 
circulation includes syncytiotrophoblastic membrane microparticles, and factors 
arising from the syncytiotrophoblast including soluble endoglin (sENG), and the 
soluble form of the vascular endothelial growth factor (VEGF) receptor, (sFLT-1). 
These and other as yet unknown factors lead to production of inflammatory 
cytokines in the maternal circulation, endothelial dysfunction and increased 
vascular reactivity. Loss of integrity of the maternal endothelium contributes to 
reversal of the physiological vascular changes in pregnancy, and subsequent 
hypertension, proteinuria and oedema (Figure 1.2).  
 
Figure 1-2 Current understanding of pathophysiology of pre-eclampsia. From Parikh et al. 
(16)  
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1.1.2.3 Animal studies 
One of the key aspects that has hindered progress in pre-eclampsia research is 
the lack of an accurate animal model to further study the disease. The disease 
appears to be unique to humans; although case reports have described 
conditions in pregnant animals such as seizures or characteristic renal lesions in 
association with elevated blood pressure, there have been no reports that have 
been similar enough to the human disease. Blood pressure tends to improve in 
pregnancy in rat models of hypertension (17), while renal function tends to 
improve in pregnant rats with various types of renal disease (18).  
A number of models have been used over the years to attempt to reproduce pre-
eclampsia, including uteroplacental ischaemia, nitric oxide synthase inhibition, 
adriamycin nephropathy and antagonism of angiogenesis (19). Each has improved 
understanding of certain aspects of pre-eclampsia, but in most studies the blood 
pressure did not improve after delivery, and the pathological appearances were 
seen both in the pregnant and non-pregnant animals.  
More recent animal models have been able to more closely replicate the human 
syndrome. The inbred mouse strain, BPH/5, is one such model. These mice 
develop a maternal and foeto-placental syndrome that resembles pre-eclampsia 
in humans, including development of late-gestational hypertension, proteinuria, 
renal glomerular lesions and endothelial dysfunction. These appearances are 
paralleled by alterations in angiogenic factors, which are known to be associated 
with the human disease (20). A further model has been developed in which mice 
are deficient in the complement component C1q; these animals also display 
multiple features resembling pre-eclampsia. One recent study using this model 
has also reported a potential role for pravastatin in reducing anti-angiogenic 
factors and blood pressure in affected animals (21).   
Finding a consistent definition for pre-eclampsia has proved difficult enough in 
humans, given the variation in presenting symptoms and signs that are seen. Any 
animal studies would have to fulfil all the criteria used in human diagnostic 
definitions; otherwise there would always be uncertainty as to how applicable 
the data would be to humans. Development of an animal model that recreates 
the full clinical spectrum of pre-eclampsia remains an important goal, and it is 
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hoped that such studies will provide a unique opportunity to examine the exact 
cause of molecular changes in angiogenic factors in pre-eclampsia. 
  
1.1.3 Maternal Risk Factors 
Although accurate prediction of pre-eclampsia remains difficult, there are a 
number of maternal risk factors which can be easily assessed in early pregnancy 
that are known to be associated with an increased risk of developing pre-
eclampsia.  
1.1.3.1 Nulliparity 
The most common of the pre-eclampsia risk factors is nulliparity, defined as 
never having previously given birth to a viable foetus; nulliparity has been shown 
to almost triple the risk of pre-eclampsia (12). The protective effect of having 
had a previous birth is lost, however, when a subsequent pregnancy is conceived 
with a new partner, or when there is a long interval between pregnancies. This 
had led to the theory that prior exposure to paternal antigens has a protective 
role against pre-eclampsia. This theory was supported by a study of nulliparous 
women, whereby women with previous termination of pregnancy with the same 
partner as the index pregnancy were nearly half as likely to develop pre-
eclampsia as women who had a previous termination with a different partner 
(22). Reduced exposure to paternal antigen, by limited exposure to their sperm 
is also a risk factor for pre-eclampsia. Women who conceive after a short period 
of sexual relations, or by alternative techniques such as non-partner donor 
insemination or intracytoplasmic sperm injection (ICSI) are also at increased risk 
of disease (10).  
1.1.3.2 Obesity 
Obesity is another important risk factor for pre-eclampsia; increased body mass 
index or increased abdominal circumference before pregnancy or in early 
pregnancy are well established risk factors for the condition (23). The maternal 
risk of pre-eclampsia increases with increasing degree of obesity, which persists 
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after accounting for other potential confounding factors (24). This is likely to be 
related to the altered metabolic state associated with marked obesity rather 
than the obesity itself.  Maternal obesity results in alteration of the plasma lipid 
profile with higher serum triglyceride and VLDL cholesterol, and lower HDL-
cholesterol concentrations than those observed in lean pregnant women. This 
pattern of dyslipidaemia is similar to that of the “metabolic syndrome” 
described in the non-pregnant population (25). Obesity is also associated with 
chronic low-grade inflammation, a feature common to many of the other risk 
factors for the condition.  
1.1.3.3 Diabetes 
The association of pre-gestational diabetes and pre-eclampsia is well recognised, 
and women with a history of diabetes have an up to 4-fold increased risk of 
development of pre-eclampsia compared to the general population.  Recent data 
from both the UK and the USA suggest that 0.5 - 0.75% of pregnant women have 
pre-existing type 1 or type 2 diabetes (26). In keeping with the general 
population, rates of gestational, type 1 and type 2 diabetes in pregnant women 
rose significantly between 1994 and 2004 in all age groups (27). The increase in 
rates of type 2 diabetes in pregnant women has been the most striking, and is 
likely to be related to increased rates of obesity.  
Diabetes in pregnancy increases the risk of poor maternal and neonatal 
outcomes. As well as the increased risk of pre-eclampsia, the condition is also 
associated with elevated risk of pregnancy loss, maternal infection, 
polyhydramnios, premature labour and failure to progress in the first or second 
stage of labour. Foetal and neonatal complications associated with diabetes 
include congenital malformation, macrosomia, respiratory distress syndrome, 
hypoglycaemia and jaundice. Further, the babies born to diabetic mothers have 
been shown in long-term follow up studies to be at increased risk of future 
obesity and type 2 diabetes themselves (26). 
Improving glycaemic control in early pregnancy is associated with a reduced risk 
of miscarriage and congenital malformations, but it has been less clear whether 
rates of pre-eclampsia are similarly affected. In a study of 290 pregnant women 
with type 1 diabetes, Temple et al. (28) reported that HbA1c, an indicator of 
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long-term glycaemic control, at week 12 and week 24 was strongly associated 
with pre-eclampsia on univariate analysis. In this study, however, pre-pregnancy 
care to target pre-conceptual glucose control, and improved glucose levels in 
very early pregnancy were not associated with a difference in rates of pre-
eclampsia.  
Gestational diabetes, the onset or first recognition of glucose intolerance in 
pregnancy, is also dramatically increasing in incidence in the Western world. 
Until recently there has been a lack of consensus on how the condition should be 
diagnosed or treated, and in particular it has not been clear how aggressively 
blood glucose should be monitored or lowered. A recent study designed to 
investigate the use of metformin and / or insulin in gestational diabetes 
examined the influence of baseline oral glucose tolerance test (OGTT) results, 
HbA1c and both fasting and post-prandial capillary glucose levels on a variety of 
maternal outcomes (29). Diagnostic OGTT results (from the time of diagnosis of 
gestational diabetes, at mean gestation 30 weeks) did not predict outcomes, but 
the key finding was that capillary glucose levels were strongly and independently 
related to the primary outcome composite of neonatal outcomes, pre-eclampsia 
and frequency of large for gestational age (LGA) babies. Pre-eclampsia itself was 
most strongly associated with elevated post-prandial glucose levels, and since 
fluctuating glucose levels are thought to contribute to endothelial dysfunction in 
non-pregnant patients with diabetes (30), this is perhaps not surprising.   
 
1.1.3.4 Ethnicity 
Pre-eclampsia rates vary significantly around the world; whether this is related 
to different diagnostic criteria, or whether there are truly differences between 
different ethnic populations remains uncertain. Further, whether both maternal 
and paternal ethnicity play a role in determining pre-eclampsia risk is also 
unclear. A retrospective American cohort study of 127,000 low-risk pregnant 
women reported that rates of pre-eclampsia were higher among African-
American women (5.2%, OR 1.41, 95% CI 1.25-1.62), and lower amongst Latina 
(4.0%, OR 0.9, 95% CI 0.84-0.97) and Asian women (3.5%, OR 0.79, 95% CI 0.72-
0.88) compared to white women (31). Paternal ethnicity followed a similar 
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pattern, with highest rates in African-American fathers, and lowest rates in 
Asian fathers. When maternal and paternal ethnic discordance were examined, 
the overall rate of pre-eclampsia was higher among mothers whose ethnicity 
differed from the father.  
 
1.1.3.5 Relative risk of individual risk factors 
Established risk factors associated with pre-eclampsia, along with relative risk 
and 95% confidence interval are shown in table 1 below.  
 
Risk Factor Relative Risk (95% CI) 
Nulliparity 2.91 (1.28 to 6.61) 
Previous pre-eclampsia 7.19 (5.85 to 8.83) 
Age > 40 yrs 1.96 (1.34 to 2.87) 
BMI ≥ 35 kg/m² 1.55 (1.28 to 1.88) 
Twin pregnancy 2.93 (2.04 to 4.21) 
Diastolic BP > 80 at booking 1.38 (1.01 to 1.87) 
Pre-existing diabetes 3.56 (2.54 to 4.99) 
Family history (mother or sister) 2.90 (1.70 to 4.93) 
Antiphospholipid antibody 9.72 (4.34 to 21.75) 
Table 1-2 Maternal risk factors for pre-eclampsia. Adapted from Duckitt et al. (12) 
 
In addition to these well-established risk factors, others have more recently 
been reported to be associated with pre-eclampsia. Asthma, another condition 
characterised by chronic inflammation, has been implicated; in a study of 650 
asthmatic and 1000 non-asthmatic pregnant women, women with moderate to 
severe asthma symptoms had an increased risk of developing pre-eclampsia, 
regardless of treatment, compared to those without symptoms (32). In addition, 
a history of coronary heart disease in the pregnant woman’s father has been 
recently reported as conferring an almost 2-fold increased risk of pre-eclampsia 
(3).  
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The problem with using these factors to stratify pre-eclampsia risk is that many 
of them are extremely common in the pregnant population. Further, the 
majority of these risk factors are non-modifiable. The relationship between 
different risk factors is also uncertain; for example it is not known whether a 
multiparous woman with high BMI remains at increased risk of pre-eclampsia if 
her previous pregnancies were uncomplicated.  
As women in modern Western society begin to have children at a later stage in 
life, and as the population as a whole becomes more obese, these risk factors 
will become less useful in risk stratification. There is now therefore more of a 
clinical need than ever to identify clinical or biochemical parameters that will 
help to inform clinicians which women are at increased risk of developing pre-
eclampsia.  
 
1.2 Factors that may reduce risk of pre-eclampsia 
Although there is no effective treatment for pre-eclampsia other than delivery 
of the baby and placenta, several potential therapeutic agents have been 
studied over the years, which are summarised below.  
1.2.1 Aspirin  
Low-dose aspirin, used almost universally in cardiovascular disease, has been 
studied extensively for its role in preventing pre-eclampsia. The rationale for its 
use is that impaired trophoblastic invasion in early pregnancy is thought to lead 
to activation of platelets and the clotting system, leading to an imbalance of the 
thromboxane A2 / prostacyclin ratio.  Aspirin treatment in pregnancy inhibits 
synthesis of platelet-derived thromboxane A2, without affecting prostacyclin 
production, potentially helping to prevent the development of pre-eclampsia 
(33).   
Initial studies using aspirin in the 1980s examined small numbers of very high-
risk women (women with a history in a previous pregnancy of severe pre-
eclampsia with foetal growth restriction or foetal death) and reported 
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significant reductions in incidence of pre-eclampsia (34) and in levels of 
thromboxane A2 (35). These initial promising results were not fully reproducible; 
a subsequent larger study, including 1100 women at medium and high risk failed 
to show any significant benefit of aspirin therapy in preventing pre-eclampsia or 
other adverse pregnancy outcomes (36).  
Several other studies have shown a small and non-significant benefit of aspirin 
use in preventing pre-eclampsia. Two systematic meta-analyses in recent years 
have therefore pooled data from these studies.  Examining 59 (37) and 31 (38) 
randomised trials respectively, a modest but consistent benefit was seen with 
aspirin in risk of pre-eclampsia (RR 0.90, 95% CI 0.84 to 0.97) , preterm delivery 
(RR 0.90, 95% CI 0.83 to 0.98) and of serious pregnancy outcomes (RR 0.90 95% CI 
0.85 to 0.96) (38). Results were similar regardless of dose of aspirin used and 
gestation at initiation of therapy. Subgroup analysis failed to demonstrate 
exactly which groups of women were most likely to benefit.  
Further studies have therefore attempted to elucidate exactly which groups of 
“at risk” women benefit from aspirin use. Nulliparity, or having a first baby, is 
one of the most important risk factors for pre-eclampsia, and is the most 
common. A study which randomised over 3000 healthy nulliparous women to low 
dose aspirin or placebo reported a relative risk of 0.7 for pre-eclampsia in the 
aspirin group (95% CI 0.6 to 1.0)(39). The reduction in risk, however, was highest 
in women with an initial blood pressure in the upper end of the normal range, 
which may have confounded results. Further, there was a small but significant 
excess of placental abruption, the most common cause of late pregnancy 
bleeding, in the aspirin group. A further study using uterine artery Doppler at 23 
weeks’ gestation to identify high risk women failed to show any reduction in pre-
eclampsia incidence with aspirin (18% in aspirin group vs 19% in control group, 
p=0.6) (40).  
The American College of Obstetrics and Gynaecology produced a clinical 
management guideline for pre-eclampsia in 2002, but the authors were unable 
to reach a consensus on which women should be treated, and at what stage of 
gestation they should be treated (41). Reflecting this uncertainty, one study 
reported that in 2399 women at “high-risk” of the condition (defined as having 
at least one risk factor), aspirin use varied throughout different regions of the 
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United Kingdom from 8% to 49% (42). Of the women who did develop pre-
eclampsia, only 33% had been on aspirin at any point during their pregnancy.  
More recent guidelines from the UK’s National Institute for Health and Clinical 
Excellence (NICE) recommend aspirin prophylaxis from 12 weeks’ gestation in 
high-risk women, who are in turn defined as those with chronic hypertension, 
diabetes, chronic kidney disease and those with autoimmune conditions such as 
systemic lupus erythematosis (43). Aspirin prophylaxis is also recommended in 
women with 2 or more “moderate” risk factors (nulliparity, age >40 years, BMI 
>35 kg/m², family history of pre-eclampsia and twin pregnancies). Aspirin is safe 
in the second and third trimesters of pregnancy (44) but its safety in the first 
trimester remains unknown. Given that the underlying pathophysiological 
mechanisms begin early in the first trimester, further research examining the 
safety of aspirin in the first few weeks of pregnancy is merited.  
   
1.2.2 Heparin 
An alternative therapeutic modality that has been studied in the prevention of 
pre-eclampsia is the anticoagulant heparin. The placenta in pre-eclampsia 
displays several features of ischaemia, including villous infarcts and decidual 
necrosis. Thrombophilias, coagulation disorders associated with thrombosis, are 
increasingly associated with pre-eclampsia pathogenesis; the antiphospholipid 
syndrome is associated with a 9 fold increase in relative risk of pre-eclampsia 
(12), and in a study of 172 pregnant women with a history of pre-eclampsia in a 
previous pregnancy, 60 (35%) were found to have a thrombophilic defect. These 
women also had an increased risk of recurrence of pre-eclampsia in a subsequent 
pregnancy (47% vs 26%, p=0.01) (45). 
A small number of studies have examined the use of heparin in preventing pre-
eclampsia. One study reported that in women with previous pre-eclampsia but 
without an inherited thrombophilia, the risk of severe pre-eclampsia or other 
placental mediated outcomes (birthweight <5th centile, major placental 
abruption) fell from 24% in the control group to 5.5% in the heparin group (46). 
When pre-eclampsia was studied alone, however, the results were non-
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significant. Other studies examining heparin administration either alone or in 
combination with aspirin have been too small to be applicable to the general 
pregnant population.   
1.2.3 Calcium supplementation 
Several reports over the years have suggested that calcium supplementation can 
reduce the incidence of pre-eclampsia (47) ; indeed as far back as 1952 it was 
reported that Ethiopian women, who had a high dietary intake of calcium, had a 
low prevalence of pre-eclampsia (48). Its use is not recommended in the healthy 
pregnant population (47), but whether calcium supplementation is beneficial in 
selected high-risk groups of pregnant women remains uncertain.   
To examine this, a Cochrane database systematic review was published in 2006 
(49). 12 studies including over 15,000 pregnant women, comparing calcium 
supplementation of 1g with placebo, were included in the analysis. The authors 
reported an overall relative risk in the calcium supplement group of pre-
eclampsia of 0.48 (95% CI 0.33 to 0.69). In high-risk women (defined as those 
with previous pre-eclampsia, teenagers, those with increased sensitivity to 
Angiotensin II and those with pre-existing hypertension) the relative risk was 
0.38 (95% CI 0.21 to 0.68). The promising results of this meta-analysis, however, 
were reported by the authors to be potentially confounded by the inclusion of 
several small trials with a high proportion of women with low dietary calcium 
intake.  
The importance of the baseline characteristics of the pregnant women being 
studied was demonstrated further in the calcium to prevent pre-eclampsia 
(CPEP) trial. Over 4500 healthy nulliparous women, at 13 to 21 weeks’ gestation, 
were randomised to either 2g of calcium daily or placebo.  Between the two 
groups there was no significant difference in rates of pre-eclampsia (6.9% in the 
calcium group, 7.3% in the placebo group), gestational hypertension, small for 
gestational age (SGA) babies, preterm deliveries, or foetal or neonatal deaths. It 
therefore remains uncertain whether calcium supplementation in those with a 
normal dietary intake is beneficial; a recent systematic review by the US Food 
and Drug Administration (FDA) concluded that a relationship between calcium 
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supplementation and gestational hypertension or pre-eclampsia was unlikely 
(50).  
1.2.4 Anti-oxidants 
1.2.4.1 Vitamins C&E 
A number of studies have been performed in recent years to examine the role of 
antioxidants in the prevention of pre-eclampsia. Oxidative stress is thought to 
play a role in the development of pre-eclampsia, and markers of oxidative stress 
have been reported to be elevated in the circulation of affected women (51). 
The antioxidants vitamins C and E, both relatively cheap and widely available, 
have been extensively studied in this context. In an initial study, high-risk 
women (those with abnormal uterine artery Doppler studies or a previous history 
of the condition) were randomised to either 1g of Vitamin C and 400 iu of 
Vitamin E per day, or placebo, from 16-22 weeks’ gestation until delivery. 
Markers of endothelial activation (Plasminogen-activator inhibitor 1, PAI-1) and 
placental dysfunction (PAI-2) were measured monthly until delivery. The authors 
reported a 21% reduction in the PAI-1 /PAI-2 ratio during gestation; the rate of 
pre-eclampsia in the placebo group was 17% compared with 8% in the treatment 
group (52). Following these promising results, the same group went on to carry 
out a much larger multicentre study, known as the Vitamins in Pre-eclampsia 
(VIP) study (53). Over 2400 women were randomised to take either Vitamin C 
and E (in the same doses as the previous study) or placebo; incidence of pre-
eclampsia was 15% in the treatment group and 16% in the control group. Rather 
than showing any benefit, in fact the treatment group had a higher incidence of 
low birthweight babies (28% vs 24% in the placebo group, p=0.023) leading to 
some concern about the safety of such agents.  
A World Health Organisation (WHO) study examined high-risk women with low 
socio-economic and nutritional status from centres in Peru, India, Vietnam and 
South Africa, women thought to be the most likely to benefit from vitamin 
supplementation. Following the same protocol as the VIP study, this paper also 
reported that vitamin supplementation did not prevent against pre-eclampsia, 
eclampsia, gestational hypertension, or any other maternal outcome. Further, 
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there was no difference between the groups in preterm deliveries or low birth 
weight babies (54). A further study which examined over 10,000 unselected low-
risk nulliparous women again showed no difference in rates of pregnancy-
induced hypertension, pre-eclampsia or adverse neonatal outcomes between 
those treated with vitamins C & E and controls (51).  
As mentioned above, women with diabetes are at two to four times increased 
risk of developing pre-eclampsia compared to the general population. Those 
with complications related to diabetes such as diabetic nephropathy are at 
further increased risk; indeed the presence of microalbuminaemia in early 
pregnancy is associated with a four-fold increase in risk of pre-eclampsia (55). 
Given that type 1 diabetes is associated with increased oxidative stress and 
depletion of antioxidants, it seems logical that these women could benefit from 
antioxidants such as Vitamins C and E during pregnancy. In a large double 
blinded randomised controlled trial, over 700 pregnant women with type 1 
diabetes were treated with either vitamins C and E or placebo. No difference 
was seen between the 2 groups in rates of pre-eclampsia, gestational 
hypertension, low birthweight deliveries, or in PAI-1 / PAI-2 ratio (56). 
Overall, these studies provide evidence of the lack of effectiveness of Vitamins C 
and E for the prevention of pre-eclampsia, when started in the first and second 
trimesters, in both high-risk and low-risk pregnant women. Whether they could 
help to prevent pre-eclampsia if given in earlier pregnancy, or pre-conceptually, 
remains unclear.   
1.2.4.2 Fish oils 
The relatively low incidence of pre-eclampsia and preterm delivery in 
populations with a fish-based diet such as inhabitants of Greenland and the 
Faroe Islands have led to several studies examining the potential role of fish oil 
supplements in preventing pre-eclampsia (57). Fish oils are rich in long-chain 
polyunsaturated fatty acids, precursors to the 3-series prostaglandins, and have 
been shown to modulate vascular and inflammatory effects via down-regulation 
of the thromboxane A2 pathway (57). The Fish Oil Trials In Pregnancy (FOTIP) 
study randomised 386 pregnant women with a history of hypertension in a 
previous pregnancy to either fish oils or olive oil at gestational week 20. A 
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further 79 women who had developed hypertension in the current pregnancy 
were also randomised at 24-30 weeks’ gestation in a “treatment” arm. No effect 
was seen on either incidence or development of hypertension (58). A Cochrane 
database meta-analysis of 6 trials of 2755 women similarly found no beneficial 
effects of fish oil supplementation (57).   
1.2.5 Cigarette smoking  
There can be little doubt that cigarette smoking has an adverse effect on 
pregnancy. As well as the maternal association with chronic lung disease, 
preterm delivery and placental abruption, smoking is associated with an 
increased risk of foetal complications such as stillbirth, intra-uterine growth 
restriction (IUGR), placenta praevia and spontaneous abortion. Paradoxically, 
however, smoking has been consistently shown over the years to be associated 
with a reduced risk of pre-eclampsia; smokers were shown in a systematic 
review of the literature to have a 32% lower incidence of pre-eclampsia 
compared to non-smokers (59). 
The GOPEC (Genetics of Pre-Eclampsia) consortium analysed over 1000 women 
with moderate to severe pre-eclampsia in a multi-centre study, and carried out 
a sub-analysis to analyse the relationship between smoking and pre-eclampsia. 
9% of the women with pre-eclampsia admitted to being current smokers, 
compared to an estimate of 27% in the general pregnant UK population (60). In 
women with pre-eclampsia, smokers had a 2-fold increased risk of requiring 
delivery at less than 34 weeks’ gestation, of delivering babies with a birthweight 
below the 3rd centile, or of any adverse outcome (60). In addition the risk of 
developing eclamptic seizures was increased five-fold in smokers compared to 
non-smokers. These data would appear to suggest therefore that smokers are 
less likely to develop pre-eclampsia than non-smokers, but that when they do, 
they develop a more severe form of the disease. The question remains; why are 
smokers less likely than non-smokers to develop pre-eclampsia? One theory 
proposed by the GOPEC consortium was that foetal demands in later pregnancy 
trigger the onset of pre-eclampsia, and since smokers tend to have smaller 
babies, they may put the placenta under less strain and so lessen the risk of pre-
eclampsia (60). 
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The “protective” effects of smoking appear not to extend to chewed tobacco. In 
a large epidemiological study of over 600,000 Nordic women, Wikström et al. 
(61) concluded that the use of Swedish snuff, a smokeless form of tobacco, was 
not associated with a reduction in rates of pre-eclampsia. They suggested that it 
was not the constituents of tobacco such as nicotine that were protective, but 
rather it was combustion products from smoking, such as carbon monoxide (CO) 
that influenced the reduced rates. At the time of trophoblastic implantation, the 
uterus is relatively hypoxic, and it has been previously proposed that CO 
increases effective trophoblastic invasion in the first few weeks of pregnancy 
(62). CO also has been shown to contribute to utero-placental blood flow, and to 
reduce the inflammatory response at the spiral arterioles, both mechanisms 
known to contribute to pre-eclampsia. Further, smoking causes a down-
regulation of endothelial sensitivity to activating signals (22), and so chronic 
endothelial injury caused by chronic smoking may in fact protect the mother 
from the endothelial dysfunction caused by pre-eclampsia.  
A further interesting observation from the Swedish population study was that 
change in tobacco habits during pregnancy also appeared to affect pre-eclampsia 
rates. Women who reported tobacco use at the first antenatal visit but not at 
30-32 weeks’ gestation did not have reduced rates of pre-eclampsia, whereas 
those who reported no tobacco use initially, but were smoking at 30-32 weeks’ 
gestation did (61). This may imply that smoking in the second half of pregnancy 
is necessary for reducing the risk of pre-eclampsia.  
Any study examining the effects of smoking in pregnancy relies on accurate self-
reporting of smoking rates, and this may be a source of bias in these studies. 
Regardless of whether or not smoking protects against pre-eclampsia, it is clear 
that any strategies that help to reduce smoking rates in pregnancy must remain 
a public health priority.  
 
1.2.6 Lifestyle measures 
Up until relatively recently, it was recommended that women increase their 
calorific intake and reduce physical activity during pregnancy. Current 
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guidelines, however, advocate regular exercise in pregnancy; as well as helping 
to prevent long term obesity, one of the perceived beneficial effects is a 
reduction in risk of pre-eclampsia. Exercise is well known to reduce risk of 
hypertension in non-pregnant subjects, while markers of insulin resistance and 
endothelial dysfunction known to be elevated in pre-eclampsia are also reduced 
by physical activity. Exercise could in theory, however, also be associated with 
an increased risk of pre-eclampsia; exercise may be associated with increased 
oxidative stress (63), one of the potential pathophysiological mechanisms for the 
development of pre-eclampsia. As a result there remains conflicting advice from 
health-care professionals about exercise during pregnancy, and some women 
remain concerned about the potentially harmful effects of vigorous exercise on 
the foetus. 
A study reported in 2003 retrospectively examined 201 women with pre-
eclampsia and 383 women with normotensive pregnancies (64). Women were 
given a structured questionnaire about type, duration, frequency and intensity 
of exercise both during pregnancy, and in the year preceding the pregnancy.  
The authors reported an overall 35% reduced risk (95% CI 0.43 to 0.99) of pre-
eclampsia in women who took regular exercise in the first 20 weeks of 
pregnancy, compared to inactive women (64).  This risk reduction remained 
significant when corrected for age, BMI, parity, smoking and race. The risk of 
pre-eclampsia was inversely related to the frequency and intensity of exercise. 
An additional finding was that women who had taken regular exercise in the year 
before pregnancy had a similar risk reduction to those who exercised during 
pregnancy (OR 0.67, 95%CI 0.42 to 1.08) (64).  
Other studies have, however, been less convincing about the beneficial effects 
of exercise in pregnancy. A prospective Scandinavian study, using a 
questionnaire at gestational week 14-22, reported an overall reduction in risk of 
pre-eclampsia with exercise of 21% (95% CI 0.65-0.96). This effect was most 
marked in women with a BMI within the normal range, and no beneficial effect 
of exercise was seen with pregnancy in those with a BMI>30 kg/m², leading 
authors to suggest that the beneficial effects of exercise in pregnancy only 
applied to the non-obese population (65).  A further prospective study, using a 
telephone interview in the first trimester, did not show any overall protective 
benefit of exercise in the first trimester. In contrast, authors reported that 
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women with more intensive exercise (more than 270 minutes per week) had an 
increased risk of severe forms of pre-eclampsia (63). A prospective study in 
which women were randomised to exercise using a home-based cycling 
programme from 20 weeks’ gestation to delivery was recently reported. Women 
who exercised regularly delivered babies with lower birth weight which 
remained significant after correction for sex and gestational age at delivery. In 
contrast to the authors’ original hypothesis, no difference was seen between the 
2 groups in blood markers of insulin resistance, gestation at delivery, or 
maternal BMI (66). 
A review of the literature in this field led to American College of Obstetrics and 
Gynaecology (ACOG) recommendations that in the absence of medical or 
obstetric complications pregnant women partake in 30 minutes of moderate 
exercise daily (67). Similarly, NICE guidelines recommend that “beginning or 
continuing a moderate course of exercise is not associated with adverse 
outcomes.” (68) Further large-scale prospective studies looking at both foetal 
and maternal outcomes are required before clinicians can give definitive 
guidance about optimal exercise duration and type during pregnancy.   
 
1.2.7 Bariatric surgery 
While the benefits and risks of exercise in pregnancy remain uncertain, there 
can be no doubt that obesity should be avoided both in pregnancy and in those 
considering pregnancy. A third of all women of reproductive age are obese (69), 
and obesity is an important risk factor for pre-eclampsia, as well as for other 
complications of pregnancy including gestational diabetes, preterm delivery and 
congenital anomalies.  
Bariatric surgery has emerged in the last decade as the single most effective 
treatment for obesity. Surgical procedures, including the Roux-en-Y gastric 
bypass and laparoscopic adjustable gastric banding, work mainly by restricting 
calorific intake via a smaller stomach reservoir, and have been reported to have 
enormous beneficial effects on blood pressure, cholesterol and diabetes (70).  
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Since bariatric surgery is a relatively new technique, there is limited experience 
of bariatric surgery in young women of reproductive age, and little is known 
about the effects of such surgery on pregnancy-related complications. A recent 
study used retrospective analysis of insurance claim forms to examine whether 
pre-eclampsia and other hypertensive disorders were affected by bariatric 
surgery. 585 women who had undergone bariatric surgery for obesity were 
included; 269 had delivered a baby prior to surgery and 316 had had their 
surgery prior to pregnancy (71). Women with surgery prior to pregnancy had 
rates of pre-eclampsia and eclampsia of 3% compared to 15% those with surgery 
after pregnancy (p<0.001), lower rates of pregnancy induced hypertension (2.5% 
vs 13%, p<0.001), and lower rates of pre-eclampsia superimposed on chronic 
hypertension (1% vs 12% p>0.001).      
As the global obesity epidemic spreads, progressively more morbidly obese 
women will be considering pregnancy. The American College of Obstetrics and 
Gynaecology recently recommended that bariatric surgery should be considered 
pre-pregnancy in women with a BMI > 40, and in those with a BMI > 35 in 
association with co-morbidities including chronic hypertension (72). Future 
studies will determine whether the beneficial effects of such surgery on mothers 
and their children will be long-standing.  
 
1.3 Screening tests for pre-eclampsia; clinical studies  
There have been many screening tests evaluated in the literature over the years 
for predicting pre-eclampsia; these have been comprehensively reviewed in a 
World Health Organisation publication (73). A further summary of predictive 
tests, including a review of preventative interventions and economic modelling 
has been published by the UK National Institute for Health Research (74). The 
most promising biochemical and clinical parameters that have been studied will 
be discussed here. 
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1.3.1 Uterine artery Doppler studies 
The advent of ultrasound has revolutionised the practice of obstetrics in the last 
50 years, by offering a window to the womb through which the anatomic 
structures of the foetus can be evaluated. The more recent addition of Doppler 
flow studies of the maternal and foetal vessels have provided further useful 
information, allowing assessment of the physiology of the foeto-maternal unit. 
Doppler studies are non-invasive, acceptable to patients, and can be carried out 
at the same time as a detailed anomaly scan, and as such have been studied 
extensively for their role in screening for adverse foetal and maternal outcomes.  
1.3.1.1 Doppler studies in normal pregnancy 
In the non-pregnant state there is a rapid rise and fall in uterine artery flow 
velocity during systole and a “notch” in the descending waveform in early 
diastole. As discussed in section 1.1.2, remodelling of the spiral arteries in early 
pregnancy is an important step in regulating and maintaining placental 
perfusion. The reduction in resistance of the spiral arteries as a result of 
remodelling in pregnancy can be reflected in uterine artery Doppler studies, by a 
high diastolic velocity with continuous flow throughout diastole, and the loss of 
the diastolic “notch” at 20 to 24 weeks’ gestation (figure 1.3.) (75). These 
changes can be quantified by demonstrating changes in the resistance index (RI, 
maximum – minimum velocity / maximum velocity) and the pulsatility index (PI, 
maximum – minimum velocity / mean velocity) of the uterine vessels which 
begin to decrease in normal pregnancy from between 8 and 18 weeks’ gestation 
(75).  
1.3.1.2 Doppler studies in pre-eclampsia 
 In pre-eclampsia the remodelling of the spiral arteries is impaired; the spiral 
arteries maintain their muscular elastic coating, and impedance to blood flow 
persists.  This pathological resistance to placental flow can be detected by 
Doppler studies of the maternal uterine vessels, offering the potential to detect 
women at risk not only of pre-eclampsia, but also of intra-uterine growth 
restriction. The majority of research has focussed either on an elevation in RI or 
PI using percentile cut-off values, or by persistence of the diastolic “notch.”  
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Figure 1-3 Week 28 uterine artery Doppler studies at week 28 in a woman with a normal 
pregnancy (left) and in a women with pre-eclampsia showing persistent “notch” and low 
flow at end-diastole (right).  From Doppler in Obstetrics, Nicolaides et al.  
 
Abnormal Doppler studies in both the first and second trimesters have been 
reported to be associated with pre-eclampsia. Abnormalities are detectable as 
early as 12 weeks’ gestation (8); for women with abnormal first trimester testing 
the likelihood ratio (LR) for development of pre-eclampsia is approximately 5, 
while normal Doppler studies carry an LR of 0.5 (75). Although this relationship 
persists into the second trimester, the optimal timing for performing these 
studies remains uncertain. 
The use of uterine artery Doppler was perhaps best summarised in a recent 
comprehensive meta-analysis. Cnossen et al. (76) reviewed 74 uterine artery 
Doppler studies including nearly 80,000 pregnant women, of whom 2,500 
developed pre-eclampsia. The majority of Doppler indices had poor predictive 
characteristics, but this varied with patient group studied and severity of 
disease. For all women the overall risk of pre-eclampsia was best predicted by 
an elevated second trimester PI accompanied by persistent bilateral uterine 
artery notching. For women deemed on the basis of risk factors to be at low-
risk, positive likelihood ratio (+LR) was 7.5, and negative likelihood ratio (-LR) 
was 0.59. For women at high risk of developing pre-eclampsia, +LR was 21, and -
LR was 0.82.  
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As a result of these findings the authors concluded that Doppler studies were 
more accurate for prediction of future pre-eclampsia when performed in the 
second trimester rather than the first trimester. Since the false positive rate was 
relatively high, they felt that the increased anxiety and expense associated with 
abnormal results could not justify their use for screening in low-risk women.  
The majority of studies using uterine artery Doppler studies to predict pre-
eclampsia have been performed in large centres with significant experience and 
expertise in their use. It remains to be seen whether these findings are 
applicable in smaller centres, or in the developing world where they would be 
more likely to be clinically useful. The tests are also relatively time-consuming, 
taking around 20 minutes to perform (75), which may preclude their use in the 
general pregnant population. The combination of these studies with maternal 
risk factors, or with analysis of serum markers such as anti-angiogenic factors 
(77) may ultimately be more clinically useful.  
 
1.3.2 Blood pressure measurement 
Although blood pressure measurement is clearly essential for the detection of 
hypertensive disorders of pregnancy, it remains to be seen whether 
measurement of blood pressure in the first or second trimesters can predict 
which women will develop problems later on. Increased diastolic blood pressure 
is associated with an increased risk of pre-eclampsia (12), but studies using 
assessment of blood pressure in the first or second trimester for prediction of 
pre-eclampsia have reported false-positive rates ranging from 7 - 52% and 
detection rates ranging from 8 – 93% (78). It is likely that these differences 
relate to differences in the populations studied, different techniques used to 
measure blood pressure, and different definitions of pre-eclampsia. A meta-
analysis of 34 studies evaluated the role of systolic pressure (SBP), diastolic 
pressure (DBP), mean arterial pressure (MAP) and increase in blood pressure 
during the first or second trimester to predict pre-eclampsia in low and high-risk 
women (79).  MAP was shown to be superior to SBP, DBP and increase in blood 
pressure between the first and second trimester in predicting pre-eclampsia; 
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second trimester MAP of ≥90 mmHg was associated with a positive likelihood 
ratio of 3.5 for pre-eclampsia and a negative likelihood ratio of 0.46.  
Ambulatory blood pressure monitoring (ABPM) allows multiple readings to be 
taken using automated blood pressure devices, in a non-clinic environment. As 
such this may provide a better estimate of true blood pressure, since it is not 
confounded by the “white-coat” effect (80). Few studies have examined ABPM in 
the context of pre-eclampsia prediction, and the majority of these are 
suboptimal (81). One study which examined over 1100 women who had 24 hour 
ABPM between 18 and 24 weeks’ gestation did not find ABPM to be a useful 
predictor of hypertension later on in pregnancy (80), since absolute differences 
in ABPM measurements were small, and overlap between hypertensive and 
normotensive women was high.  
1.3.3 Sympathetic nervous system activation 
Since vascular tone is largely determined by the sympathetic nervous system, it 
has been proposed that sympathetic vasoconstrictor activity may be important in 
regulating the increase in peripheral resistance seen in pre-eclampsia. Indirect 
evidence of this association is provided by methyldopa, a drug which acts by 
reducing central sympathetic outflow, which was previously the drug of choice 
for hypertensive disorders of pregnancy. Plasma catecholamines have also been 
reported to be elevated in pre-eclampsia (82), but these are insensitive markers 
of sympathetic nervous system activity, and their levels are influenced by 
several different factors.  
More recent studies have used alternative techniques to measure sympathetic 
nervous system activity in pregnancy and pre-eclampsia. Schobel et al. (83) 
measured postganglionic action potentials in sympathetic nerve-fibres 
innervating vessels in skeletal muscle of women with pre-eclampsia. They found 
that sympathetic discharge to skeletal muscle was elevated in women with pre-
eclampsia compared to women with normal pregnancies, and normalised after 
delivery. Age-matched non-pregnant women with essential hypertension did not 
have such increases in sympathetic activity. It seems likely therefore that the 
increase in vascular resistance in pre-eclampsia is due at least in part to an 
increase in sympathetic vasoconstrictor activity. Any method for its 
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measurement in pregnancy, however, is unlikely to be feasible in large clinical 
studies of pregnant women.   
 
1.3.4 Studies of endothelial function 
The vascular endothelium is thought to be responsible for many of the 
physiological changes in normal pregnancy such as reduction in blood pressure 
and peripheral resistance, changes which are largely thought to be regulated by 
nitric oxide. Pre-eclampsia is associated with vasoconstriction of a number of 
maternal beds, and dysfunction of the endothelium is thought to have a key role 
in its pathogenesis. Detection of endothelial dysfunction remains difficult; the 
gold standard for measurement of endothelial function is angiographic response 
to intra-arterial injection of acetylcholine. This method is clearly too invasive to 
be used in large clinical studies, while the majority of other methods of 
assessment of endothelial function cannot be safely used in pregnancy. Less 
invasive methods for the detection of endothelial dysfunction that are safe in 
pregnancy and applicable in large scale studies are therefore required.  
1.3.4.1 Brachial artery ultrasound 
Measuring the change in brachial artery diameter as a response to increased flow 
(flow-mediated dilatation, FMD) using high-resolution ultrasound has emerged as 
a reliable non-invasive method for detection of endothelial dysfunction. FMD 
after a 5 minute period of occlusion with a blood pressure cuff has been shown 
to depend mainly on nitric oxide release (84), and endothelial dysfunction 
measured using this technique has been shown to correlate with response noted 
on coronary angiography after acetylcholine injection (85). Pre-test preparation 
is important, since a number of factors can affect FMD measurement including 
caffeine, alcohol, temperature and the stage of women’s menstrual cycle.  
Normal pregnancy has been reported to be associated with an increase in FMD of 
the brachial artery of 38%, an increase which is apparent from at least 10 weeks’ 
gestation (84). Baseline brachial artery diameter and volumetric flow also 
increases significantly in a linear fashion, in keeping with the generalised 
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vasodilatation seen in pregnancy. From around 32 weeks, FMD falls significantly, 
and by 6 weeks post-partum levels fall to non-pregnant values (86).  
If FMD is to be useful as a screening tool for pre-eclampsia, it is important to 
understand the effect that maternal risk factors for pre-eclampsia have upon 
results. Kinzler et al. (87) examined 28 high risk women (7 with pre-gestational 
diabetes, 4 with chronic hypertension, 6 with twins, and 11 with a history of pre-
eclampsia in a previous pregnancy), as well as 44 low risk women, of whom 11 
were nulliparous. They found no difference in FMD after 5 minutes occlusion 
between the first and second trimesters, in either high or low-risk women. High-
risk women had a significantly reduced brachial artery diameter change 
compared to low-risk women in both trimesters. Women with pre-gestational 
diabetes and chronic hypertension had significant reductions in response 
compared to low-risk women, while women with twin pregnancies had an 
increased response compared to women with singleton pregnancies. When low-
risk women were analysed alone, nulliparous women had increased response 
compared to multiparous women. Potential limitations of this study were that it 
did not include non-pregnant controls, that high-risk women were older than 
those at low-risk, and that women who went on to develop pre-eclampsia were 
not analysed separately.  
FMD has been reported to be reduced in women at the time of diagnosis of pre-
eclampsia compared to normotensive women (88), but it is unclear whether this 
is a cause or a consequence of the disease. Few studies have examined the 
ability of brachial artery FMD to predict future pre-eclampsia. Garcia et al. (89) 
examined 506 Colombian women at gestational week 22, of whom 14 
subsequently developed pre-eclampsia. The women who went on to develop pre-
eclampsia had a lower FMD (13.4% ± 4.3 vs 18.2% ± 7.2, p=0.022) than those with 
normal pregnancies.  
 
1.3.4.2 Ex-vivo studies 
Further evidence for the relationship between endothelial dysfunction and pre-
eclampsia has been provided by measurement of FMD using ex-vivo organ bath 
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studies of small arteries. Cockell et al. (90) examined small arteries dissected 
from subcutaneous fat samples obtained during Caesarean section and 
gynaecological surgery. Arteries from women with pre-eclampsia, women with 
normotensive pregnancy, and non-pregnant healthy controls were of similar 
internal diameter, and constricted appropriately in response to addition of 
noradrenaline. Arterial response to increments of intraluminal flow was then 
recorded; vessels from normotensive women showed substantial flow-induced 
relaxation, while those from non-pregnant women and from women with pre-
eclampsia demonstrated modest constriction. The authors concluded that flow-
induced shear stress is part of the physiological stimulus to vasodilatation in 
normal pregnancy, and that failure of this vasodilatation can contribute to the 
hypertension which is seen in pre-eclampsia.  
 
1.3.5 Studies of arterial stiffness 
Normal pregnancy is associated with a number of changes to the maternal 
circulation, with an increase in heart rate and cardiac output and a 
corresponding reduction in vascular resistance and arterial blood pressure.  In 
contrast pre-eclampsia is characterised by an increase in vascular resistance and 
generalised vasoconstriction (91). The traditional measurement of peripheral 
blood pressure using sphygmomanometry means that much of the information 
contained in the shape of the arterial waveform is lost; it may be that 
assessment of central pressures and arterial stiffness can provide further 
information about risk of development of pre-eclampsia.  
1.3.5.1 Pulse wave analysis 
Although the arterial pulse waveform has been used as an assessment tool since 
the end of the 19th century, it is only more recently that technological advances 
have allowed detailed recording and analysis of the waveforms for clinical use. 
Applanation tonometry is one such technique that allows non-invasive 
assessment of the various components of the pulse wave, which is simple, 
validated, non-invasive and reproducible (92).  
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1.3.5.2 Physiology 
Left ventricular ejection pumps blood into the arterial tree, creating a pulse 
pressure wave that travels forward in the arterial system. Once the wave 
reaches areas of bifurcation or other areas of impedance mismatch, a retrograde 
(reflected) waveform is initiated (93). The shapes of the arterial pulse 
waveforms vary at different sites, related to both varying elastic qualities along 
the arterial tree and to wave reflection. The wave form at the proximal aorta is 
important since it is the blood pressure profile here rather than the peripheral 
blood pressure which determines left ventricular afterload and coronary artery 
blood flow. The contour and amplitude of the pressure waveform are influenced 
by large artery pulse wave velocity (PWV); with compliant arteries and slow 
PWV, reflected waves return to the central aorta in diastole, augmenting DBP 
and subsequently coronary blood flow. On the contrary when arteries are less 
compliant and PWV is faster, the reflected waves return earlier and augment 
central SBP, increasing left ventricular workload and compromising coronary 
blood flow (94). 
 
Figure 1-4 Typical arterial pulse waveform showing ejected wave and reflected wave 
 
Pulse wave analysis (PWA) recordings are generated from pulse pressure 
waveforms obtained with applanation tonometry. When recorded at the radial 
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artery the waveform is calibrated to the brachial BP (measured using an 
oscillometric machine).  The SphygmoCor software uses a generalised transfer 
function to derive central aortic waveforms from those acquired from the 
peripherally acquired arterial waveform.  
The characteristics of the transfer function generated by SphygmoCor are 
determined by the physical properties of the arterial system, such as arterial 
diameter, wall elasticity, wall thickness and the condition of the peripheral 
vascular beds. Not all brachial vasculature is identical in all adults, and it would 
be expected that there are differences in the overall transfer function among 
individual subjects. More recently, however, the transfer function has been 
validated under different conditions including age, disease, medication and state 
of vasodilatation (95), supporting its use in the generalised population. The 
transfer function has not, however, been validated for use in pregnancy. 
Millasseau and colleagues have previously suggested that similar information on 
central pressure wave reflection can be obtained directly from the radial pulse 
and radial AIx without use of a generalised transfer function, and so it may be 
that such generalised transfer functions are not necessary (96).  
From the generated central aortic waveform central blood pressure values and 
the augmentation index (AIx) can then be calculated. The AIx is the proportion 
of central PP that results from arterial reflection and is a commonly used 
measure of arterial stiffness. A typical central pressure wave is shown in figure 
1.5.  
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Figure 1-5. An aortic pulse waveform as produced by the SphygmoCor system from 
applanation tonometry of the radial artery. Augmentation pressure is the difference between 
the systolic peak (forward wave) and first systolic inflection (reflected wave) pressures. This 
difference divided by the pulse pressure generates the augmentation index, from Mills et al. 
(97) 
 
 
 
PWA is widely used as a measurement of arterial stiffness, although the use of a 
generalised transfer function for estimation of central pressures has led to some 
criticism of this technique (98). AIx is affected by changes in heart rate; an 
increase in heart rate shortens the duration of systole. As a result the reflected 
wave reaches the advancing wave in diastole rather than systole, resulting in 
reduced augmentation of the advancing wave and reduced AIx. Many PWA 
software systems therefore standardise AIx for a heart rate of 75 beats per 
minute (AIx75).  
 
1.3.5.3 PWA in cardiovascular disease 
Arterial stiffness is increasingly recognised as an important technique in the 
assessment of cardiovascular disease, since aortic stiffness and arterial pulse 
wave reflection are key determinants of central systolic and diastolic pressures 
55 
(98). In addition, arterial stiffness as assessed by PWA has been shown to be 
associated with multiple traditional risk factors for cardiovascular disease; both 
AIx and augmentation pressure (AP) are independent risk markers for premature 
coronary artery disease (99). In patients with end stage renal failure, AIx is a 
highly predicative indicator of cardiovascular mortality (100). As with the other 
vascular parameters derived using applanation tonometry, AIx is sensitive to 
modulations of NO bioactivity. Inhibition of basal NO synthesis, with intra-
arterial infusion of L-NG-monomethyl arginine (L-NMMA), has been shown to lead 
to a dose dependent increase in mean arterial pressure, peripheral vascular 
resistance, and both aortic and systemic arterial stiffness (101).  
As well as being used in the assessment of cardiovascular disease, the possibility 
of targeting arterial stiffness with therapeutic strategies has been a topic of 
recent interest. Increased arterial stiffness may be reversible; one study 
reported that smoking cessation is associated with an improvement in 
parameters of arterial stiffness, returning to levels found in non-smokers after 
10 years of cessation (102). The effect of different blood pressure agents on AIx 
has also been examined in a study in which 59 patients with untreated isolated 
arterial hypertension were randomised to receive either an angiotensin 
converting enzyme (ACE) inhibitor, a thiazide diuretic, a beta-blocker or a 
calcium channel blocker. Although all 4 drugs led to a similar reduction in blood 
pressure, beta blockers did not reduce pulse pressure. Only calcium channel 
blockers led to a reduction in AIx, while beta blockers appeared to have a 
deleterious effect (103).  
It may be, therefore, that PWA can aid in the stratification of patients with 
hypertension and cardiovascular disease; this potential was highlighted by the 
inclusion of PWA in the 2003 guidelines from the European Society of 
Hypertension (ESH) on the management of arterial hypertension (104). 
 
1.3.5.4 PWA in pre-eclampsia 
It is well established in the non pregnant population that arterial stiffness is 
associated with traditional risk factors for cardiovascular disease. Given that 
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pre-eclampsia and cardiovascular disease share a number of common 
mechanisms, several studies have examined the relationship between arterial 
stiffness and pre-eclampsia. In non-pregnant women, AIx decreases during the 
luteal phase of the menstrual cycle, and rises at the beginning of the menstrual 
cycle (105). AIx is lower in pregnant women compared to non-pregnant controls, 
and within pregnancy AIx decreases further, reaching its nadir at mid-pregnancy 
and rising towards term (106-108). This fall is thought to be related to NO-
mediated vasodilatation.  
Several studies have shown that, at term, women with pre-eclampsia have 
increased AIx, indicating increased arterial stiffness, compared to non-pregnant 
controls (91,109,110). Women with pre-eclampsia have a higher AIx compared to 
women with gestational hypertension without proteinuria, an increase that 
persists after correction for blood pressure (110). No difference has been 
reported between women with pre-eclampsia at term and those with pre-
eclampsia requiring preterm delivery (105), nor has a difference been reported 
between different ethnic groups studied (95).  
Although these studies may help our understanding of vascular haemodynamics 
in pre-eclampsia, in order to be a clinically useful test for its prediction these 
abnormalities would need to be detectable prior to the onset of clinical disease. 
Due in part to the rarity of pre-eclampsia, few longitudinal studies have been 
performed. One study examined PWA in 210 women with singleton pregnancies 
at gestational week 11-14, at the initial antenatal hospital “booking” visit. Of 
them, 14 (6.7%) developed pre-eclampsia and 196 remained normotensive 
throughout pregnancy.  AP and AIx75 were significantly elevated in the women 
who went on to develop pre-eclampsia compared to normotensive controls, 
while the 3 women who developed severe pre-eclampsia had a higher AIx75 than 
those with mild disease (95). For a false positive rate of 11%, pulse wave analysis 
predicted 79% of women who went on to develop pre-eclampsia and 88% of those 
who developed severe disease. The relatively high incidence of pre-eclampsia in 
the study cohort, and the low numbers of affected women mean that these 
findings may not be applicable to the general pregnant population; this area 
merits further research.  
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1.4 Screening tests for pre-eclampsia; biomarkers 
1.4.1 Angiogenic factors 
 
As research in the field of pre-eclampsia progresses, much of the attention in 
recent years has been focused on peptides related to angiogenesis. Angiogenesis, 
the development of new blood vessels from existing endothelium, is essential for 
normal placental development. Two of the angiogenic growth factors, vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF) are thought 
to contribute to normal trophoblastic proliferation and implantation (111), and 
it has been hypothesised that an imbalance in levels of these growth factors has 
a crucial role in pre-eclampsia. As normal pregnancy progresses, maternal VEGF 
expression is reduced (112), but placental levels of mRNA encoding VEGF have 
been shown to be much lower in women with pre-eclampsia compared to 
controls (113). Similarly, maternal plasma levels of PIGF have been reported to 
be significantly reduced in the second trimester in women who went on to 
develop pre-eclampsia compared to controls (114). The use of anti-VEGF 
antibodies for systemic treatment in cancer is associated with a dose dependant 
increase in rates of hypertension and proteinuria (115), which may further 
indicate the role of these factors in the development of pre-eclampsia. Many 
recent studies have therefore concentrated on factors which antagonise VEGF 
and PIGF, to assess their role in the development of pre-eclampsia. Two of the 
most extensively studied peptides, which are produced by the placenta, are 
soluble FMS-like tyrosine kinase (sFLT-1) and soluble endoglin.  
 
1.4.1.1 Soluble FMS-like Tyrosine Kinase  
Soluble FMS-like tyrosine kinase (also known as soluble VEGF receptor 1 or sFLT-
1) is a secreted splice variant of FLT-1. It binds to and neutralises the angiogenic 
actions of VEGF and PlGF (116), and is thought to be one of the key peptides 
involved in the development of pre-eclampsia. Maternal serum levels of sFLT-1 
have been shown to be elevated in women with pre-eclampsia compared to 
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normotensive controls (117-119), to correlate with disease severity (119), and to 
decrease markedly following delivery (117). It has also been reported that levels 
of sFLT-1 are increased in women during their first pregnancy (an important risk 
factor for development of pre-eclampsia) when compared to multiparous women 
(120). A series of studies by Maynard et al. (121) revealed that mRNA of sFLT-1 is 
up-regulated in the placenta of women with pre-eclampsia, leading to increased 
systemic levels. Furthermore, these authors demonstrated that when a 
recombinant adenovirus encoding sFLT-1 was injected into pregnant rats, 
hypertension and proteinuria, as well as glomerular endotheliosis, one of the 
typical pathological lesions seen in pre-eclampsia, were observed.  
Further evidence for the placental origin of the elevated sFLT-1 was provided by 
Staff et al. (122) Given that “delivery” includes both the foetus and the 
placenta, the group investigated whether foetal as well as maternal levels of 
sFLT-1 were elevated in pre-eclampsia. They found that although foetal levels of 
sFLT-1 (measured in cord blood) are elevated in pre-eclampsia, the maternal 
serum levels were 29-fold higher, and concluded that there was no substantial 
foetal contribution to the elevated circulating maternal sFLT-1 levels seen in 
pre-eclampsia. Further evidence for the role of sFLT-1 in pre-eclampsia is that 
levels have also been reported to be increased in women with pre-eclampsia 
superimposed upon systemic lupus erythematosis (123) and glomerulonephritis 
(124).   
1.4.1.2 sFLT-1 and smoking 
As discussed in section 1.2.5, smokers appear to be relatively protected against 
pre-eclampsia, and the reasons for this remain poorly understood. Smoking is 
associated with reduced levels of sFLT-1 in men and in non-pregnant women 
(125,126). It has been hypothesised, therefore, that reduced levels of sFLT-1 in 
smoking pregnant women would put them at lower risk of pre-eclampsia, since 
sFLT-1 is thought to be a key factor in the development of the condition. To 
examine this relationship Kamareinen et al. (127) compared third trimester 
plasma sFLT-1 levels and first trimester placental sFLT-1 levels (obtained at 
termination of pregnancy) between pregnant smokers and non-smokers; no 
significant differences between the two groups was found. 
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1.4.1.3 Effects of anti-hypertensives on sFLT-1 levels 
Another mechanism that has been proposed for altering placental production of 
sFLT-1 is through the use of anti-hypertensive agents. Carr et al. (128) examined 
whether anti-hypertensive therapy with the beta-blocker atenolol could affect 
sFLT-1 levels throughout pregnancy. In a longitudinal study, women who were at 
high risk for pre-eclampsia (defined by previous pre-eclampsia, obesity, mid-
trimester hypertension or chronic hypertension) and had high cardiac output as 
measured by Doppler studies were treated with atenolol, while women without 
risk factors and with normal cardiac output were defined as low-risk for pre-
eclampsia, and were not treated. The authors had previously reported that such 
treatment was associated with a reduction both in incidence of pre-eclampsia 
and in levels of the pro-inflammatory cytokine tumour necrosis factor alpha 
(TNFα) (129), and retrospectively examined sFLT-1 levels in the treatment and 
control groups. In keeping with the TNF-α levels, the authors reported that the 
rise in sFLT-1 with increased gestation was blunted in the treatment group when 
compared to controls. In addition, cardiac output and mean arterial pressure 
were reduced in those receiving atenolol. Potential limitations to this study 
were that it was not a randomised trial and there was neither a placebo nor an 
active control group. Further, given that there is no convincing evidence that 
continuing anti-hypertensive agents in pregnant women with chronic 
hypertension has any effect on incidence of pre-eclampsia (130), it is clear that 
further work is required in this area.  
 
1.4.1.4 Soluble Endoglin 
The other anti-angiogenic peptide implicated in the pathogenesis of pre-
eclampsia is soluble endoglin (sEng). Endoglin, a co-receptor for transforming 
growth factors β1 and β3 (131) is highly expressed on endothelial cell 
membranes and syncytiotrophoblasts. Mutations in the gene encoding Eng are 
the underlying cause of hereditary haemorrhagic telangiectasia, a genetic 
condition characterised by AV malformations, epistaxis and telangiectasiae 
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(116). In normal pregnancy, levels of sEng fall between the first and second 
trimesters but in women who go on to develop pre-eclampsia this reduction is 
blunted (132). Consistent with studies involving sFLT-1, it has also been 
demonstrated that levels of sEng are elevated in the serum of pregnant women 
with pre-eclampsia, correlate with disease severity and fall after delivery (116). 
A promising discovery in terms of predicting the condition was that levels of sEng 
are elevated several weeks before the development of clinical symptoms in 
women who developed pre-eclampsia; furthermore, in patients who developed 
pre-term pre-eclampsia the serum sEng levels are elevated (approximately 2-
fold) as early as gestational weeks 17-20 (133). These findings have led 
researchers to examine sFLT-1 and sENG levels in the first trimester in women 
who subsequently developed pre-eclampsia. Rana et al. (132) reported that 
levels of sEng and sFLT-1 were elevated in the serum of pre-eclamptic women at 
17-20 weeks’ gestation when compared to controls, but reported that the levels 
at 11-13 weeks were similar between cases and controls. Baumann et al. (134) in 
contrast reported elevated levels of both sEng and sFLT-1 in the first trimester 
in samples from gestational week 11 to 14.  
The molecular mechanisms regulating the release of sFLT-1 and sENG remain 
poorly understood. This is an important area of research, since mechanisms to 
block their release may help to delay or even prevent the onset of pre-
eclampsia, improving both maternal and foetal outcomes. It has previously been 
shown that trophoblastic cells produce VEGF, PIGF and sFLT-1. Li et al. (135) 
demonstrated that sFLT-1 production by trophoblastic cells was increased, while 
PIGF levels were decreased when the cells were exposed to hypoxic conditions.  
They also reported an increased level of lipid peroxidase production, a marker of 
oxidative stress, in these cells. This led them to propose that hypoxic placental 
conditions in the placenta and subsequent oxidative stress lead to alterations in 
trophoblastic production of VEGF, PIGF and sFLT-1.  
 
1.4.1.5 Haem Oxygenase pathway 
Further work in this area has explored the role of the haem oxygenase (HO) 
pathway. Haem oxygenase, an enzyme that catalyses the degradation of haem, 
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has 3 known isoforms: HO-1 is induced by a wide variety of stimulants known to 
be associated with oxidative stress, HO-2 responds to glucocorticoid stimuli, 
while HO-3 has little known enzymatic activity. Previous studies by Ahmed et al. 
(136) have shown that HO-1 is anti-inflammatory, and provides a defence against 
oxidative stress. Adenoviral over expression of HO-1 leads to reduced VEGF-
induced sFLT-1 production in endothelial cells, while inhibitors of HO-1 cause an 
increase in its production (136). 
The same group carried out further work examining the relationship between 
sFLT-1 and the HO pathway, in particular looking at the role of the cholesterol-
lowering HMG-CoA reductase inhibitors, more commonly known as statins. As 
well as their role in reducing cholesterol, statins have been shown to have anti-
inflammatory actions in conditions as diverse as rheumatoid arthritis (137) and 
kidney transplant rejection (138). When human umbilical vein endothelial cells 
(HUVECs) from women with pre-eclampsia were incubated with simvastatin, HO-
1 was upregulated while sFLT-1 release was reduced. When cells were incubated 
with the anti-oxidants vitamins C and E, there was no effect on sFLT-1 and sENG 
release. This finding was perhaps not surprising, since as discussed in section 
1.2.4 these vitamins do not appear to have any role in preventing pre-eclampsia. 
This work has led to the proposal that statins may have a role in the prevention 
of pre-eclampsia in high-risk women. Statins are contra-indicated in pregnancy 
because early studies revealed skeletal malformations in rat-foetuses exposed to 
large doses. A recent observational study however, did not find an increase in 
rates of congenital anomalies in women who took statins in the first trimester of 
pregnancy (139). The role of statins in pre-eclampsia prevention is the basis of 
an ongoing trial, “Statins to ameliorate early onset pre-eclampsia” or “STAMP.” 
This study, funded by the Medical Research Council and co-ordinated by the 
University of Birmingham, will recruit women with pre-eclampsia at between 24 
and 33 weeks’ gestation. Women will be randomised to pravastatin 40 mg or 
placebo, to be continued until delivery. The primary outcome will be maternal 
sFLT-1 levels at 48 hours post-randomisation, and secondary outcomes include a 
variety of maternal and foetal outcomes describing severity of disease. The trial 
aims to complete recruitment by December 2011.  
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1.4.1.6 HO-1 and carbon monoxide 
In addition to exogenous sources such as smoking and exhaust fumes, carbon 
monoxide (CO) is generated in cells by the catalytic breakdown of free haem by 
HO-1. CO and CO-releasing molecules have been reported to lower sFLT-1 and 
sENG production in both endothelial cells and placental organ cultures (136), 
which potentially provides a molecular explanation for the lower levels of sFLT-1 
and sENG noted in smokers during pregnancy. Additional observations that 
women with pre-eclampsia exhale more CO than those with normal pregnancies, 
and that HO-1 expression decreases as the severity of pre-eclampsia increases 
(140) lend weight to the argument that this pathway plays an important role in 
pre-eclampsia development.  
 
1.4.2 Uric acid 
Hyperuricaemia was first reported to be elevated in pre-eclampsia in 1917 (141), 
and it remains one of the most common blood tests used in assessment of the 
condition in clinical practice in the UK. Uric acid is a marker of oxidative stress, 
tissue injury and renal dysfunction, and several studies have reported a positive 
correlation between elevated maternal serum uric acid levels and adverse 
pregnancy outcomes (142). In view of this the National Heart, Lung and Blood 
Institute (NHLBI) in the United States recommend measurement of serum uric 
acid in high-risk women with normal blood pressure (143).    
A systematic review of the literature, however, examining 18 studies of 4000 
pregnant women, consistently observed poor performance of uric acid in 
predicting various maternal and foetal outcomes (142). Furthermore, a study 
designed to examine the impact of the uricosuric agent Probenacid  in lowering 
uric acid in 40 women with pre-eclampsia did not demonstrate any effect on 
maternal blood pressure, nor on any other foetal or maternal outcomes (141).  It 
therefore appears that while uric acid may be of value in the detection of pre-
eclampsia, it is not useful in the early prediction of disease.  
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1.4.3 Placental Protein 13  
Placental protein 13 (PP-13), a 32-kDa dimer protein highly expressed in the 
placenta, is involved in placental implantation and maternal vascular 
remodelling (144). During normal pregnancy levels of PP-13 gradually increase,  
but abnormally low levels of PP-13 have been reported at gestational weeks 11-
13 (145) and weeks 9-12 (146) in women who went on to develop pre-eclampsia 
and foetal growth restriction compared with controls. In women who 
subsequently developed pre-eclampsia, second and third trimester PP-13 levels 
have also been reported to be independently associated with intra-uterine 
growth restriction and preterm delivery (147).  
Combining maternal serum PP-13 levels with uterine artery Doppler studies early 
in pregnancy may further improve ability to predict more severe forms of pre-
eclampsia. Nicolaides et al. (144) reported that women who went on to develop 
early onset pre-eclampsia associated with preterm delivery had a higher median 
uterine artery pulsatility index and a lower median serum PP-13 in the first 
trimester when compared to controls. Thus they concluded that for a 90% 
detection rate of the condition, using serum PP-13 for all women and Doppler 
studies in the 14% at highest risk, a false-positive rate of 6% could be achieved.  
 
1.4.4 Pregnancy-Associated Plasma Protein A  
Pregnancy-Associated Plasma Protein A, (PAPP-A) is a large and highly 
glycosylated protein complex produced by the developing trophoblast (148), 
which is used in many centres as a marker for Down’s syndrome. It has been 
shown to be responsible for the cleavage of insulin-like growth factor (IGF) 
binding proteins, which are inhibitors of IGF action, in several biological fluids 
(149). PAPP-A was first reported to be altered in the plasma of pre-eclamptic 
women nearly 30 years ago (150). More recent studies have shown that although 
reduced first trimester serum levels of PAPP-A are associated with pre-
eclampsia, levels are also reduced in women with other pregnancy-related 
complications such as ante-partum haemorrhage and stillbirth (151-153). 
Further, it has been suggested that PAPP-A is more useful as a marker of foetal 
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growth restriction than of pre-eclampsia (154). Spencer et al. (155) described 
only a small increase in likelihood ratio of developing pre-eclampsia with 
decreasing levels of PAPP-A, and suggested that, similarly to PP-13, sensitivity 
could be improved by combining with uterine artery Doppler studies.  
 
 
1.4.5 Sex hormone binding globulin 
Insulin resistance has long been implicated in the pathogenesis of pre-eclampsia. 
Carbohydrate metabolism is known to be altered in women with pre-eclampsia, 
while fasting insulin levels have also been shown to be elevated prior to the 
onset of disease (156). Furthermore, as mentioned in section 1.1.3, type 1, type 
2 and gestational diabetes are all well-established risk factors for the condition 
(157). Normal pregnancy is characterised by increased insulin secretion by the 
pancreatic β cells, and, following initially increased insulin sensitivity, there 
follows a progressive increase in insulin resistance throughout the second and 
third trimesters (158).  
Sex-hormone binding globulin (SHBG) is a glycoprotein produced by the liver 
which binds circulating oestrogens and testosterone. Production of SHBG is 
inhibited by insulin; low levels of SHBG are associated with elevated insulin and 
as a result several studies have used low SHBG levels as a marker of insulin 
resistance in both cardiovascular disease (159) and in pre-eclampsia 
(156,157,160). One study looking at first trimester (mean gestation 10.6 weeks) 
SHBG levels in 45 nulliparous women who went on to develop pre-eclampsia 
found that levels were significantly reduced when compared with controls (157). 
In contrast, however, a further study looking at SHBG levels at gestational weeks 
10-14 in 103 women who went on to develop pre-eclampsia, 64 women who 
developed hypertension without proteinuria and 400 controls with normotensive 
pregnancies found no significant difference between cases and controls (156). 
This retrospective study included multiparous women, which may have 
confounded results. A further study reported no difference in SHBG levels at 
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either gestational weeks 17 or 33 between 29 women who went on to develop 
pre-eclampsia and 142 controls (160). 
 
1.4.6 Adiponectin 
Although obesity is associated with increased overall body fat, it is the 
distribution of body fat rather than its total amount which is the major 
determinant of morbidity related to obesity (161). Adipocytokines, derived from 
adipose tissue include adiponectin, leptin, and tumour-necrosis factor-α, and are 
produced preferentially by visceral rather than subcutaneous fat. Adiponectin 
levels are reduced in obesity, and its levels are inversely correlated with insulin 
resistance; high concentrations have been reported to be protective against the 
development of type 2 diabetes (162). Adiponectin is thought to have a 
protective role on the vasculature, by reducing levels of adhesion molecules 
such as ICAM-1, E-Selectin and VCAM-1 (161).  
Given the role of insulin resistance in the pathogenesis of pre-eclampsia it has 
been hypothesised that visceral fat accumulation during pregnancy may induce 
dysregulation of adipocytokines, contributing to the development of the 
condition. As a result adiponectin levels have been studied for their role in pre-
eclampsia prediction. D’Anna et al. (163) examined first trimester serum 
adiponectin levels in 36 women who subsequently developed pre-eclampsia, of 
whom 16 had early onset disease, and 36 controls. They found that levels were 
significantly lower in cases than in controls, and that levels were significantly 
different between those who developed early-onset and late-onset disease. 
Further studies have shown that adiponectin levels correlate negatively with BMI 
and with weight gained during pregnancy, and positively with flow-mediated 
dilatation (161). Further, serum levels of adiponectin have also been reported to 
correlate with sEng levels in women with established disease (164).  
In contrast, however, Ramsay et al. (165) found that serum adiponectin levels in 
the third trimester were in fact higher in women with pre-eclampsia compared 
with controls, a finding which has been confirmed elsewhere (166), and has led 
to speculation that adiponectin forms part of the physiological response to pre-
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eclampsia by improving insulin sensitivity later in pregnancy (166). The role of 
adipocytokines in disease prediction in pre-eclampsia therefore remains 
uncertain.  
1.4.7 Apolipoprotein E  
A further mechanism by which pre-eclampsia has been postulated to develop is 
via abnormal lipid metabolism associated with oxidative stress. Women with pre-
eclampsia have an abnormal lipid profile, with elevated concentrations of 
triglyceride-rich lipoproteins, which may contribute to endothelial dysfunction 
(167). Apolipoprotein E is a major constituent of very low-density lipoproteins 
(VLDLs) whose role involves modifying inflammatory responses, and removal of 
excess cholesterol from the circulation via regulation of hepatic uptake (168). 
The Apolipoprotein E (ApoE) gene on Chromosome 19 has 3 common isoforms, 
which translate into 3 alleles of the gene: e2, e3 and e4. ApoE e4 is associated 
with familial Alzheimer’s disease, whilst both e2 and e4 have been associated 
with abnormally high triglyceride and VLDL levels (169). It has been postulated 
that Apolipoprotein E levels and polymorphisms of its gene are associated with 
an increased risk of pre-eclampsia. Nagy et al. (170) found a higher incidence of 
ApoE e2 amongst women with pre-eclampsia at the time of disease diagnosis 
compared to controls. Makkonen et al. (171) studied 133 women with pre-
eclampsia, and in contrast found that none of the ApoE alleles were over 
represented when compared with controls, findings that have been confirmed 
elsewhere (168). Elevated Apolipoprotein E levels have been reported in a study 
of serum proteomic analysis in women with established pre-eclampsia, but not 
before the onset of clinical symptoms (172), and as such it seems unlikely to 
have a role in disease prediction.  
 
1.4.8 Inhibin A and Activin A  
Many studies have been reported using Inhibin A and Activin A as predictors of 
pre-eclampsia. Both are glycoproteins, are members of the transforming growth 
factor β family, and during pregnancy are largely released by the feto-placental 
subunit (173). Inhibin A has an important endocrine role in the negative 
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feedback of gonadotrophins, while Activin A is thought to have activity in various 
biological tissues. In normal pregnancy, concentrations of both hormones rise in 
the third trimester, and levels have been shown to be elevated approximately 
10-fold in women with severe pre-eclampsia compared to controls (174). Second 
trimester levels of Inhibin A have been reported to be elevated in both serum 
(175) and amniotic fluid (176) in women who went on to develop severe pre-
eclampsia, and when measured at term, serum levels have been shown to 
correlate with pre-eclampsia severity (177). In addition, urinary Activin A and 
Inhibin A levels have also been found to be elevated in women with pre-
eclampsia, as have uterine vein levels (178). 
Second trimester levels of both Inhibin A and Activin A have been reported to 
add significant prognostic information when measured in women with abnormal 
uterine artery Doppler studies (179). Davidson et al., (180) however, found that 
although second trimester levels of Activin A were elevated in women who went 
on to develop pre-eclampsia, Inhibin A levels were not different between cases 
and controls, findings confirmed by D’Anna et al. (181). Studies using first 
trimester Inhibin A (182) have also shown a low predictive value.  
 
1.4.9 Markers of inflammation 
As outlined in section 1.1.2, it is generally accepted that pre-eclampsia is a 
disease occurring in  2 main stages; the “placental stage” occurring as a result of 
a poorly-developed utero-placental blood supply, and the “maternal stage” 
which arises from a systemic maternal inflammatory response. Several markers 
of inflammation and the inflammatory cascade have therefore been studied in 
pre-eclampsia, both to explore their role in pathogenesis, and to examine 
whether they are useful predictors of disease.  
1.4.9.1 CRP 
C-reactive protein (CRP) is a marker of the acute phase of the systemic 
inflammatory response; levels are elevated within hours of detection of 
inflammatory stimuli. Several large prospective studies have reported that, 
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when measured by highly-sensitive assay, CRP is an independent predictor of 
future cardiovascular events (183) and of all-cause mortality (184). Normal 
pregnancy is characterised by a mild systemic inflammatory response, which 
begins during the luteal phase of the menstrual cycle before implantation, and 
develops as pregnancy progresses. In keeping with this, CRP levels have been 
reported to be elevated in normal human pregnancy from as early as 4 weeks’ 
gestation (185). 
 In pre-eclampsia a similar inflammatory response occurs, but is of far greater 
intensity. CRP in the third trimester is elevated in women with pre-eclampsia 
compared to those with normal pregnancies, and levels have been shown to 
correlate with disease severity (186). The potential role of CRP measurement in 
the early prediction of pre-eclampsia has been less well defined. For example, 
Garcia et al. (89) reported elevated levels at 22 weeks’ gestation in women who 
subsequently developed pre-eclampsia, while Teran et al. (187) reported no 
difference when levels were checked at gestational week 16. One possible 
explanation for this discrepancy is that CRP levels in pregnancy have been shown 
to vary between different racial groups, with higher levels in black women 
compared to Caucasian women (188).   
1.4.9.2 Adhesion Molecules 
As has been mentioned above, disruption of the vascular endothelium plays a 
key role in the development of pre-eclampsia. Adhesion molecules support the 
adherence of leucocytes to endothelial cells and the subsequent migration of 
leucocytes as part of the inflammatory response. Expression of these molecules 
on the endothelial surface is a tightly regulated process, and increased serum 
levels of adhesion molecules are thought to indicate the presence of endothelial 
dysfunction (189). Specific forms of adhesion molecules mediate specific steps of 
the leucocyte-endothelial cell interaction, and the concentration of each of 
these molecules is thought to reflect the degree of activation of a specific cell 
type. Elevations in P-selectin reflect platelet activation, elevations in E-Selectin, 
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-
1 (ICAM-1) reflect endothelial cell activation and changes in L-selectin are 
indicative of leucocyte activation (190). 
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Normal pregnancy is associated with alterations in adhesion molecule levels; 
elevation in P-Selectin, reduction in L-Selectin, and no change in E-Selectin, 
VCAM-1 or ICAM-1 have been reported compared to non-pregnant controls (190). 
Several studies have examined levels of adhesion molecules at delivery in 
women with pre-eclampsia; compared to normotensive controls, significant 
elevation in P-Selectin (189,190), E-Selectin, (189,190) VCAM-1 (189-192) and 
significant reduction in L-Selectin (190) have been reported. Further studies 
using placental biopsies have shown that spiral artery endothelial cells stain 
positive for ICAM-1 and VCAM-1, but that there is no difference in their levels 
between women with pre-eclampsia and normotensive controls (193).  
As with any other biomarker for pre-eclampsia, to be clinically useful elevated 
levels would have to be detectable prior to the onset of clinical disease. 
Chavarria et al. (194) examined pregnant women at 20 weeks’ gestation and 
reported elevated levels of E-Selectin, P-Selectin and ICAM-1, and lower levels 
of L-Selectin and VCAM-1 in women who subsequently developed pre-eclampsia. 
In a separate longitudinal study of 70 pregnant women of whom 20 later 
developed pre-eclampsia, P-Selectin levels were reported to be elevated as 
early as week 10-14 in affected women (195).  
Research in this field has been somewhat limited by inconsistent results, and by 
lack of comparison with non-pregnant controls. Although adhesion molecules are 
thought to have a role in the development of the endothelial dysfunction 
associated with the condition, none have been specific enough to be used 
routinely. An improved understanding of adhesion molecule levels in normal 
pregnancy is required before they can be considered as useful predictors of 
hypertensive disorders.  
1.4.9.3 Cytokines 
The failure of the uterine vasculature to remodel in early pregnancy and 
subsequent placental hypoperfusion is thought to lead to the generation of 
cytotoxic factors that circulate and injure the maternal circulation. Among these 
factors are inflammatory cytokines, upregulated by the placenta. In keeping 
with adhesion molecules, several of these cytokines have been studied for their 
role in the development of pre-eclampsia.  
70 
Interleukin 6 (IL 6) and tumour necrosis factor alpha (TNF α) have been shown in 
several studies to be elevated in women with pre-eclampsia when measured at 
delivery,(196,197) while elevated levels of Interleukin-10 (IL 10) have also been 
reported (198). Placental levels of these and other pro-inflammatory cytokines 
have not, however, been found to be different between pre-eclamptic women 
and women with normotensive deliveries, suggesting that tissues other than the 
placenta may contribute to their production (196). These findings are in keeping 
with the theory that there are separate placental and maternal responses 
underlying pre-eclampsia.  
 
1.4.10 Aldosterone 
Aldosterone, a mineralocorticoid synthesised from cholesterol in the zona 
glomerulosa of the adrenal cortex, has emerged in recent years as a key 
cardiovascular hormone. In addition to regulation of fluid and electrolyte 
balance and blood pressure, it is now known to exert its effects on a number of 
different non-adrenal sites including the heart and the central nervous system. 
Up to 15% of patients with essential hypertension have inappropriate regulation 
of aldosterone (199), and the hormone is thought to play an important role in 
determining cardiovascular risk.  
Aldosterone concentrations rise in the luteal phase of the menstrual cycle, and if 
conception occurs, its levels increase significantly (around 20-fold) throughout 
pregnancy towards term (200). Normal pregnancy is characterised by marked 
vasodilatation, and by an increase in extracellular and intracellular volume of 
around 6-7 litres (201) ; the increased aldosterone concentrations are thought to 
facilitate this volume expansion, ensuring adequate utero-placental perfusion. 
Much of the increased mineralocorticoid activity in pregnancy is related to 
increased production of deoxycorticosterone (DOC), produced from 
progesterone. Levels of the glucocorticoid cortisol are also markedly increased 
throughout normal pregnancy. The developing placenta is protected from high 
levels of cortisol, however, by the enzyme 11-β-hydroxysteroid dehydrogenase 
type 2 (11- βHSD-2), which converts cortisol into the inactive cortisone. As a 
result cortisol is virtually absent in normal placentas (200).   
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In pre-eclampsia, the balance of cortisol and aldosterone regulation is altered; 
11- βHSD-2 activity is reduced, and as a result trophoblasts are exposed to 
increased concentrations of cortisol. Aldosterone levels are also substantially 
reduced in pre-eclampsia, and this reduction is paralleled by a reduction in 
plasma volume expansion and placental growth (202).   
Given the key role that cortisol and aldosterone play in blood pressure regulation 
in the non-pregnant population, these findings have led to the suggestion that 
genetic variations in their production may contribute to the development of pre-
eclampsia. Shojaati et al. (202) reported in 2004 that some women with pre-
eclampsia carry genetic mutations that lead to decreased activity of aldosterone 
synthase (CYP11B2), resulting in elevated levels of aldosterone precursors but 
reduced and inefficient production of aldosterone itself. Supporting this theory, 
increased aldosterone concentrations, measured as urine tetra-aldosterone 
excretion, are associated with lower maternal blood pressure in pregnancy and 
with larger, healthier neonates (203). Further work has shown that aldosterone 
increases proliferation of cultured human trophoblasts, an effect reversed in 
animal studies by the aldosterone antagonist spironolactone and by high-dose 
glucocorticoids (200).  
This work suggests therefore that uncompromised aldosterone production can 
contribute to an uneventful pregnancy outcome. Diminished aldosterone 
production, due to genetic variations in the CYP11B2 gene, or for other reasons, 
in the face of increased progesterone availability may therefore reduce the 
compensatory potential for shifts in circulating volume. The practical 
consequences of these findings are unclear; tailored follow up during pregnancy 
based upon CYP11B2 genotype could be one possibility. Given its role in essential 
hypertension, aldosterone may also help to explain the increased cardiovascular 
risk seen in women with a history of pre-eclampsia.  
 
1.5 Genetic influences 
There are clearly genetic factors involved in the development of pre-eclampsia. 
As discussed in section 1.1.3, women with a family history of pre-eclampsia in 
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their mother or sister are at nearly 3 times higher risk of development of the 
condition compared to those without a family history (12); the role of paternal 
genes remains uncertain. A Swedish study examining over 700,000 pregnancies 
from 240,000 sibling pairs reported a 35 % contribution of maternal genes to the 
risk of development of pre-eclampsia. The foetal genes, with similar 
contribution of genetic effects from both parents, were responsible for 20% of 
the risk (204). In a further Swedish family study in which 2.8% of women studied 
were affected by pre-eclampsia, odds ratios of 3.3 (95% CI 3.0-3.6) for sisters 
and 2.6 (95% CI 1.6-4.3) for daughters of those affected were reported, 
compared to odds ratios of 1.4 (95% CI 0.9-2.2) for maternal half-sisters and 1.0 
(95% CI 0.6 to 1.6) for paternal half-sisters of those affected. Full sisters of 
women with pre-eclampsia were also reported to be at increased risk of 
pregnancy-induced hypertension without proteinuria, with a reported odds ratio 
of 2.5 (95% CI 2.2 to 2.8) (205).   
From these and other epidemiological studies there is clearly evidence of a 
genetic component to the development of pre-eclampsia, and several modes of 
inheritance have been suggested. One of the problems with research in this 
field, however, is the rarity of the condition. The magnitude of genetic influence 
in disease is often assessed using twin studies; the rarity of pre-eclampsia has 
meant that very few twin studies have been possible. The Swedish group did 
report on 928 monozygotic twin pairs, reporting a substantial increase in risk of 
pre-eclampsia (odds ratio 33.6, 95% CI 7.8 to 145) in the identical twins of those 
affected (205). 
Several candidate genes have been proposed as having a role. Genes encoding 
elements of the renin-angiotensin system, inherited thrombophilias, synthesis of 
the vasorelaxant endothelial nitric oxide synthase (eNOS) and tumour necrosis 
factor alpha (TNFα) have featured amongst the most common genes studied 
(206). Linkage studies examining the genetic contribution to pre-eclampsia have 
mainly implicated loci on Chromosome 2 (207-209), although loci on 
Chromosomes 4, 7,9 and 10 have also been studied (206,210-213). The majority 
of studies, however, have examined different populations and have had 
inconsistent results.  
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The Genetics of Pre-eclampsia (GOPEC) consortium attempted to further 
elucidate the role of genetic influences in pre-eclampsia. Seven candidate genes 
which had previously been reported as conferring susceptibility to pre-eclampsia 
were extensively studied in over six-hundred Caucasian women with strictly 
defined pre-eclampsia. These women and their families were genotyped at 28 
single-nucleotide polymorphisms (SNPs): none of the SNPs or haplotypes 
achieved statistical significance (214). It is hoped that more recent advances in 
genotyping technology will facilitate genome-wide association studies (GWAS) in 
pre-eclampsia which may result in novel candidate genes for the disorder. 
Results from studies into other polygenic disorders such as coronary artery 
disease and diabetes have been promising (Wellcome Trust Case Control 
Consortium (WTCCC) 2007)(215), and pre-eclampsia is being investigated as part 
of the latest phase of the consortium’s studies (WTCCC 3). It is clear, however, 
that investigators have to follow strict rules to avoid false positive and 
underpowered negative results (216).  
 
1.6 Proteomics 
1.6.1 Introduction 
Proteomics is the study of the proteome, the protein complement of the 
genome. The terms “proteome” and “proteomics” were coined in the mid-1990s 
to mirror the terms “genome” and “genomics,” which describe the entire 
collection of genes in an organism.  
Proteomics is defined as the “knowledge of the structure, function and 
expression of all proteins in the biochemical or biological contexts of all 
organisms” (217), and has emerged in recent years as an important tool for early 
detection of disease. Traditional definitions of disease usually rely on 
description of the observed symptoms and signs, often without full 
understanding of the pathophysiology underlying the disease process. For 
complex conditions such as pre-eclampsia and other cardiovascular diseases, the 
use of single “markers” to diagnose, stage and assess prognosis of disease is 
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perhaps unrealistic. The majority of previous pre-eclampsia research has been 
driven by pathways that are known to be involved in the development of the 
condition, and one advantage of proteomics-based research is that many of 
these mechanisms can be integrated, developing a “multimarker” approach. In 
addition, since proteomics is a “hypothesis-generating” research tool, it is likely 
that this line of investigation will open new avenues for potential biomarker 
discovery, and for new diagnostic and preventative measures. 
Recent technological advances have allowed for a shift towards multi-parametric 
“omic” based approaches for biomarker discovery. All classes of biological 
compounds can be studied; genes (genomics), mRNA (transcriptomics), proteins 
(proteomics) and metabolites (metabolomics) are all important areas of 
research.  
The human genome contains around 20,000 genes; each gene can be subject to 
differential splicing, translation and post-translational modification. As a result 
each gene can code for at least 10 times as many proteins, all of which can 
determine different cellular functions. It can be said, therefore, that while 
genomics explains one’s disposition to disease, proteomics gives a more accurate 
reflection of proteins expressed and therefore of exact disease processes at the 
time of study (218).  
 
1.6.2 Choice of sample type 
Clinical proteomic research can be carried out using any type of human tissue, 
bodily fluid or cultured cells. Samples of tissue are the optimal way in which to 
detect pathological changes, but large scale studies of human tissue will always 
be limited by the invasive measures necessary to obtain them. Bodily fluids such 
as blood, cerebrospinal fluid (CSF), ejaculate and urine have all been used for 
proteomic research; substances in bodily fluids contain a huge amount of 
information that can be used to monitor the well-being of an organism.   
Polypeptides in all bodily fluids are prone to proteolytic degradation; for 
example peptides in human serum have been shown to be exposed to high 
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proteolytic activity immediately upon clotting (219).  For that reason the Human 
Proteome Consortium (HUPO) recommend the use of plasma rather than serum 
for proteomic analysis (220). Although proteolytic activity in plasma is 
significantly less than serum, there is still sufficient activity to render accurate 
proteomic analysis difficult.  
Urine may represent a more stable platform for proteomic research. As well as 
being available non-invasively in large volumes, the lack of proteolytic activity 
means that urine peptides are stable enough for accurate proteomic analysis. 
Urine contains a rich source of information relating to the function of several 
internal organs. The peptide composition of the urine depends on a number of 
factors: glomerular filtration, absorption in the proximal tubules and lysosomal 
proteolytic activity at the brush border. Peptides present in the urine may 
therefore provide a signature for particular pathological processes (221).  
Urine can be stored for several years at -20°C without significant alterations in 
the proteome (222). Further studies have shown that the urine proteome does 
not undergo significant changes when stored for 3 days at 4°C or for 6 hours at 
room temperature (223).  
One of the key considerations with proteomic research of bodily fluids is sample 
preparation. The presence of compounds such as albumin in urine, or lipids and 
carbohydrates in blood can cause bias and artefact in proteomic results. A key 
element of proteomic research is minimising variability in sample collection, 
preparation and analysis. For the purpose of this study a number of steps were 
used to minimise variability, and are outlined in Chapter 2.  
 
1.6.3 Different proteomic platforms  
Several different platforms for proteomic analysis have been developed over the 
last few decades, which will be briefly described in the following paragraphs.  
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1.6.3.1 2-dimensional gel electrophoresis 
Two-dimensional gel electrophoresis (2-DE) separates proteins on 2 dimensions, 
their isoelectric point and molecular mass. Proteins are then treated with a 
proteolytic in-gel digest, the gel is extracted and mass spectrometry (MS) is used 
to analyse the resultant peptide fragments. 2-DE provides high resolution protein 
separation and identification, and is most useful for comparative analysis of 
proteins. Since 2-DE is not an automated process, a potential drawback is that it 
is too time-consuming for analysis of large numbers of proteins simultaneously.   
1.6.3.2 Liquid Chromatography – Mass Spectrometry 
Liquid chromatography (LC) is a powerful method of fractionation, which 
separates large numbers of analytes on an LC column with high sensitivity. For 
further analysis, sequential separation using different matrices can be 
performed in independent steps, generating large amounts of information. The 
main limitation of LC-MS is the length of time (days) taken for analysis of a 
single sample. In addition, large proteins (>10 kD) have to be cleaved by a 
protease before analysis.  
When data from tryptic digests were analysed using both 2-DE and LC-MS, 
different proteins were detected by the 2 techniques (223). Both techniques, 
either independently or together can therefore analyse proteins with high 
sensitivity, but neither is suitable for the comparative analysis of large numbers 
of samples.  
1.6.3.3 SELDI-Mass Spectrometry 
Surface-enhanced laser desorption / ionisation (SELDI) uses different hydrophilic 
surfaces to selectively adsorb proteins while the unbound proteins are washed 
away. A matrix is then added to the surface which crystallises with the sample 
peptides. Binding to the matrix surface separates the proteins making 
subsequent MS analysis less complex. The aim of SELDI is to bind a small but 
well-defined fraction of proteins to the surface, depending on the pH, 
concentration and salt content. SELDI has the capacity to analyse multiple 
samples in a short time, but reproducibility of peptide binding (and therefore 
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subsequent MS analysis) appears to be low (218). Further, since much of the 
biological sample is eliminated during preparation, comparing data sets for 
different samples is limited.  
1.6.3.4 Capillary Electrophoresis – Mass Spectrometry  
Capillary electrophoresis separates proteins in a single step based on their 
migration through a buffer-filled capillary. The separated proteins are delivered 
from the end of the capillary into a mass-spectrometer in a small stream of 
liquid by nano-ion spray. CE-MS has the advantage over other techniques that it 
provides fast separation with high resolution, it uses inexpensive capillaries 
instead of expensive LC columns and it is compatible with the majority of 
buffers and analytes. CE-MS enables the generation of comparable high-
resolution data sets, allowing the rapid analysis of large numbers of biological 
samples. As with LC, a drawback of CE is that it is not ideally suited for the 
analysis of large proteins, which are removed with ultrafiltration prior to CE-MS 
analysis.   
1.6.4 Clinical applications for urinary proteomics 
1.6.4.1 Kidney disease 
Identification of patients with chronic kidney disease (CKD) at an early disease 
stage, and early diagnosis of specific kidney diseases without requirement for 
renal biopsy is one area of clinical research in which urine proteomics may have 
an important role. To date proteomic studies have determined disease-specific 
urine peptide patterns for IgA-associated nephropathy (224), ureteropelvic 
junction obstruction (225) and ANCA-associated vasculitis (226).  
Peptide patterns specific to diabetic nephropathy have also been described, 
which can predict the development of diabetic nephropathy before 
microalbuminaemia can be detected (227). As well as early detection of renal 
changes, urine proteomics may also be a useful way to monitor treatment of 
diabetic renal disease; one study showed that treatment of macroalbuminuric 
diabetic patients with the angiotensin-receptor blocker candesartan for 2 
months led to significant changes in the urine proteome (228). 
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1.6.4.2 Coronary artery disease 
Current methods for detection of significant coronary artery disease (CAD) rely 
almost entirely on coronary angiography, an invasive procedure which is 
associated with a risk of bleeding, coronary artery perforation and stroke. Non-
invasive detection of CAD is therefore a further area studied in the context of 
proteomics. Using CE-MS technology, Zimmerli et al. (221) reported a set of 15 
urine peptides that defined a characteristic CAD signature panel, which had a 
sensitivity of 98% (95% CI 88.7-99.6) and a specificity of 83% (95% CI 51.6-97.4). 
This study used patients with severe CAD on coronary angiography, comparing 
them with controls recruited from a health club with no symptoms suggestive of 
CAD or other vascular disease. In a further study which reflected the “real-life” 
situation faced by clinicians, urine and plasma proteomics of patients with acute 
chest pain and cardiovascular risk factors were examined; all patients 
subsequently underwent coronary angiography to confirm or exclude significant 
coronary artery disease. Using a combination of 17 peptides the authors reported 
a sensitivity for diagnosing CAD of 81% (95% CI 60-93) and a specificity of 92% 
(95% CI 62-99) (229). The majority of urinary peptides associated with CAD 
originated from collagen, reflecting its central role in the pathophysiology of 
atherosclerosis. Plasma proteomics did not accurately discriminate between 
patients with CAD and those without, perhaps related to latent protease activity 
in plasma (219). Further evidence for the dynamic nature of the proteomic 
patterns associated with coronary disease is that treatment with the angiotensin 
receptor-blocker irbesartan can lead to significant changes in the pattern, with 
many peptides changing towards levels seen in the healthy proteomic signature 
(230).  
 
1.6.4.3 Other conditions 
Improvements in the early detection of cancers are a further vitally important 
area of medical research. The majority of studies using urinary proteomics to 
improve early detection of malignancies have focused unsurprisingly on the renal 
tract;  disease specific urine peptide profiles have been reported for bladder 
cancer, renal cancer and for differentiation between prostate cancer and benign 
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prostatic hyperplasia (226). Given that peptides in the urine reflect the protein 
constituents of the plasma, diseases distal to the renal tract may also be 
identifiable in the urine proteome. For example, urinary proteomic biomarkers 
for bowel cancer (231), lung cancer (232) and graft-versus-host disease after 
bone marrow transplantation have all been described (233). 
 
1.7 Proteomics studies in pre-eclampsia 
1.7.1 Gel electrophoresis studies 
1.7.1.1 Serum studies 
While the field of proteomics research in renal disease is fairly well established, 
there have been few studies in reproductive medicine. An early study by 
Watanabe et al. (234) used 2-dimensional gel electrophoresis to examine 
maternal serum from 6 patients with established pre-eclampsia associated with 
foetal growth restriction, and 6 matched women with normal pregnancies. Over-
expressed spots on 2-D GE were then identified using MALDI-TOF mass 
spectrometry, Western blot analysis and searches of a protein database. Using 
these techniques pre-eclamptic women were found to over-express clusterin, a 
protein which induces cholesterol efflux from lipid laden macrophages and is 
associated with vascular disease, renal disease and oxidative stress. The group 
then validated the finding in 80 pre-eclamptic women, and found that clusterin 
levels were significantly higher (1.62 ± 0.46 vs 1.30 ± 0.46 times the reference 
level) than in 80 matched women with normal pregnancies.  
1.7.1.2 Plasma studies 
A further study using 2-D GE techniques for protein separation was reported by 
Wang et al. (235) who examined plasma in 11 women with pre-eclampsia and 11 
controls. Using mass spectrometry to identify peptides, they were able to 
demonstrate a significant reduction in pre-eclamptic women in H-ficolin and L-
ficolin, factors thought to play a role in innate immunity. These findings were 
then validated in plasma samples from a separate cohort of 20 patients. 
80 
Although these studies potentially introduce new pathways for pre-eclampsia 
research, they highlight some of the limitations in pre-eclampsia research to 
date; samples were taken at time of disease rather than before it, and sample 
numbers were small.  
A more recent study used differential gel eletrophoresis (DIGE)  to examine the 
plasma proteome at 20 weeks’ gestation in a cohort of 27 women who went on 
to develop pre-eclampsia with appropriately grown babies, 12 who developed 
pre-eclampsia in association with foetal growth restriction and 57 controls who 
had normal pregnancies (236). Protein spots of interest were then identified 
with liquid-chromatography / mass spectrometry (LC-MS). The authors found 
that 36 moderate to high-abundance proteins were differentially expressed in 
pre-eclamptic women at 20 weeks, prior to the onset of clinical disease. The 
proteins identified are involved in lipid metabolism, the complement cascade, 
inflammation and haem scavenging, all mechanisms thought to be involved in 
pre-eclampsia. Of interest, 18 of the proteins identified overlapped with those 
identified in a previous study reporting the role of HDL cholesterol in 
cardiovascular disease. The authors also reported elevated levels of ApoA-1, the 
predominant lipoprotein in HDL cholesterol, clusterin and fibrinogen. As well as 
being a large, clinically useful study, these findings also provide an interesting 
insight into the link between pre-eclampsia and cardiovascular disease later in 
life.  
1.7.1.3 Placenta studies 
The placenta is thought to be the source of many of the circulating factors which 
cause maternal endothelial damage in pre-eclampsia. Placental tissue can be 
easily obtained at delivery, and as a result placental tissue has been used in 
proteomic studies to elucidate further information about the condition. In a 
relatively small study with 5 affected women, 2-dimensional gel electrophoresis 
(2D-GE) was used to generate biomarker patterns that characterised pre-
eclampsia, and peptides were identified using TOF mass spectrometry. Pre-
eclampsia was associated with elevated levels of Apolipoprotein A1, Interleukin-
8 and altered expression of coagulation factors and anti-oxidants.  
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1.7.2 LC-MS studies 
1.7.2.1 Plasma studies 
As discussed in section 1.6.3, gel-free techniques for proteomic analysis such as 
LC-MS have the advantage over gel electrophoresis that they are less labour 
intensive, and several samples can be analysed simultaneously. A recent proof of 
concept study described the use of iTRAQ (isobaric tagging for relative and 
absolute quantification) in association with LC-MS for proteome analysis. 
Blankley et al. (237) examined 23 women with pre-eclampsia at the time of 
disease, and 23 gestation matched controls. In the pre-eclamptic women 
elevated levels of several peptides were reported, including PAPP-A, SHBG, 
endoglin and pregnancy-specific β-1 glycoprotein, all of which have featured in 
previous pre-eclampsia research (237). Although these findings are encouraging, 
it is clear that demonstrating elevations of these and other peptides prior to 
disease onset would be far more clinically useful.  
1.7.3 SELDI-TOF studies 
1.7.3.1 Urine studies 
Since renal pathology is a hallmark of pre-eclampsia, and since the level of 
proteinuria is often related to disease severity, it may be that proteomic 
analysis of the urine will help point to novel mechanisms in this area of 
research.  
To date only one study has been published using urinary proteomics in pre-
eclampsia research. Buhimschi et al. (238) studied urine from 284 women, of 
whom 29 had mild pre-eclampsia, 31 had severe pre-eclampsia and 28 had pre-
eclampsia superimposed on chronic hypertension. Urine samples were taken at 
the time of disease onset; proteomic profiles for pre-eclampsia were generated 
using surface-enhanced laser desorption / ionisation, and peptides were then 
identified using tandem mass spectrometry. The proteomic profile for pre-
eclampsia was then validated in a separate cohort of 225 pregnant women, and 
was compared with other markers of disease severity including sFLT-1 : PIGF 
ratio and albumin : creatinine ratio. 
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The proteomic signature profile for pre-eclampsia was largely characterised by 
fragments of serpin peptidase inhibitor (SERPINA) 1 and albumin. SERPINA1 is an 
abundant plasma protein, which has a role in the inhibition of neutrophil 
elastase, trypsin and pancreatic elastase. Elevated SERPINA1 levels were shown 
to be most strongly associated with severe pre-eclampsia requiring early 
delivery; furthermore placental levels were also found to be elevated in women 
with pre-eclampsia compared to those of women with normal deliveries. This 
work therefore demonstrated that a urine proteomic “fingerprint” made up of 
SERPINA1 and albumin fragments can diagnose pre-eclampsia, and can 
differentiate severe forms of the disease from milder variants. As well as being a 
potential biomarker it may be that fragments of SERPINA1 have a role in the 
pathogenesis of pre-eclampsia. Future studies with larger numbers of pre-
eclamptic women followed longitudinally throughout pregnancy are clearly 
required to determine whether this is a clinically useful biomarker.  
One factor relating to urinary proteomics is that whole proteins do not generally 
pass unfiltered into the urine, and that it is only peptides that can be detected. 
Identification of the parent proteins requires further mass-spectrometry based 
sequencing techniques.  
1.7.3.2 Plasma studies 
SELDI-TOF mass spectrometry has also been used to identify plasma biomarkers 
for pre-eclampsia. In a pilot study, Myers et al. (239) identified 26 women at 18-
20 weeks’ gestation as being high risk based on uterine artery Doppler studies. 
Plasma was taken at 26 weeks’ gestation; protein profiles were examined using 
Ciphergen protein chip technology, which uses SELDI-TOF mass spectrometry to 
detect protein binding to a biochip array. 18 of the women subsequently 
developed pre-eclampsia and 8 had a normal pregnancy outcome; 5 proteins 
were found to be significantly elevated in the affected women, although the 
technology did not facilitate identification of the proteins. 
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1.7.3.3 Amniotic fluid studies 
Another bodily fluid that has been studied in reproductive proteomic research is 
amniotic fluid. Amniotic fluid, sampled using amniocentesis, is used in certain 
circumstances to obtain information about fetal genetic health. One study used 
SELDI-TOF mass spectrometry to examine the amniotic fluid proteome in 18 
women with pre-eclampsia, 7 with chronic hypertension, and 16 women with 
normotensive pregnancies (240). Amniotic fluid samples were taken either at the 
time of Caesarean section, or were taken during clinically indicated 
amniocentesis. Two discriminatory proteomic peaks were identified; one which 
differentiated women with pre-eclampsia and chronic hypertension from 
controls was identified as proapolipoprotein A-1, a prohormone for 
apolipoprotein A-1. The other, which differentiated women with pre-eclampsia 
from normotensive controls, was a peptide of unknown functionality called 
SBB142. Given that polymorphisms of the apolipoprotein E gene have been 
postulated to cause pre-eclampsia (241), it is of interest that a further member 
of the apolipoprotein family was identified in this study as being associated with 
pre-eclampsia. The invasive nature of amniocentesis, however, and the 
associated risk of miscarriage, mean that this technique is not feasible for large 
scale studies.    
 
1.7.3.4 Cerebrospinal fluid 
Neurological complications such as seizures (eclampsia), headaches and stroke 
are associated with severe variants of pre-eclampsia; the aetiology of the 
neurological manifestations remains unclear. To further examine this, Norwitz et 
al. (242) examined the cerebrospinal fluid (CSF) in 7 women with severe pre-
eclampsia, 8 with mild pre-eclampsia and 7 normotensive controls. CSF, which 
was obtained at the time of spinal anaesthesia prior to delivery, was analysed 
using SELDI-TOF mass spectrometry, while gel digests, Western blot analysis and 
immunoassays were used to identify the protein biomarkers. Total CSF protein 
and leucocyte concentrations were not different between the 3 groups, but a 
protein profile made up of α- and β- chains of haemoglobin distinguished severe 
pre-eclampsia from mild disease and normal controls. In addition women with 
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severe pre-eclampsia were found to have nanomolar amounts of free 
haemoglobin in the CSF, as measured by spectrophotometry. The authors 
speculated that the free haemoglobin in the CSF may act not just as a marker 
for pre-eclampsia, but may also contribute to the neurological manifestations 
commonly seen in these women.  
 
1.8 Metabolomics 
In complement to studies examining the human genome and proteome, 
metabolomics, the study of the human metabolome has emerged as a further 
important research tool in recent years. The low molecular weight chemicals 
(metabolites) studied are the final downstream product of gene expression, and 
have been described as the “the unique chemical fingerprints that specific 
cellular processes leave behind” (243). 
 In common with proteomics, studies of the human metabolome can be carried 
out on routine samples of urine, plasma or serum and require minimal specialist 
preparation of samples. Metabolomics (also referred to as metanomics or 
metabonomics) has been used to characterise signature chemical profiles for 
cardiovascular disease (244), for Alzheimer’s disease (245), and for hypertension 
(246).  
Initial studies using plasma from women with established pre-eclampsia 
identified 8 metabolic peaks that were elevated in women with pre-eclampsia, 
which were then validated in a separate cohort of women and identified using 
mass spectrometry (247).  Among the metabolites identified were uric acid, a 
marker which is used clinically to assess severity of disease, and 2-oxoglutarate, 
a marker for oxidative stress. 
A more recent study using metabolomics was reported using plasma samples 
from the “Screening for Pregnancy Endpoints” (SCOPE) study cohort (248). In this 
prospective international study, nulliparous women with no history of 
hypertension, renal disease or diabetes were recruited at gestational week 14-
16. In a nested case control design, samples from 60 cases and controls were 
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analysed in a “discovery” phase, and samples from 39 cases and 40 controls were 
analysed in a “validation” phase. Using ultra-performance liquid 
chromatography-mass spectrometry (UPLC-MS), 45 unique metabolic “peaks” for 
pre-eclampsia were identified, of which 14 were used to generate a multivariate 
predictive model, with an area under the receiver operator characteristics curve 
(AUC) of 0.94. The 45 molecules came from 11 clear metabolite classes, 
including fatty acids, lipids, steroids, pophyrins and phospholipids. The 14-
metabolite model was reported by the authors to compare favourably with other 
studies using anti-angiogenic peptides, and ongoing studies from the same group 
will attempt to validate the findings in different ethnic populations. Other 
metabolomic studies in pre-eclampsia have been confined to studies of placental 
tissue from women with established pre-eclampsia (249), but in keeping with 
proteomics these studies may help to explain some of the underlying 
mechanisms in this disease.  
 
1.9 Pre-eclampsia and future maternal health  
 
Evidence has mounted in recent years that pre-eclampsia is not just a disease of 
pregnancy, but that the condition has important implications for future maternal 
health, in particular cardiovascular health. Pre-eclampsia and cardiovascular 
disease share many risk factors such as diabetes, obesity and underlying 
hypertension. In addition several proposed pathological mechanisms such as 
oxidative stress, endothelial dysfunction and insulin resistance are common to 
both conditions (figure 1.6). It is not known, however, whether pre-eclampsia 
itself, or underlying maternal genetic and pathophysiological risk factors, or a 
combination of both contribute to future cardiovascular disease. In this section 
the evidence for the long-term implications of pre-eclampsia, the evidence for 
the causes of it, and potential future areas of research will be discussed.   
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Figure 1.6. From Carty et al. (250) 
 
1.9.1 Epidemiological data 
A link between pre-eclampsia and future maternal hypertension was first 
suggested 50 years ago (251), but it has not been generally accepted until fairly 
recently that pre-eclampsia had long term implications for maternal health. As 
has been mentioned in section 1.1, different diagnostic criteria for pre-
eclampsia are used worldwide, making accurate comparison of epidemiological 
studies difficult. Further, there can be huge variation in onset, severity and 
duration of disease.  
Despite these obstacles, the linkage of birth records with registers of morbidity 
and hospitalisation has allowed several recent studies to examine the 
relationship between pre-eclampsia and future maternal health.  In a systematic 
review of the literature and meta-analysis, Bellamy et al. (252) examined the 
relationship between pre-eclampsia, cardiovascular diseases and cancer. When 
women with previous pre-eclampsia were compared with women who had not 
developed the condition, relative risks (95% confidence intervals (CI)) of 3.70 
(2.70 to 5.05)  for hypertension, 2.16 (1.86 to 2.52) for ischaemic heart disease, 
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and 1.81 (1.45 to 2.27) for stroke were reported, with follow-up of 14 yrs, 11 yrs 
and 10 yrs, respectively. There was no difference seen in rates of breast cancer, 
or of cancers in general, between those with and without previous pre-
eclampsia. In several of the studies analysed, the risk of future cardiovascular 
disease appeared to relate to disease severity. For example, one study found 
that women with previous pre-eclampsia associated with preterm delivery and 
low birth-weight babies had a 7 fold increase (95% CI 3.3 to 14.5) in death or 
hospitalisation from ischaemic heart disease at 15-19 years follow-up. Preterm 
delivery, independent of other co-morbidities, was associated with a 1.8 fold 
(95% CI 1.3 to 2.5) increase in risk of future ischaemic heart disease (7). 
Studies in recent years have also examined the relationship between pre-
eclampsia and future maternal renal disease.  It has previously been shown that 
women have an increased incidence of microalbuminuria, a potential marker of 
both renal damage and cardiovascular disease, when examined 3-5 years after a 
pre-eclamptic pregnancy (253). This would appear to suggest either that these 
women have underlying previously unrecognised renal disease, or that pre-
eclampsia has had an adverse effect on the future kidney function.  
In a Norwegian study, researchers used birth registers and renal registers to 
examine the relationship between pre-eclampsia and future end-stage renal 
disease (ESRD)(254). The group had previously shown that, compared with 
women with normal deliveries of babies of birth-weight >2.5kg, women with a 
history of pre-eclampsia in the first pregnancy have an increased risk of 
requiring kidney biopsy (for either proteinuria >1g / 24 hrs or serum creatinine 
>150 µmol/L with suspicion of renal parenchymal disease) in future life (255). In 
a study examining over 550,000 women who delivered between 1967 and 1991, 
women with previous pre-eclampsia in their first pregnancy were found to be 4.7 
times (95% CI 3.6 to 6.1) more likely to develop ESRD than those with 
uncomplicated pregnancies. The risk of ESRD was reported to be higher in those 
who had pre-eclampsia in more than one pregnancy, and in those who had an 
uncomplicated first pregnancy and were affected in later pregnancies. In 
keeping with cardiovascular studies, the risk of ESRD was also found to be higher 
in those affected by pre-eclampsia in association with intra-uterine growth 
restriction (255). 
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The typical histopathological changes seen in pre-eclampsia are of glomerular 
endotheliosis, characterised by fibrin deposition, endothelial swelling and loss of 
capillary space (256).  These changes had been previously thought to resolve 
after pregnancy, but it has been proposed that the characteristic renal changes 
are more long-standing.  One study examining the nature of the association 
between pre-eclampsia and renal disease examined 127 middle-aged women 
aged between 45 and 65 with chronic kidney disease who had undergone renal 
biopsy. Of them, 32 (25%) had a history of pre-eclampsia. The most common 
renal lesion seen in the patients with previous pre-eclampsia was of focal 
glomerular sclerosis, which was unique to women with previous pre-eclampsia.  
All other causes of chronic renal failure including IgA nephropathy were 
commonly seen in both groups, indicating that these syndromes are less likely to 
be related to pre-eclampsia (257).  
Although the relative risk for developing ESRD is low, these studies do provide an 
insight into future maternal renal health, and may assist in future disease 
screening and prevention. 
1.9.2 Insulin resistance 
As mentioned in section 1.4.5, insulin resistance is a mechanism thought to be 
implicated in the pathogenesis of pre-eclampsia, which could potentially help to 
explain the link with future cardiovascular disease. During normal pregnancy, 
there is a progressive increase in insulin production from the beta cells of the 
pancreas, with a corresponding reduction in insulin sensitivity in the second and 
third trimesters (258). Women with pre-eclampsia have a further reduction in 
insulin sensitivity as measured by euglycaemic hyperinsulinaemic clamp studies, 
an abnormality which persists for up to 3 months post delivery (259). Girouard et 
al. (260) examined women at an average of 7.8 years after an index pregnancy 
complicated by pre-eclampsia and gestational hypertension, to assess whether 
they were more insulin resistant than those with uncomplicated pregnancies. 
Women with previous gestational hypertension or pre-eclampsia had a higher 
apolipoprotein B : A1 ratio, higher leptin and insulin levels, and lower 
adiponectin and LDL cholesterol levels compared to controls, indicating insulin 
resistance. In addition these women had higher insulin resistance as measured by 
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homeostasis model assessment (HOMA2). When women with pre-eclampsia or 
gestational hypertension alone were analysed, these results were less 
convincing. In addition the women with previous pre-eclampsia or gestational 
hypertension had a higher BMI at follow-up, which may have confounded results.  
Libby et al. (261) examined the relationship between pre-eclampsia and future 
risk of type 2 diabetes both in the mothers and  their children. The study, 
examining more than 7,000 women for a mean of 45 years after an index 
pregnancy found no difference in death rates between women with previous pre-
eclampsia and those with uncomplicated pregnancies. Women with previous pre-
eclampsia had an increased risk of developing type 2 diabetes with adjusted 
odds ratio of 1.37 (95% CI 1.12 to 1.75). In the offspring, the risk of type 2 
diabetes was highest in those with a low birth-weight, and was not related to 
maternal pre-eclampsia. A potential limitation of this study, however, was that 
the presence or absence of gestational diabetes was not recorded, which may 
have influenced the number of women going on to develop future type 2 
diabetes. 
Further studies have examined the relationship between pre-eclampsia and 
future diabetes in the mothers. Callaway et al. (262) used questionnaires to 
study self-reported diabetes in over 3600 women at 21 years after delivery. They 
found that women with previous hypertensive diseases of pregnancy (including 
both gestational hypertension and pre-eclampsia) had a 2-fold increase (95% CI 
4.42 to 2.91) in the risk of future diabetes compared to those with normal 
pregnancies. In another study using either laboratory results or prescriptions for 
diabetes medications to confirm future diabetes, over 2,000 women with 
previous pre-eclampsia and 29,000 women without pre-eclampsia were 
examined. They reported an adjusted hazard ratio of 1.82 (95% CI 1.26 to 2.62) 
for future diabetes in the pre-eclampsia group, at a median follow-up of 8.2 
years (263). These studies confirm that increased surveillance for development 
of diabetes should be considered in women with a history of pre-eclampsia.    
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1.9.3 Vascular function studies 
As has been mentioned in section 1.3.4, endothelial dysfunction is thought to 
have a key role in the pathophysiology of pre-eclampsia, and is known to 
contribute to the pathogenesis of hypertension and cardiovascular disease. Flow-
mediated dilatation has been used in many studies as a measure of endothelial 
function, and has been shown to be impaired in women with pre-eclampsia 
compared to those with normal pregnancies (90,264). Women with HELLP 
syndrome, a severe variant of pre-eclampsia which is characterised by 
haemolysis, deranged liver function and thrombocytopenia, did not have such 
impairment, suggesting that this syndrome may be characterised by different 
cardiovascular adaptive processes (264).  
A number of studies have evaluated women to determine whether they have 
ongoing endothelial dysfunction after a pre-eclamptic pregnancy. The largest 
study of its type examined 78 women with a single episode of pre-eclampsia, 35 
women with recurrent episodes, and 48 women with uncomplicated pregnancies, 
at a median of 3 years post-partum. Women with previous pre-eclampsia had 
reduced flow mediated dilatation, indicating endothelial dysfunction, while 
glyceryl trinitrate (GTN) induced vasodilatation, which is endothelium-
independent was not different between the two groups. Endothelial dysfunction 
was more marked in those with a history of recurrent pre-eclampsia, a finding 
which was not explained by traditional risk factors such as maternal obesity or 
hypertension (265). Further studies using plethysmography to assess forearm 
blood flow have demonstrated ongoing endothelial dysfunction at 6-12 months 
(266) and at one year (267) after a pre-eclamptic pregnancy. A study examining 
women 5-6 years after a pre-eclamptic pregnancy found impaired response in 
forearm blood flow to low and high doses of the endothelium-independent 
vasodilator sodium nitroprusside and the endothelium-dependant vasodilator 
acetylcholine, when compared to women with previous uncomplicated 
pregnancy (268). A longer-term study using laser Doppler perfusion studies and 
examining response to vasodilators as a measure of endothelial function 
reported persistent abnormalities at 15-25 years after a pre-eclamptic pregnancy 
compared to women with previous uncomplicated pregnancies (269). 
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As discussed in section 1.3.5, pulse wave analysis has also been reported as a 
technique both for early prediction of pre-eclampsia and for cardiovascular 
disease. Few studies, however, have examined the use of pulse wave analysis to 
examine women after pre-eclamptic pregnancy. In one study in which women 
were examined 5 years post-natally, no difference was found in augmentation 
index between women who had pre-eclampsia and those who had normal 
pregnancies (109). This study may have been limited, however, by the exclusion 
of women on anti-hypertensive therapy. Whether pulse wave analysis provides 
additional information on cardiovascular risk in previously pre-eclamptic women 
remains to be seen, and it is clear that further studies are required in this area.  
 
1.9.4 Cardiac data 
Normal pregnancy is associated with a 50% increase in cardiac output, which is 
mediated by an expansion of plasma volume, generalised vasodilatation and a 
reduction in total peripheral resistance. The development of pre-eclampsia is 
associated with alterations in the maternal vasculature, with reduced cardiac 
output and elevated peripheral resistance at the time of onset of symptoms. 
There are few longitudinal studies examining echocardiographic abnormalities in 
women who subsequently develop pre-eclampsia. Abnormalities do, however, 
appear to develop prior to the onset of clinical symptoms, with elevated cardiac 
output and signs of hyperdynamic circulation reported as early as week 10-14, 
and a subsequent fall in cardiac output and rise in peripheral resistance at time 
of diagnosis (270).  
Women with a history of pre-eclampsia have been reported to have 
echocardiographic evidence of diastolic dysfunction in a subsequent pregnancy 
(271), and to have impaired cardiac response to exercise (272). There is, 
however, very little information in the literature regarding the longer term 
cardiac consequences of pre-eclampsia. Imaging studies using cardiac 
echocardiography, or more sophisticated techniques such as magnetic resonance 
imaging (MRI) are required in women years after a pre-eclamptic pregnancy. 
Such studies may help to further explain the relationship between pre-eclampsia 
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and future cardiovascular disease, leading to potential screening and 
therapeutic opportunities.   
1.9.5 Carotid artery ultrasonography 
Carotid artery ultrasound is a further imaging modality that has been used to 
determine cardiovascular risk after pre-eclampsia. Ultrasound-based 
measurement of carotid artery intima-media thickness (IMT) and detection of 
atherosclerotic plaque are useful measures of preclinical atherosclerosis, and of 
progression of atherosclerotic disease in non-pregnant populations. IMT 
measurement is non-invasive, reliable and simple to perform, and has been 
reported as a risk factor for future development of ischaemic heart disease and 
stroke.  
Increased IMT of the femoral artery (but not the carotid arteries) has been 
reported in women one year after a pre-eclamptic pregnancy compared to 
controls (273), but the long-term significance of this finding remains uncertain. 
One study examined carotid artery IMT and plaque volume at thirty years after a 
pre-eclamptic pregnancy, a time-point when one might expect a clinically 
detectable difference. The study reported increased atherosclerotic plaque 
volume in women with a history of pre-eclampsia, but that IMT was not different 
between cases and controls (274).  On logistical regression analysis, age and a 
history of pre-eclampsia were independent risk factors for development of 
atherosclerotic plaque. Whether this imaging modality can help to further 
determine future cardiovascular risk in affected women, however, remains 
uncertain.  
  
1.9.6 Biomarkers 
In keeping with other inflammatory markers, CRP levels are elevated in normal 
human pregnancy (275), and as mentioned in section 1.4 have been reported to 
be elevated in women with pre-eclampsia when compared to women with 
uncomplicated pregnancies (276), although this has not been a consistent finding 
(275).  
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Given the relationship between CRP and cardiovascular disease, several studies 
have examined whether CRP and other inflammatory markers remain elevated in 
later life in women with a history of pre-eclampsia. A group in Iceland examined 
post-menopausal women 30 years after they had eclampsia, the severe variant 
of the pre-eclampsia syndrome characterised by seizures (277). They reported 
elevated CRP levels in women with previous eclampsia when compared to 
controls, which remained significant after correction for smoking status, BMI, 
hormone replacement therapy (HRT) use and current age. Studies looking at 
women with pre-eclampsia alone, however, have been less convincing. One 
group examined inflammatory markers in women 20 years after a pregnancy 
complicated by pre-eclampsia. They reported a significantly higher ratio of pro-
inflammatory cytokine IL-6 to anti-inflammatory cytokine IL-10 in women with 
previous pre-eclampsia, but levels of CRP were not statistically different 
between the 2 groups, and there was no difference in TNF-α levels (278). A 
further study looking at women six years after a pre-eclamptic pregnancy 
similarly found no difference in CRP levels when compared to those with a 
history of normal pregnancies (279), while another group reported that the 
elevated CRP in previously pre-eclamptic women lost statistical significance 
after correction for BMI (260).  
As has been mentioned in section 1.4, many other biomarkers are associated 
with pre-eclampsia, but few have reported persistent abnormalities in the years 
after pre-eclamptic pregnancies. One group examined intracellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-Selectin, 
as well as leptin, fasting insulin and glycosylated haemoglobin (HbA1c) in a 
cohort of women 15-25 years after a pre-eclamptic pregnancy. Compared to 
women matched for BMI, smoking and time since index pregnancy, they reported 
significantly elevated levels of VCAM-1 (p=0.038), ICAM-1 (p=0.002) and HbA1c 
(p=0.004), with a trend towards elevated insulin (p=0.08) levels in the formerly 
pre-eclamptic group (280). Although these studies may emphasise the role of 
insulin resistance and endothelial dysfunction in these women’s future 
cardiovascular disease, it is again unclear whether it is the pre-eclampsia itself 
or the underlying risk factors predisposing to cardiovascular disease that cause 
the abnormalities.  
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1.10 Aims of this thesis 
 
Although improvements in obstetric and neonatal care have led to a reduction in 
morbidity and mortality from pre-eclampsia, the ability of clinicians to 
accurately predict the condition in earlier pregnancy has not improved 
significantly. The overall aim of this work is to design a large prospective study 
to identify clinical and biochemical markers which might help to improve our 
ability to predict pre-eclampsia. 
The first hypothesis that this thesis will test is that proteomics can be used to 
develop a disease specific peptide pattern that predicts pre-eclampsia before 
the onset of clinically detectable disease. As discussed, in a multi-factorial 
condition such as pre-eclampsia identifying a single biomarker for predicting 
disease is perhaps unrealistic. To test this hypothesis I will use urinary 
proteomics to try to identify novel pathways and mechanisms that might lead to 
novel biomarkers for disease prediction.  
The second hypothesis that this thesis will test is that levels of inflammatory 
markers and anti-angiogenic peptides are already altered in the first trimester in 
women who go on to develop pre-eclampsia. Many of the proposed biomarkers 
for pre-eclampsia are raised at the time of onset of hypertension and 
proteinuria, a time-point where the only real option available to obstetricians is 
delivery of the baby. To test this hypothesis I will examine a panel of 
inflammatory cytokines, adhesion molecules and anti-angiogenic biomarkers in a 
mixed parity general obstetric population: to examine whether they are 
elevated in the first trimester, what happens to their levels throughout 
pregnancy, and how are their levels affected by maternal risk factors such as 
obesity and increasing maternal age.  
The third hypothesis that this thesis will test is that vascular function studies can 
be used to predict pre-eclampsia before the onset of hypertension and 
proteinuria. Endothelial dysfunction and arterial stiffness underpin many of the 
pathophysiological mechanisms behind pre-eclampsia, but the optimal method 
for their measurement remains unknown. Since such methods would have to be 
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safe in pregnancy, well tolerated and applicable in large scale studies, to test 
this hypothesis I will focus on pulse wave analysis and peripheral arterial 
tonometry, techniques which are simple to perform and are user-independent. 
Further, since techniques such as these are unlikely to be feasibly used in all 
pregnant women, I will focus on women known, based upon risk factor profile to 
be at increased risk, to see whether vascular function testing helps to further 
discriminate between those likely to be affected.  
The fourth hypothesis that this thesis will test is that vascular function remains 
abnormal after delivery in pregnancy affected by pre-eclampsia. To test this 
hypothesis I will examine the use of these vascular function analysis techniques, 
after both pre-eclamptic and unaffected pregnancies, to identify whether they 
might help to explain why they are more likely to develop cardiovascular disease 
in the future. 
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Chapter 2 
 
Materials and methods
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2. Materials and methods 
 
2.1 Summary 
This chapter provides a description of the general protocols of the clinical 
techniques used in the studies described in this thesis.  
2.2 Ethical approval 
All studies were approved by the West Glasgow Ethics committee. Patient 
information sheets and consent forms are enclosed in Appendix 1-3.  
2.3 Recruitment of pregnant women 
2.3.1 Description of maternity care in Glasgow & Ayrshire 
Prior to January 2010, maternity services in Greater Glasgow were served by 3 
main maternity units: the Queen Mother’s Hospital (QMH), the Southern General 
Hospital (SGH) and the Princess Royal Maternity Hospital (PRMH), with 
approximately 3500, 3000 and 4500 annual deliveries respectively. The Calder 
report of 2006 (http://www.scotland.gov.uk/Topics/Health/NHS-
Scotland/17273/CalderGroup/mbs) recommended that the number of maternity 
units in Glasgow be reduced from 3 to 2. The decision was therefore made to 
extend maternity services at the Southern General Hospital, with plans to 
ultimately build a new hospital incorporating adult, maternity and paediatric 
services on one site.  In January 2010 the Queen Mother’s Hospital closed, with 
pregnant women from its catchment areas choosing to attend either the 
Southern General Hospital or the Princess Royal Maternity Hospital.  
In August 2006 the new Ayrshire Maternity Unit (AMU) opened at the Crosshouse 
Hospital campus, Kilmarnock. This hospital replaced maternity services at 
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Ayrshire Central Hospital, Irvine, and in keeping with service changes in Glasgow 
allowed incorporation of adult, maternal and paediatric services on a single site.  
2.3.2 Routine antenatal care 
Routine antenatal care for pregnant women in Glasgow and Ayrshire is as 
follows.   Following a positive pregnancy test in the community, women visit 
their General Practitioner (GP) for a confirmatory urine human chorionic 
gonadotrophin (HCG) test, and if this is positive they are subsequently referred 
to secondary care for a “booking visit.” Depending on their history and location, 
women are either referred to community midwife-led maternity units, or to 
their local maternity hospital. In general, women with previous medical or 
obstetric problems are seen at hospital, while those deemed to be at low-risk 
are referred to the community units. The booking visit, normally at 12-16 weeks 
gestation, consists of an ultrasound scan which assesses the viability and number 
of foetuses, as well as measuring the crown-rump length to assess gestational 
age (281). Women with a non-viable foetus are referred to the perinatal team 
for counselling. Those with a continuing pregnancy are then seen by a midwife, 
who takes a detailed medical, family and obstetric history, takes routine urine 
and blood collections, and discusses delivery options. Women then have the 
opportunity to meet their Consultant, who will be in charge of their overall care, 
providing an opportunity to discuss specific concerns about the pregnancy, as 
well as to discuss delivery options. 
Maternity services in the UK are currently in a state of change. Instead of 
hospital based care, there has been an emphasis in recent years of 
multidisciplinary community-based care, in order to emphasise the “normality” 
of pregnancy. A “hub and spoke” system is coming into practice in Scotland. 
Women who are deemed to be medium or high risk are seen at the “hub” units, 
where a full range of antenatal services, in-patient services and perinatal 
services are available. Women who are deemed to be low risk are seen at the 
“spoke” units, which are midwife led, with an emphasis on birth planning, breast 
feeding and education. Within the areas included in this study, the “hubs” were 
the main obstetric centres at the Southern General Hospital, the Princess Royal 
Maternity Hospital, the Queen Mother’s Hospital and Ayrshire Maternity Unit.  
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Much of the work in this thesis is directed towards finding clinical or biochemical 
“markers” for early prediction of pre-eclampsia. Such tests would be useful in 
this modern design of maternity care; women found to be “low-risk” would be 
cared for in the “spoke” units, while those at higher-risk would be seen in the 
hospitals.  
 
2.3.3 Initial recruitment 
Women were recruited for the “Proteomics in Pre-eclampsia” (PIP) study at the 
initial antenatal (booking) visit, at gestational week 10-18. An invitation letter, a 
patient information sheet and a consent form were sent to all expectant women 
along with their appointment for their booking visit at the maternity units at 
QMH, PRMH, SGH and AMU. At the booking visit women were invited to 
participate in the study by either myself or a study nurse. Invitation letters, 
consent forms and patient information sheets are included in Appendix 1-3. All 
women aged over 16 yrs were invited to participate. Women who were unable to 
give informed consent, due to language barriers or learning difficulties, were not 
included in the study. In addition, since this was largely a study aiming to 
identify early pregnancy markers, women whose ultrasound appearances were in 
keeping with a gestational age of over eighteen weeks were not included.  
Informed consent was obtained, and in addition to samples taken for routine 
clinical purposes, a sample of blood (five millilitres whole blood, EDTA tube, 
Vacutainer system) and urine (mid-stream, fresh, universal container) were 
obtained. Samples were stored in a fridge at 4°C, and at the end of the clinic 
were transferred refrigerated to the BHF Glasgow Cardiovascular Research 
Centre. Immediately on arrival samples of urine were separated into three 1ml 
aliquots and were labelled and stored at -70°C. Blood samples were centrifuged 
at 4°C, at 3000 revolutions per minute (RPM) for 10 minutes. 3 x 0.5 ml aliquots 
of plasma were then aliquoted, labelled and stored at -70°C. The remaining 
blood was then stored at 4°C for DNA extraction.  
The following clinical information was collected from women agreeing to take 
part in the study: age, gestational age according to crown-rump length (weeks), 
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height (m), weight (kg), BMI (kg/m²), blood pressure after 5 minutes seated 
(mmHg) and dipstick urinalysis findings. In addition the following background 
information was obtained: parity, history of pre-eclampsia in a previous 
pregnancy (yes / no), history of diabetes (yes / no), history of kidney problems 
(yes / no), history of hypertension (yes / no), number of years since last 
pregnancy (years),  family history (mother or sister) of pre-eclampsia (yes / no), 
smoking status (yes / no), presence of a multiple pregnancy (yes / no), history of 
antiphospholipid syndrome (yes / no), or history of autoimmune disease (yes / 
no). Information was recorded on a study data collection form, which is included 
in Appendix 4. Pregnant women were allocated a study code N-00001, where N 
was the first letter of the hospital in which they were recruited (Q=Queen 
Mother’s Hospital, P=Princess Royal Maternity Hospital, X=Ayrshire Maternity 
Hospital, and S=Southern General Hospital), followed by their study number. In 
addition women were asked if they would be willing to participate in further 
studies at gestational weeks 16 (visit 2) 28 (visit 3) and post-natally (visit 4).  
Pregnant womens’ details (name, date of birth, hospital number and community 
health information (CHI) number) were entered into a Microsoft Access database 
along with patient study code. Only the lead research nurse and I had access to 
this database.  In a separate Microsoft Access database the patient study code 
was used as an identifier and all clinical information was then entered. Both 
databases were password protected and double encrypted.  
2.3.4 “Risk-factor” group 
A number of risk factors are known to be associated with an increase in risk of 
developing pre-eclampsia, and are summarised in Chapter 1. In brief, nulliparity 
(having the first baby), a family history of pre-eclampsia (mother or sister,) age 
over 35 yrs or under 20 years, a history of pre-eclampsia in a previous 
pregnancy, body mass index >30 kg/m², and a history of diabetes, hypertension, 
renal and autimmune disease are all implicated. Also known to be at increased 
risk are those with a multiple pregnancy and those who have a gap of more than 
ten years since their last pregnancy. Women with 2 or more of these risk factors 
were initially identified based on information given at the booking visit. These 
women were contacted by telephone by me and invited to attend the BHF 
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Glasgow Cardiovasular Research Centre for additional studies at gestational 
week 16 (14-18), week 28 (26-30,) and at 6-9 months post-natally.   
 
In addition, a cohort of healthy nulliparous non-pregnant women were recruited 
to the study to act as “controls.” These women, aged between eighteen and 
forty years, were recruited using advertising posters in the University of 
Glasgow. Study protocols were exactly the same as those described for the 
pregnant women, except that these women were only seen on one occasion. 
Finally, a cohort of women recruited for the study who went on to develop pre-
eclampsia, but who had not been seen for vascular function studies at 
gestational week 16 and 28, were invited for vascular function studies at 6-9 
months post-natally. A flowchart outlining the study is shown in figure 2.1 
below.  
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Figure 2-1 Flowchart describing overall study design 
 
 
2.4 Vascular Function Sub-studies 
2.4.1 Study protocol 
Women who agreed to attend for vascular function studies were sent an 
information sheet, a consent form and a map by post. All women were seen in 
the afternoon at the British Heart Foundation Glasgow Cardiovascular Research 
Centre. Appointments were on Mondays, Tuesdays and Wednesdays, at 1300, 
1430 or 1600 hrs. Women were asked to abstain from alcohol, caffeine and 
cigarettes on the day of the study. All studies were carried out in a dedicated 
room which was quiet, with minimal artificial lighting, and with temperature 
controlled between 22-24°C.  
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Following written informed consent, body weight and height were measured 
with women in light clothes and without shoes to the nearest 0.5kg of weight 
and the nearest 0.5cm of height. Exactly the same equipment was used for all 
studies, and the weighing scales (Seca, Germany) were calibrated regularly. 
Body mass index (BMI, kg/m2) was calculated as: 
BMI = weight (kg) / height (m)² 
Blood pressure was measured after 5 minutes seated using the Omron MX2 
automated device, which was calibrated regularly by the University of Glasgow’s 
Department of Medical Physics. If blood pressure was elevated, this was 
communicated back to the woman’s General Practitioner or midwife, and if 
necessary women were referred directly to hospital for assessment. Throughout 
the course of the study a total of 3 pregnant women were referred to the 
hospital Day Care Unit for assessment: 2 because of hypertension, and 1 because 
of concern about reduced foetal movements. 
A 12-lead ECG was performed with the woman lying supine. Any significant 
abnormalities were reported to the woman’s General Practitioner.  
 
2.4.2 Urine samples 
A sterile container was used to collect a mid-stream sample. The sample was 
then transferred to a universal container, while a Dipstick was used to analyse 
the urine remaining in the sterile container. Results of Dipstick measurement 
and blood pressure were then forwarded to the woman’s General Practitioner, 
along with a letter informing them of their participation in the study. If 
glycosuria was detected, women were referred to their midwife for repeat 
sampling and oral glucose tolerance testing if required. Two pregnant women 
were referred to the hospital day care unit because of glycosuria.  
Urine samples in the universal container were then transferred to the 
laboratory. Urine was separated into three 1ml aliquots, which were frozen at        
-70°C.  
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2.4.3 Blood samples 
Samples were taken from the antecubital fossa of the non-dominant arm using 
the Vacutainer system. The non-dominant arm was chosen since it was the 
dominant arm that would be used for blood pressure cuff inflation during the 
subsequent endothelial function studies. A standard tourniquet was used and the 
following samples were obtained:-  
• 7 mls in a Lithium Heparin tube 
• 7 ml in an EDTA tube 
• 7 ml in a serum tube 
• 2.5 ml in a PAXgene blood RNA tube 
The RNA tube contained an additive that stabilises the gene transcription profile 
by reducing RNA degradation and minimising gene induction. In view of this the 
blood was collected for the RNA tube last. The tourniquet was released as soon 
as blood started to flow into the RNA tube, and the tube was inverted 8-10 times 
immediately after blood collection.  
On arrival of the samples in the laboratory, 50µl of whole blood was removed 
from the EDTA tube to a vial on ice for subsequent glutathione (GSH) analysis. 
100µl was removed from the EDTA tube to a vial on ice, to which was added 10µl 
of M2VP scavenger, for subsequent oxidised glutathione (GSSG) analysis. The 
RNA blood tube was kept at room temperature for a minimum of 2 hours and a 
maximum of 72 hours before processing. All other blood samples were then 
centrifuged at 2700 rpm, at 4°C, for 10 minutes.  
Samples were then aliquoted as follows:- 
• EDTA tube 
o 2 x 500µl plasma  
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o 1 x 200µl plasma 
o 1 x 150µl plasma 
• Lithium Heparin tube 
o 2 x 1ml plasma 
o 2 x 100µl plasma 
• Serum tube 
o 3 x 500µl serum 
• Whole blood 
o 50µl for GSH analysis 
o 100µl for GSSG analysis 
All samples were then labelled using the study code and stored at -70°C.  
2.5 Laboratory studies 
2.5.1 Cytokines and adhesion molecules 
2.5.1.1 Sample collection 
Samples were collected and spun as outlined above, stored at -70°C and thawed 
prior to analysis. For all measurements batch analysis was performed to 
minimize inter assay variability. Each sample from a woman who went on to 
develop pre-eclampsia (case) was matched for age, body mass index (BMI) and 
parity with 2 controls; cases and their controls were analysed during the same 
batch.  
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2.5.1.2 Biochip technology 
Analysis was performed using Evidence Investigator Technology (Randox 
Laboratories Ltd). This system uses biochips measuring 9x9 mm, each of which is 
supplied pre-fabricated with an array of discrete test regions deposited in 
exactly pre-defined co-ordinates on the surface of the biochip. This allows 
simultaneous analysis of multiple parameters. When analytes are present in the 
patient sample they attach to the surface-bound specific ligands, and the 
concentration of each analyte can be determined relative to the calibrators of 
known concentration.  
2.5.1.3 Biochip carrier 
The biochip carrier has nine separate reaction wells arranged in a 3x3 format 
(figure 2.2). Each reaction well contains a biochip, secured in the base of the 
well, each of which accommodates a single patient sample. Carrier trays 
facilitate handling of 6 carriers at a time.  
The multi-biochip carrier is supplied with a handle to facilitate biochip handling 
during the assay procedure, and to minimise human contact with the biochip 
surface.  
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Figure 2-2. Biochip carrier with 9 reaction wells. 
 
2.5.1.4 Adhesion molecules array protocol  
To each well 225µl assay diluent and 25µl of sample or standard was added.  The 
carrier well was incubated at 37°C for 60 minutes at 370 rpm. Following this 
50µl conjugate was added, and the carrier was incubated for a further 60 
minutes at 37°C at 370rpm. Liquid was then decanted and each well was then 
washed with buffered saline; 2 quick washes and 4 x 2 minute soaks. Following 
this 250µl signal reagent mix was added to each well. Samples were then kept at 
room temperature and protected from light with tin foil for 2 minutes, prior to 
imaging.   
The following analytes were measured using this protocol: VCAM-1, ICAM-1, E-
Selectin, P-Selectin and L-Selectin.  
2.5.1.5 Cytokine & Growth factors profile protocol 
To each well 225µl assay buffer and 100µl of sample or standard was added. The 
carrier was incubated at 37°C for 60 minutes at 370 rpm on the thermoshaker, 
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covered, and then further incubated for 16-20 hours at 2-8°C at 0rpm. The liquid 
was then decanted, and the wells were washed with buffered saline; 2 quick 
washes and 4 x 2 minute soaks. 300µl conjugate was then added to each reaction 
well, and the carrier was then incubated at 37°C for 60 minutes at 370 rpm. 
Liquid was then decanted, and wells were again washed with buffered saline; 2 
quick washes and 4 x 2 minute soaks. Liquid was decanted, 250µl signal reagent 
was added, and the wells were incubated at room temperature for 2 minutes, 
protected from light, prior to imaging.  
The following analytes were measured using this protocol: Interleukins -1α, -1ß, 
-2, -4, -6, -8, -10, VEGF, TNF-α, IFN-γ, MCP-1, EGF.  
2.5.1.6 Chemiluminescent technology 
Chemiluminescence is the production of light via a chemical reaction. It is used 
in immunassays to determine the level of analyte present in a sample. The 
“Evidence Investigator” system uses a chemiluminescent substrate with 
horseradish peroxidise (HRP) label for the detection of antibodies or analytes 
bound to the biochip surface. The intense signal output enables the detection of 
picogram quantities of antigen or antibody. The signal reagent used in these 
experiments comprises a 1:1 mixture of luminol / enhancer solution and a 
peroxide solution.  
The reaction mechanism is based on oxidation and reduction reactions, which 
results in the formation of free radical components and the emission of light. 
HRP reacts with peroxide to form an intermediate compound. This compound 
then reacts with luminol to form the luminol radical, which itself decomposes 
with emission of light. Enhancer molecules regenerate free radicals, which aid 
the chemiluminescent reaction.  
2.5.1.7 Chemiluminescence detection 
Light emitted from the chemiluminescent reactions taking place at the discrete 
test reactions on the surface of the biochip is detected and quantified with a 
charge coupled device (CCD) camera. This camera simultaneously records the 
light emitted from each of the discrete test regions on each of the nine biochips 
109 
in the biochip carrier. The CCD is made up of a collection of tiny light-sensitive 
diodes which convert photons of light into electrons which produce electrical 
charge. Each diode or photosite is sensitive to light; the brighter the light that 
hits a photosite the greater the electrical charge that accumulates. The degree 
of light emission can therefore be quanitified based on the strength of the 
electrical signal generated.  
2.5.2 Enzyme linked immunosorbent assays 
2.5.2.1 Assay principles 
Enzyme linked immunosorbent assays (ELISAs) employ the quantitative sandwich 
antibody principle. Plasma (or other appropriate medium) samples containing 
the antigen of interest and standards of known concentration are pipetted into a 
plate of test wells which are coated with primary antibody to the antigen. After 
incubation sufficient to allow >95% of the antigen to bind the primary antibody, 
the wells are washed to remove any unbound material. An enzyme-linked 
polyclonal antibody, specific for the antigen of interest, is then added to each 
well.  After incubation time to allow end-point binding of the secondary 
antibody to the captured antigen, the plate is washed to remove excess unbound 
conjugate antibody.  
A substrate for the specific enzyme on the secondary antibody is then added, 
and colour develops in proportion to the amount of antibody bound in the initial 
step. An acid solution is then added to stop the reaction at a point where the 
standard curve added is detectable and linear. The colour change in each well is 
then measured photometrically using an appropriate wavelength on a plate 
reader (Multi Scan EX, Thermo Electron Corporation, UK). The plate reader is 
programmed to draw a standard curve and infer the concentrations of the 
plasma samples from this curve using each relevant optical density (OD). An 
example of a standard curve obtained for an ELISA is shown in figure 2.3. All 
R&D systems standard operating procedures can be procured from links on the 
website: 
http://www.rndsystems.com/product_detail_objectname_elisa_assay_product.a
spx 
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Figure 2-3 Example of a standard curve obtained for E-Selectin ELISA comparing measured 
values with known concentrations of standard test solutions 
 
 
2.5.2.2 sFLT-1 (sVEGF-r1) 
 
Soluble FMS-like tyrosine kinase-1 (also known as serum VEGF receptor-1) was 
measured with a commercially available ELISA kit (R&D systems, Abingdon, 
UK).The manufacturers claim the assay is sensitive to 1.5pg/ml. The reported 
intra-assay CV is 2.6-3.2%, and the reported inter-assay CV is 5.5-9.8%.  
2.5.2.3 sENG measurement 
Soluble endoglin (sEng) was measured with a commercially available ELISA kit 
(R&D systems, Abingdon, UK.) The manufacturers claim that the assay is 
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sensitive to 0.007 ng/ml. The reported intra-assay CV is 2.8-3.2%, and the 
reported inter-assay CV is 6.3-6.7%%.  
2.5.2.4 PlGF measurement 
Placental Growth Factor (PlGF) was measured with a commercially available 
ELISA kit (R&D systems, Abingdon, UK). The manufacturers claim that the assay 
is sensitive to less than 7 pg/ml. The reported intra-assay CV is 3.6%, and the 
reported inter-assay CV is 11%.  
2.5.2.5 E-Selectin measurement 
E-Selectin was measured with a commercially available ELISA kit (R&D systems, 
Abingdon, UK). The manufacturers claim that the assay is sensitive to less than 
0.009 ng/ml. The reported intra-assay CV is 5.2-6.6%, and the reported inter-
assay CV is 7.3-8.7%. 
 
2.5.3 Urinary Proteomics 
2.5.3.1 Sample preparation 
Each pregnant woman recruited to the study had 3 x 1000 µl aliquots of urine 
stored at -20°C at the BHF Glasgow Cardiovascular Research Centre. Samples 
were stored for up to 3 years before analysis. All proteomic analysis was 
performed at Mosaiques Diagnostics, Hannover, Germany, and samples were 
transferred on dry ice to Germany via courier. Previous studies at Mosaiques 
have shown no significant storage-related degradation in samples stored for 10 
years compared to those stored for 6 weeks (222). 
Shortly before proteomic analysis, each 0.7 ml aliquot of urine was thawed and 
diluted with 0.7ml of 2 mol/L urea and 20 mmol/l NH4OH containing 0.02% SDS. 
To remove proteins with a high molecular mass such as albumin, samples were 
then filtered using a Centrisart ultracentrifugation filter device (Sartorius, 
Goettingen, Germany) with a 20 kDa molecular weight cut-off.  Centrifugation 
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was carried out at 3000g, until 1.1 ml of filtrate was obtained. The filtrate was 
then applied onto a PD-10 desalting column (GE Healthcare Bio-Sciences, 
Uppsala, Sweden), pre-equilibrated with 0.01% NH4OH in HPLC-grade H2O, to 
remove urea and salts, and to enrich the low molecular-weight peptides present. 
Finally, samples were lyophilised in a freeze-drier (Speed-Vac RVC 2-18/Alpha 1-
2, Christ, Osterode a.H, Germany) and stored at 4°C suspended in high 
performance LC-grade H2O until CE-MS analysis.  
2.5.3.2 Capillary electrophoresis separation 
Peptides were first separated based on differential migration through a liquid 
filled capillary column. For capillary electrophoresis (CE) separation of urine 
sample peptides, the P/ACE MDQ system (Beckan Coulter, Fullerton, USA) was 
used. A 90 cm length, 75µm inner diameter fused-silica capillary was first rinsed 
with running buffer (30% methanol, 0.5% formic acid) for 3 minutes. The urine 
sample was then injected into the capillary for 99 seconds with 1 psi positive 
pressure, resulting in an injection of approx 700 nl. The separation was then 
performed by applying a charge of +30kV at the inlet of the capillary, resulting 
in a current of approximately 13µA. The temperature was kept constant at 35°C 
for the entire length of the capillary. After each sample analysis, the capillary 
was rinsed first with 0.1M NaOH, then for 5 minutes with water, then with 
running buffer.  
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Figure 2-4. Capillary electrophoresis (left), microTOF mass spectrometer (middle) and 
computer for data acquisition (right).  
 
2.5.3.3 Mass spectrometry 
The capillary electrophoresis instrument was coupled online with a micro time-
of-flight (TOF) mass spectrometer (Bruker Daltronic, Bremen, Germany.) The 
electrospray ionisation interface (Agilent technologies, Palo-Alto, Ca, USA) was 
grounded, and the potential was set to -4 to -4.5 kV. Acquisition of data was 
controlled automatically by the capillary-electrophoresis program through close-
contact relays. Mass spectra were accumulated every three seconds over a range 
of mass:charge (m:z) ratio of 350-3000, and the mean was then calculated.  
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Figure 2-5. Interface of capillary and mass spectrometer  
 
2.5.4 Data Processing 
Each CE-MS run provides a large amount of information, with over 1000 
individual spectra for each sample. A number of steps are therefore required in 
order to accurately process the data.  
2.5.4.1 Deconvolution 
Data is analysed using a specific software tool, Mosaiques-Visu. Initially, CE/MS 
peaks are detected using a signal / noise (S/N) ratio of eight. The charge of each 
peak is then calculated, based on isotopic distributions and conjugated masses. 
The Mosaiques-Visu software then deconvolutes the data, so that mass spectral 
ion peaks from the same molecule at different charge states are recorded as a 
single mass.  
2.5.4.2 Calibration 
MS data needs to be normalised to correct for analytical issues such as signal 
suppression, and biological issues, for example state of hydration of the patient 
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studied. Migration time and ion signal intensity (amplitude) are normalised based 
on 29 peptides that serve as internal standards. These peptides are the result of 
normal biological processes, and do not appear to be affected by age, sex or 
disease state. Normalisation using these “housekeeping” peptides has been 
shown to be as accurate as absolute peptide quantification using urinary 
quantification or stable isotope labelled synthetic marker analogues (282).  
2.5.4.3 Annotation 
The resulting peak list characterises each peptide by its molecular mass (in 
daltons), CE migration time and signal intensity, providing a unique 
identification mark. Data are then entered into a Microsoft SQL database, which 
allows further analysis and comparison with other samples. Mass spectrometry 
peaks from different samples were presumed identical if mass deviation is less 
than 100 ppm, and the migration time deviation is less than 5 mins.  
2.5.5 Derivation of classification factor 
The information about the multiple peptide patterns associated with pre-
eclampsia was then transformed into a single number, or classification factor, 
allowing analysis of the different peptide levels in different patient groups. 
Classification factors were generated using the MosaCluster software (225); using 
a support-vector-machine (SVM) based mathematical model, MosaCluster 
displays data points (urine samples) from n proteomic markers as an n-
dimensional vector, and attempts to separate them in an n-dimensional 
hyperplane. The resultant classification factor was calculated for each patient 
sample from the distance and direction of its vector to the separating 
mathematical hyperplane. 
2.5.6 Sequencing 
Candidate biomarkers were sequenced using LC-MS/MS analysis using instruments 
with electron transfer dissociation (ETD) capability (283-285). Mass spectrometry 
data were searched against the IPI human database using the Open Mass 
Spectrometry Search Algorithm (OMSSA; 
http://pubchem.ncbi.nlm.nih.gov/omssa), using an e-value cut-off of 1.00E-2. 
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All matched sequences were manually validated. All sequences obtained from 
human urine can be assessed at the Mosaiques human urine proteome database 
(http://mosaiques-
diagnostics.de/diapatpcms/mosaiquescms/front_content.php?idcat=257).(286) 
 
2.5.7 Statistical methods and sample classification 
Estimates of sensitivity and specificity were calculated based on tabulating the 
number of correctly classified samples. Confidence intervals (95% CI) calculated 
using MedCalc version 8.1.1.0 (MedCalc Software, Mariakerke, Belgium). The 
reported unadjusted p-values were calculated using the natural logarithm-
transformed intensities and the Wilcoxon Rank-Sum Test. Statistical adjustment 
for multiple testing was performed using the false discovery rate (FDR) 
adjustments of Benjamini and Hochberg (287). 
 
2.5.8 Definition of biomarkers 
2.5.8.1 Training set 
In order to identify potential biomarkers, urine samples from women who went 
on to develop pre-eclampsia (cases) were compared with samples from women 
who had normotensive pregnancies (controls). Women were matched for age, 
BMI and parity. Peptides that were present in at least 75% of the samples in 
either group (cases or controls) were identified as potential biomarkers, and 
were further evaluated using receiver operator characteristics (ROC) statistics. 
The amplitude distribution of CE-MS data peptides present in the samples was 
used as the ROC variable, and the affiliation to a diagnostic group (cases or 
controls) was used as the classification variable. The obtained area under the 
ROC curve for a particular peptide was used as a measure of its discriminatory 
potential. An initial list of potential biomarker candidates was then further 
refined using the Mann-Whitney test, with p ≤ 0.05 being indicative of 
significance. Model establishment and sample classification were performed 
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using a linear classification algorithm. This algorithm generates a classification 
model based on peptides that are most able to discriminate between cases and 
controls. In general models consisted of fewer peptides than samples, in order to 
avoid over-fitting.  
2.5.8.2 Test set 
Using the peptides identified, the ability of the model to differentiate between 
cases and controls was then evaluated using a blinded assessment of urine 
samples, from women who went on to develop pre-eclampsia (cases) and  
women who had normotensive deliveries (controls).  
2.5.9 Statistical analysis 
All of the statistical analyses for pregnant women’s characteristics and clinical 
data were performed using the SPSS software package (SPSS inc., Chicago, USA). 
Normality of data distribution was assessed using the Kolmogorov-Smirnov test 
and manual inspection of Q-Q plots. Data were expressed as mean ± standard 
deviation (SD) if normally distributed, or as median ± interquartile range if their 
distribution was not normal. For continuous variables, differences between the 
groups were evaluated using the unpaired Student's t test if data was normally 
distributed, or Mann-Whitney U test for variables that were not normally 
distributed. Fisher’s exact test was used for comparison of categorical variables. 
A p-value of <0.05 was considered significant.  
Sensitivity and specificity were calculated based on tabulating the number of 
correctly classified samples. Confidence intervals (95% CI) were calculated in 
MedCalc (MedCalc for Windows 8.1.1.0, Medcalc Software, Mariakerke, Belgium). 
The ROC plot was obtained by plotting all sensitivity values (true positive 
fraction) on the y axis against their equivalent (1 − specificity) values (false 
positive fraction) for all available thresholds on the x axis (MedCalc Software).  
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2.6 Clinical studies 
 
2.6.1 Pulse Wave Analysis 
Pulse wave analysis was carried out using the SphygmoCor (Atcor Medical, West 
Ryde, Australia) system. Pregnant women lay supine in a dedicated room, 
temperature controlled at 22-24°C. The SphygmoCor device consists of a pencil 
shaped applanation tonometer (Millar instruments, Houston, Texas, USA), which 
was placed over the radial artery of the dominant hand, with the wrist 
extended. The wrist was used since the radial artery is easily accessible in the 
majority of individuals. The radial artery was gently compressed with the tip of 
the manometer at the site of maximal pulsation. The radial artery recording was 
calibrated with the blood pressure measured at the brachial artery, since the 
blood pressure is practically identical in both vessels. The probe was connected 
to a laptop computer upon which data was collected directly.  
The supporting software applies a generalised transfer function to the radial 
artery waveform which is used to derive the aortic waveform. The generalised 
transfer function is described in Chapter 1. From the aortic waveform the 
augmentation pressure (AP) and the augmentation index (AIx) were calculated. 
The AP is defined as the height of the late systolic peak above the inflection 
point on the waveform. The AIx is defined as the AP expressed as a percentage 
of the aortic pulse pressure (PP). AIx is affected by heart rate; with a faster 
heart rate the duration of systole is shortened. This leads to the reflected wave 
meeting the advancing wave in diastole, rather than the usual systole. This in 
turn leads to reduced augmentation of the advancing wave, or a reduced AIx 
with a faster heart rate. Since there is a linear relationship between heart rate 
and AIx, the AIx was standardised to a heart rate of 75 bpm (AIx-75).  
After a waveform was established, sequential waveforms over a 9 second period 
were recorded, and the proprietary software created an average arterial 
waveform. The recordings were included if they passed certain quality controls; 
if systolic or diastolic variability between waveforms exceeded 5% then the 
reading were discarded, and if the amplitude of the waveform was below a 
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certain threshold the readings were excluded. In addition, the SphygmoCor 
system has its own quality control, or “operator index” which is displayed on 
screen. An operator index of ≥80% is deemed acceptable, 100% is the best 
achievable. Fifty PWA recordings performed by me were selected at random and 
were reviewed by an observer employed by SphygmoCor, to ensure the standard 
of recordings was acceptable. A typical aortic pulse waveform is shown in figure 
2.6 below.  
 
Figure 2-6. Aortic waveform generated from SphygmoCor system. 
 
PWA was recorded until 3 separate acceptable recordings had been recorded for 
each study visit. All PWA studies were carried out by me. The mean of the 3 
recordings was used for analysis. 
 
2.6.2 Endothelial Function assessment 
PAT (peripheral arterial tone) measurement is a non-invasive technique for 
assessment of endothelial function which is safe and well-tolerated in 
pregnancy, is user-independent, and may be applicable in large clinical studies. 
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PAT technology captures a beat-to-beat plethysmographic recording of the 
finger arterial pulse wave amplitude (PWA) with pneumatic probes. PAT probes, 
which are fitted to the index fingers of both hands, exert a uniform pressure 
field around the entire surface of the distal phalynx, measuring pulsatile volume 
changes. The inflated probes apply a counter-pressure of approximately 70mmHg 
to the finger tips, avoiding venous distension which could distort results. Probes 
are attached by flexible tubing to isolated volume reservoirs which buffer 
pressure changes within the probes. These pressure changes are then filtered, 
amplified and diplayed on screen. Women were asked to switch off mobile 
telephones, and not to move or speak during the recordings.  
PAT recordings were performed using the EndoPAT 2000 system (Itamar medical, 
Caesarea, Israel) after a period of at least twenty minutes rest, in order to allow 
women to acclimatise to their surroundings. This is particularly important in the 
winter months, when study participants are relatively peripherally 
vasoconstricted.  In practical terms this meant that women would have their 
ECG, followed by pulse wave analysis, and then PAT assessment. After 10 
minutes of baseline recordings at rest, a blood pressure cuff (Hokanson SC12, 
Bellevue, USA) was inflated around the dominant arm to either 60 mmHg above 
the systolic blood pressure or at least 200 mmHg, whichever was higher, with a 
maximum inflation to 300mmHg. The signal in the study arm was amplified to 
20,000 arbitrary units (au), to ensure that the blood supply was fully occluded. 
This was constantly monitored during the occlusion to ensure that there was no 
visible pulsatile waveform, with the cuff being inflated a further 20 mmHg if 
there was any breakthrough. After exactly 5 minutes the cuff was immediately 
deflated, which induced flow-mediated reactive hyperaemia, which was 
recorded over a further 5-10 minutes. The contralateral (non-dominant) arm 
remained uncuffed and acted as a “control” to correct for any systemic artefact, 
for example temperature changes. The test therefore lasted for approximately 
20 minutes.  
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Figure 2-7. PAT typical clinical set-up. 
 
The magnitude of flow-mediated hyperaemia was then calculated as a measure 
of endothelial function. Pulse wave amplitude in the minute beginning exactly 
60 seconds after release of the blood pressure cuff was compared with a 210 
second period prior to occlusion. The use of the 1 minute period beginning 
exactly 1 minute after cuff release is based on data showing that this time-point 
provides the closest correlation with coronary artery endothelial function on 
ROC (Receiver Operator Characteristic) curve (288). To correct for systemic 
factors including arm ischaemia itself this ratio was corrected for readings in the 
uncuffed left arm. The result of the test is the reactive hyperaemia index, (RHI) 
a measure of endothelial function. The majority of PAT recordings were 
performed by myself, the remainder were performed by a research nurse trained 
by myself. All PAT studies were reviewed by myself; PAT measurements were 
analysed using proprietary software in an automated, operator-independent 
manner.  
122 
 
Figure 2-8. RHI was calculated as pulse amplitude following occlusion (A) / pulse amplitude 
before occlusion (B) in the study arm, divided by the same ratio in the control hand,  (A/B) / 
(C/D).   
 
 
Figure 2-9. PAT recording with 5 minutes of baseline recording, 5 minutes of arm occlusion 
and 5 minutes of post-occlusion recording. (a) is a subject with normal reactive hyperaemia, 
(b) is a subject with impaired reactive hyperaemia while (c) is the control arm which corrects 
for systemic factors.  
 
In addition the Endo-PAT 2000 device was also used to calculate a peripheral 
augmentation index (AIx). Using an automated computerised algorithm, peak 
volume and inflection points were identified on the pulse waveforms. Peripheral 
AIx was calculated as the ratio of the difference between the early and late 
systolic peaks of the waveform relative to the early peak (P2-P1 / P1), expressed 
as a percentage.  
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The following measurements were then recorded in the database: reactive 
hyperaemia index (RHI), Augmentation Index (AIx) and baseline pulse amplitude 
in both the study arm and the control arm. 
 
2.6.3 Brachial artery FMD 
Doppler ultrasound was used to measure flow-mediated dilatation (FMD) at the 
brachial artery. Following 5 minutes lying supine after the PAT examination, the 
brachial artery was identified and scanned longitudinally at 5 to 10 cm proximal 
to the antecubital fossa using an 8.0 MHz linear array transducer (Acuson 8L5 
system, Sequioa 512, Siemens). Baseline measurements of artery diameter and 
peak flow velocity were obtained at end diastole. Vessel diameter was measured 
using ultrasonic callipers to assess the distance between the anterior and 
posterior interface between the media and adventitia (m-line). 
Electrocardiographic recordings were made throughout the study, and images 
were triggered on the R wave.  
Baseline scanning was recorded for 5 minutes; a pneumatic blood pressure cuff 
was then inflated to 250mmHg on the forearm distal to the artery. The cuff was 
released after 5 minutes and the artery was then scanned for a further 5 minutes 
to record the effects of reactive hyperaemia.  
The study was recorded and analysed offline with Vascular Research Tools 
(Medical imaging Applications LLC, USA). FMD was expressed as the percentage 
change in the arterial diameter pre and post cuff occlusion, relative to the 
baseline diameter. All recordings were performed by the same experienced 
investigator.  
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2.7 Delivery outcomes 
2.7.1 Diagnostic criteria 
Diagnostic criteria for pre-eclampsia are described in Chapter 1. In order to fulfil 
diagnostic criteria for pregnancy-induced hypertension, women had to have 2 or 
more blood pressure readings of ≥140 mmHg systolic and ≥90 mmHg diastolic at 
least 6 hrs apart, but before the onset of labour, along with proteinuria as 
outlined in Chapter 1. Those with hypertension arising before 20 weeks gestation 
were classified as having chronic hypertension. Women with positive urinalysis in 
the context of urinary infection were not included.  
2.7.2 Delivery outcomes 
The methods used for achieving accurate outcomes of pre-eclampsia varied 
between the different maternity units involved in the study. I used the following 
methods to ensure that I obtained delivery information on the maximal possible 
number of women in the study.    
2.7.2.1 Labour wards 
In all hospitals participating in the study a poster was placed in the labour ward, 
inviting midwives to use a patient label sticker to identify all women admitted 
with hypertension in pregnancy. These stickers were collected at the end of 
each month, were checked against study databases, and notes were requested 
for all highlighted women who had been recruited for the study.   
2.7.2.2 Day care units 
Each hospital has a “day care” area, which is where women attend when they 
are referred from the community for assessment of pregnancy related problems. 
In general the majority of women who develop hypertension at any stage in 
pregnancy are referred to the day care unit. Here, they are assessed by an 
experienced midwife, and are referred to a doctor if necessary. Posters 
advertising the study were placed in the day care unit, and for women with 
hypertension, a sticker with hospital number was attached to the poster. Posters 
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were checked against study databases, and case notes for all identified women 
who had been recruited into the study were requested.  
2.7.2.3 Induction books 
The majority of women who develop hypertension and pre-eclampsia which 
cannot be adequately controlled medically will have induction of labour or 
Caesarean section arranged. Each labour ward has an “induction book” which 
has details of all women requiring induction of labour or Caesarean section 
arranged. I analysed each of these induction books monthly, and took details of 
all women who required induction or Caesarean section for hypertension, pre-
eclampsia or intra-uterine growth restriction. These lists were checked against 
the study databases, and case notes were requested for each woman who had 
been recruited into the study.  
2.7.2.4 Databases 
Different hospitals have different systems of database where details of deliveries 
are recorded. QMH, SGH and AMU have systems through which all delivery 
reports are uploaded onto a centralised database. These allow for a search each 
month for all women with a mention of hypertension, pre-eclampsia or intra-
uterine growth restriction in their delivery summary. All such women were then 
checked against the study database, and case notes were reviewed if the 
mentioned women had been recruited for the study.  
 
2.7.2.5 Record of delivery 
A record of delivery is generated for each delivery in each hospital. For each 
woman recruited to the study, the following information was extracted from the 
record of delivery: gestation at delivery, sex of baby, weight of baby (grams), 
mode of delivery, presence of any medical problems including hypertension and 
diabetes, and blood pressure post-partum. Case notes were reviewed by myself 
for all women in the study who had developed hypertension before, during or 
after delivery.   
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2.7.2.6 Case note analysis 
I analysed the case notes in detail of each woman who was said to have had 
hypertension, pre-eclampsia or intra-uterine growth restriction. Diagnostic 
criteria as described in Chapter 1 were used to identify true cases of pre-
eclampsia, those with isolated pregnancy-induced hypertension, and those 
without either condition, for example those women who only had hypertension 
during labour.  
For the purposes of these experiments, each woman who went on to develop 
pre-eclampsia was matched with at least 2 “controls” who had uncomplicated 
pregnancies. Cases were matched with controls as closely as possible for age, 
body mass index, parity and gestational age at time of booking. Women who 
developed any degree of hypertension or gestational diabetes were not included 
as controls. Women who had their baby before 36 weeks gestation for any reason 
were not included, since it could be argued that they could have gone on to 
develop pre-eclampsia had their pregnancy gone to term. Similarly women who 
had babies under the 10th corrected birth centile (which is indicative of intra-
uterine growth restriction, a hallmark of hypertensive disorders) or those with 
babies bigger than the 90th corrected centile (in keeping with hyperglycaemic 
disorders) were also not eligible to be used as controls.  
2.7.2.7 Corrected centile charts 
It has long been argued that “normal values” for birthweight and foetal growth 
need to be locally applicable, and cannot necessarily be transferred from one 
country to another. Such reference values need to reflect physiological variation 
in maternal height and weight, ethnic origin and sex of the baby (once known).  
The West Midlands Perinatal Research Institute have developed corrected centile 
charts based upon the principles of the gestation related optimal weight (GROW) 
program. Coefficients for each of the factors mentioned above have been 
derived and validated for maternity population datasets in the UK (N=40,000), 
Sweden (N=400,000), New Zealand (N=5,000), Australia (N=12,500) and the 
United States (N=35,000) (289).  
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Microsoft Excel (2003) based calculators were used to calculate corrected 
birthweight centiles. The following data were entered into the calculator:- 
• Maternal height (cm) 
• Maternal weight (kg)  
• Parity 
• Maternal ethnicity 
• Parity at beginning of pregnancy 
• Baby sex 
• Birthweight 
• Baby sex 
These corrected centile charts have been used in several international studies, 
and have demonstrated that physiological parameters appear to affect growth 
similarly in different countries and continents (290). The group now aim to add 
to the existing data by examining these coefficients in different populations in 
different geographic areas. In particular the effect of social deprivation (which 
was not included in the PIP study) is important, since it is known to affect 
perinatal mortality rates. 
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2.8 Overall study numbers  
At the time of the final study analysis 3919 women who had been recruited to 
the study had delivered. Delivery information was available for 3631 women 
(93%); after exclusion of women who had miscarriages or terminations at ≤ 20 
weeks’ gestation, information was available on 3592 women who had live births. 
Demographics of women at booking are shown in table 2.1. The reconfiguration 
of maternity services within Glasgow, and in particular the closure of the Queen 
Mother’s hospital in January 2010, is likely to have contributed to the 
incomplete delivery information. Figure 2.10 outlines the overall recruitment 
rates at the various sites.  
Of the women on whom delivery information was available, a total of 83 (2.3%) 
developed pre-eclampsia, while 69 (1.9%) women developed gestational 
hypertension without significant proteinuria. Delivery information from women 
at each of the maternity hospitals in the study is shown in table 2.1. 
 
 
Figure 2-10. Breakdown of pregnant women recruited at each centre 
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Total (3919) QMH   (1582) SGH   (1469) PRMH   (643) ACH     (224) 
Age (years) 30.1 (6.0) 30.4 (6.0) 29.9 (5.9) 30.8 (6.0) 28.0 (5.8) 
Ethnicity 
      Caucasian 
      Non-Caucasian 
 
3552 (91%) 
367 (9%) 
 
1452 (92%) 
130 (8%) 
 
1273 (87%) 
196 (13%) 
 
603 (94%) 
40 (6%)  
 
223 (99.6%) 
1 (0.004%) 
Height (cm) 163 (12) 164 (11) 162 (12) 162 (15) 164 (8) 
Weight (kg) 69.9 (16) 69.4 (15) 70.1 (16) 70.2 (17) 71.1 (17) 
BMI (kg/m²) 26 (5) 25 (5) 26 (5.6) 26.5 (6) 26.8 (6) 
Nulliparous 1788 (46%) 754 (48%) 688 (47%) 255 (40%) 90 (37%) 
Smoking 534 (14%) 251 (16%) 118 (8%) 105 (16%) 60 (27%) 
Previous pre-eclampsia 106 (2.7%) 31 (1.9%) 40 (2.7%) 32 (5%) 3 (1.3%) 
FH of pre-eclampsia 150 (3.8%) 43 (2.7%) 68 (4.6%) 33 (5%) 6 (2.7%) 
Previous hypertension 101 (2.5%) 52 (3%) 34 (2.3%) 13 (2%) 2 (1%) 
Previous renal disease 12 (0.003%) 7 (0.004%) 5 (0.003%) 0 (0%) 0 (0%)  
Gestation at booking 13.4 (1.7) 13.3 (1.8) 13.6 (1.7) 12.6 (1.5) 12.5 (1.4) 
SBP at booking (mmHg) 111 (28) 111 (34) 113 (13) 114 (15) 109 (10) 
DBP at booking (mmHg) 67 (12) 67 (13) 67 (11) 71 (11) 64 (7) 
Table 2-1. Demographics of pregnant women at booking visit. FH= family history.  
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 Total (3919) QMH   (1582) SGH   (1469) PRMH   (643) ACH     (224) 
Delivery information available 3631 (93%) 1408 (89%) 1384 (94%) 635 (99%) 204 (91%) 
Live births 3592 (92%) 1392 (88%) 1375 (94%) 623 (97%) 202 (90%) 
Stillbirth / termination < 20 weeks 24 (0.006%) 8 (0.006%) 6 (0.004%) 8 (0.01%) 2 (0.008%) 
Stillbirth > 20 weeks 15 (0.004%) 8 (0.006%) 3 (0.002%) 4 (0.006%) 0 (0%) 
Pre-eclampsia 83 (2.3%) 38 (2.7%) 32 (2.3%) 10 (1.6%) 3 (1.5%) 
Pregnancy-induced hypertension 69 (2%) 28 (2%) 24 (1.7%) 7 (1.1%) 10 (4.9%) 
Eclamptic fits 2 (0.0002%) 0 (0%) 1 (0.0006%) 1 (0.002%) 0 (0%) 
Gestational diabetes 22 (0.005%) 8 (0.005%) 5 (0.003%) 8 (1.2%) 1 (0.004%) 
Gestation at delivery 39.5 (2.6) 39.5 (2.7) 39.7 (2.2) 39.2 (3.2) 39.7 (2.2) 
Caesarean section 942 (26%) 321 (23%) 372 (27%) 187 (29%) 62 (28%) 
Birthweight (grams) 3396 (599) 3416 (633) 3370 (570) 3412 (588) 3390 (581) 
Corrected centile 46.1 (30.4) 47.1 (30) 44 (30.5) 49 (30.7) 42.4 (31) 
Table 2-2. Delivery information of women recruited to PIP study. 
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 Pre-eclampsia 
(n=83) 
No pre-
eclampsia (3548) 
p-value 
Age (years) 28.7 (6) 30.2 (6) 0.03 
Ethnicity 
      Caucasian 
      Non-Caucasian 
 
78 
5 
 
2967 
362 
 
 
0.21 
Height (cm) 163 (12) 163 (12) 0.9 
Weight (kg) 76 (16) 69.8 (16) 0.001 
BMI (kg/m²) 28 (6) 26 (5) <0.001 
Nulliparous 69 (83%) 1718 (52%) <0.001 
Smoking 9 (11%) 525 (16%) 0.28 
Previous pre-eclampsia 2 (2.4%) 104 (3%) 1.0 
FH of pre-eclampsia 9 (11%) 141 (4%) 0.009 
Previous hypertension 5 (6%) 96 (3%) 0.04 
Previous renal disease 0 (0%) 12 (0.003%) 1.0 
Gestation at booking 13.6 (2) 13.4 (2) 0.3 
SBP at booking (mmHg) 117 (20) 111 (28) 0.04 
DBP at booking (mmHg) 73 (14) 67 (12) <0.001 
Table 2-3. Comparison of demographics at booking between women with and without pre-
eclampsia. FH=family history 
 
2.8.1 Discussion 
At booking, women who went on to develop pre-eclampsia were younger, had a 
higher BMI, were more likely to be nulliparous and were more likely to have a 
family history of pre-eclampsia than those who did not develop the condition. 
Systolic and diastolic blood pressure was already higher at booking in women 
who went on to develop pre-eclampsia. There was no difference in ethnicity or 
in smoking rates between affected and unaffected women.  
These findings are in largely in keeping with the literature, since nulliparity, 
increased BMI, blood pressure in early pregnancy, and a family history in the 
mother or sister, are all known to be associated with an increased risk of 
development of pre-eclampsia (12). Smoking is associated with a reduced risk of 
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pre-eclampsia; in this cohort there was no significant difference between 
affected and unaffected women. I relied, however, on self-reported smoking 
rates, which can often be inaccurate. Women who developed pre-eclampsia 
were also younger than those who remained normotensive; this goes against 
what one would expect, since increased age is reported to be associated with an 
increased risk of pre-eclampsia, with the risk increasing from the age of 34 
onwards (12).  
 
 Pre-eclampsia 
(n=83) 
No pre-eclampsia 
(n=3548) 
p-value 
Gestation at delivery (wks) 37.3 (3.6) 39.6 (2.5) <0.001 
Birthweight (g) 2918 (790) 3408 (589) <0.001 
Corrected centile 36.5 (31) 46.3 (30) 0.009 
Caesarean Section 33 (40%) 953 (29%) 0.007 
Table 2-4. Comparison of delivery information between women with and without pre-
eclampsia 
 
Delivery information again confirmed that women who developed pre-eclampsia 
were more likely to have delivered at an earlier gestation, to have had smaller 
babies and to have been delivered by Caesarean section.  
 
Women who attended for booking at QMH or SGH were asked if they would be 
willing to attend for vascular function studies and further sampling at 
gestational week 16 and 28. Those who were willing to participate in further 
studies and who and had 2 or more traditional risk factors for pre-eclampsia 
were then contacted by telephone and invited to attend. 214 women with risk 
factors attended at week 16, of whom 180 (84%) attended again at week 28.  
Analysis of vascular function studies was restricted to the 180 women who 
attended at gestational weeks 16 and 28. Women were invited to attend at 6-9 
months post-natally, of whom 80 attended.  
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Figure 2-11. Flowchart depicting women recruited for vascular function studies and 
sampling  
 
 
 
 
 
 
 
 
 
134 
 
 
Chapter 3 
A study of urinary proteomics for the prediction of 
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3. A study of urinary proteomics for the prediction 
of pre-eclampsia 
3.1 Introduction 
As discussed in Chapter 1, the prediction of pre-eclampsia before the onset of 
clinically detectable disease remains a challenge. The use of medications to 
delay or even prevent the onset of disease has been reported widely; several 
potential therapeutic agents have been studied, but inability to screen for high-
risk women has limited the number of proper randomised controlled trials 
performed. To be most likely to be effective, such agents would have to be 
started before 20 weeks gestation; discriminating affected pregnancies from 
unaffected pregnancies is not yet possible.  
It has long been proposed that toxins in the maternal circulation contribute to 
the development of pre-eclampsia; the traditional term pre-eclamptic toxaemia, 
or abbreviation PET reflects this. Several biochemical markers have been 
proposed for the early prediction of pre-eclampsia, but none have yet been 
sensitive or specific enough to be adopted for use in routine clinical practice 
(81). The pathogenesis of pre-eclampsia is complex, with an interaction 
occurring between impaired placentation and a maternal response to factors in 
the maternal circulation that culminates in the clinical manifestations of the 
disease.  Several studies support the theory that the under-perfused placenta 
releases circulating factors (291), and that the maternal response includes 
endothelial cell dysfunction, vasoconstriction and activation of inflammatory and 
coagulation pathways (236).  
To date, the identity of the majority of these circulating markers remains 
unknown; syncytiotrophoblast debris and angiogenesis related factors such as 
vascular-endothelial growth factor-1 (VEGF) and its receptor (VEGFr-1 or sFLT-1) 
have been reported as being involved (121), but many others remain 
uncharacterised. The use of a “hypothesis-generating” strategy such as 
proteomics may lead to the discovery of these markers, leading to the discovery 
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of novel pathways and mechanisms that could themselves be targets for 
potential therapeutics.  
Proteomics, the large-scale study of peptides and proteins, holds promise for the 
discovery of new biomarkers for pre-eclampsia, and as discussed in section 1.6.2 
urine appears to be a stable platform for proteomic-based research. Renal 
pathology is one of the hallmarks of the condition, and the degree of proteinuria 
is said to reflect the severity of disease (292).  In keeping with serum, urinary 
levels of anti-angiogenic peptides have been shown to be altered in women who 
went on to develop pre-eclampsia (293,294). In contrast to many other human 
tissues, urine is relatively stable against proteolytic degradation (229); freezing 
urine samples at -70°C for several years has been shown to have little or no 
impact on the proteome (222). As a filtrate of blood, urine contains an 
abundance of information about the functioning of many internal organs, and 
the appearance in the blood of certain proteins may result in their appearance 
in the urine, either as intact proteins or as peptide fragments. Normal urine 
contains small amounts of intact albumin, as well as much larger quantities of 
low-molecular-weight albumin fragments. Although most antibody-based or 
other assays detect the intact form of albumin, the majority fail to detect 
smaller fragments of albumin. Since mass spectrometry can be used to measure 
and characterise these small peptide fragments, it could prove to be a useful 
tool for identifying predictive biomarkers. As discussed in section 1.6.4, urinary 
proteomic biomarkers have been validated for the early diagnosis of various 
diseases, including coronary artery disease (221,229), diabetes (295) and 
diabetic nephropathy (296). As well as providing potentially clinically useful 
biomarkers, these studies have given insight to novel pathophysiological 
mechanisms.  
In this study, therefore, capillary electrophoresis / mass spectrometry (CE / MS) 
based technology was used to examine the urinary proteome in pregnancy. Once 
the changes in the urinary proteome in pregnancy had been determined, a 
further aim was to identify a urinary proteomic peptide pattern that could be 
used to accurately predict which women are likely to go on to develop pre-
eclampsia.  
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3.2 Methods 
3.2.1 Patient recruitment 
The Proteomics in Pre-eclampsia (PIP) study protocol is described in detail in 
chapter 2.The study was designed primarily to investigate urinary proteomics for 
the ability to predict pre-eclampsia, and was extended to include blood markers 
and vascular function studies which form the bulk of this thesis.  In brief, 
pregnant women were recruited at their initial antenatal hospital visit 
(gestational week 12-16) at the Southern General Hospital, the Queen Mother’s 
Hospital and the Princess Royal Maternity Hospital, Glasgow, and Ayrshire 
Maternity Hospital, Kilmarnock. Written informed consent was obtained either 
by myself or by a midwife. 
Information about past medical history, past obstetric history, family history and 
risk factors for pre-eclampsia were obtained and recorded on a data collection 
form (Appendix 4). Blood pressure was recorded after 5 minutes seated with an 
automated device and body mass index was calculated. Blood and urine samples 
were also obtained.  
In order to examine the peptide patterns later in pregnancy, a cohort of women 
with ≥2 traditional risk factors for pre-eclampsia were invited for further 
sampling at gestational weeks 16 and 28, and at 6-9 months post-natally, as 
outlined in Chapter 2.  
For the purpose of this initial urinary proteomics study, the first 2500 women 
with singleton pregnancies who had been recruited into the study were included. 
Delivery information, obtained from hospital databases and labour ward delivery 
books, was available on 2407 women (95%); those who had foetal losses <20 
weeks gestation (n=22) were not included, leaving 2385 women in the final 
analysis. Case notes and patient hand-held records were reviewed by myself for 
every woman who developed hypertension at any stage during pregnancy, to 
ensure accurate diagnosis of pre-eclampsia. Women with a history of 
hypertension outwith pregnancy, diabetes and renal disease were excluded from 
the proteomic analysis study. Although women with twin pregnancies were 
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included in the overall PIP study, these women were not included in this 
proteomics study. Overall, 45 (1.9%) of the 2385 women who delivered >20 
weeks gestation developed pre-eclampsia (cases); these women were matched 
in a nested case-control design with 90 women who had uncomplicated 
pregnancies (controls). Cases and controls were matched as closely as possible 
for age, body mass index at booking and gestational age at sampling; controls 
were women who delivered appropriately grown healthy babies at ≥37 weeks’ 
gestation with no antenatal obstetric or medical complications. Samples from 4 
controls were unsuitable for proteomic studies, leaving 86 controls for the final 
analysis. Subject characteristics are shown in table 3.1.  
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      Pre-eclampsia 
n=45 
    Controls 
n=86 
   p-value 
   Maternal Characteristics    
Age (years) 29 (5) 28 (5) 0.686 
Ethnicity 
       Caucasian 
       Other 
 
42 (93%) 
3 (7%) 
 
81 (94%) 
5 (6%) 
 
1.00 
Body mass index (kg/m2) 29 (5) 29 (5) 0.763 
Nulliparous 39 (87%) 55 (64%) 0.007 
Smoker  4 (9%) 21 (24%) 0.04 
Previous pre-eclampsia 1 (2%) 6 (7%) 0.42 
Family history of pre-eclampsia 
(mother or sister) 
8 (17%) 7 (8%) 0.14 
    At Booking    
Systolic blood pressure (mmHg)  121 (10) 114 (12) 0.002 
Diastolic blood pressure (mmHg) 76 (9) 69 (10) 0.001 
Proteinuria (≥++ on dipstick) 1 (2%) 2 (2%) 1.00 
Gestation at sampling (wks) 13.8 (1.6) 13.7 (1.3) 0.606 
   Pregnancy Outcome    
Highest systolic blood pressure 
(mmHg) 
165 (11) 125 (12) <0.001 
Highest diastolic blood pressure 
(mmHg) 
101 (8) 71 (9) <0.001 
Caesarean section 20 (44%) 10 (12%) <0.001 
Gestation at delivery (wks) 38.3 (2) 40 (1.4) <0.001 
Birthweight (g) 3155 (621) 3558  (416) <0.001 
Customised birthweight centile 39.4 (30) 48.5 (23) 0.09 
Small for gestational age                           
(<10th customised birthweight 
centile) 
 
12 (27%) 3 (3%) <0.001 
Table 3-1.  PIP study patient characteristics. Shown as mean (SD) or number (% of total). 
 
132 of the women with at least two risk factors for pre-eclampsia (12) attended 
for further sampling at gestational week 28 as outlined in Chapter 2. Of them, 18 
(13.6%) developed pre-eclampsia, and were matched for age and body mass 
index at sampling to 17 controls who had normotensive deliveries, delivering 
140 
appropriately grown babies after 37 weeks gestation. Patient characteristics of 
the women in the sub-study are shown in Table 3.2.  
      Pre-eclampsia 
n=18 
     Controls 
n=17 
   p-value 
   Maternal Characteristics    
Age (years) 30 (4) 29 (4) 0.62 
Ethnicity 
        Caucasian 
        Other 
 
16 (89%) 
2 (11%) 
 
17 (100%) 
0 (0%) 
 
0.49 
Body mass index (kg/m2) 30 (5) 30 (4) 0.75 
Nulliparous 16 (89%) 9 (53%) 0.03 
Smoker  1 (6%) 4 (24%) 0.18 
Previous pre-eclampsia 1 (6%) 5 (29%) 0.09 
Family history of pre-eclampsia 
(mother or sister) 
8 (44%) 4 (24%) 0.29 
   At Week 28    
Systolic blood pressure (mmHg)  130 (10) 126 (9) 0.17 
Diastolic blood pressure (mmHg) 80 (8) 73 (6) 0.006 
Proteinuria (≥+ on dipstick) 2 (11%) 1 (6%) 1.0 
Gestation at sampling (wks) 28.2 (1.4) 28.6 (1.5) 0.37 
   Pregnancy Outcome    
Highest systolic blood pressure 
(mmHg) 
159 (9) 126 (10) <0.001 
Highest diastolic blood pressure 
(mmHg) 
100 (6) 73 (7) <0.001 
Caesarean section 4 (22%) 3 (17%) 1.0 
Gestation at delivery (wks) 39.3 (2) 40.5 (1) 0.02 
Birthweight (g) 3277 (419) 3722 (468) 0.001 
Customised birthweight centile 34.4 (24) 45 (19) 0.16 
Small for gestational age                           
(<10th customised birthweight 
centile) 
 
4 (22%) 0 (0%) 0.10 
Table 3-2. PIP study : patient characteristics for “risk factor” sub-group 
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3.2.2 Validation in an independent study cohort 
Further studies were then performed to validate the biomarker patterns in an 
independent cohort of pregnant women. Early pregnancy urinary samples were 
obtained from the “Screening for Pregnancy Endpoints” (SCOPE) study, an 
international cohort study of healthy nulliparous women with singleton 
pregnancies (297).  Between November 2004 and October 2008, 3234 women 
were recruited into the SCOPE study in Auckland, New Zealand and Adelaide, 
Australia. Women were interviewed, examined and specimens obtained at 20±1 
weeks gestation. Women were followed prospectively throughout pregnancy with 
outcome data collected by research midwives. Pregnancy outcome data was 
available on 99% (n=3196). After exclusion of women with foetal losses before 22 
weeks’ gestation (n=26) and women not attending the 20 week interview (n=69), 
the base population for the study comprised 3101 women (96% of recruits). Of 
the 3101 women, 175 (5.6%) developed pre-eclampsia, of whom 158 (5.1%) 
delivered after 34 weeks’ gestation. For the current study, SCOPE cases (n=50) 
were randomly selected from the late onset pre-eclampsia subgroup and controls 
(n=50) from women with uncomplicated pregnancies (n=1767), defined as no 
antenatal obstetric or medical complications with delivery of an appropriately 
grown healthy baby at 37 or greater weeks’ gestation. Urinary samples from 
gestational week 20 were used for proteomic analysis, with 1 control specimen 
excluded for technical reasons. SCOPE study patient characteristics are shown in 
table 3.3.  
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      Pre-eclampsia 
n=50 
   Controls 
  n=49 
  P-value 
   Maternal Characteristics    
Age (years) 26 (6) 26 (6) 0.93 
Ethnicity 
Caucasian 
Other 
 
41 (82%) 
9 (18%) 
 
     42 (86%) 
      7 (14%) 
 
0.62 
Body mass index (kg/m2) 27 (6) 25 (6) 0.12 
Gravidity 
1 
≥2 
 
37 (76%) 
12 (24%) 
 
      42 (84%) 
7 (16%) 
 
0.04 
Smoker 5 (10%) 7 (14%) 0.51 
   At 20 weeks gestation    
Systolic blood pressure (mmHg) 114 (10) 109 (10) 0.01 
Diastolic blood pressure (mmHg) 68 (10) 64 (7) 0.05 
Gestation at blood sampling (wks) 20.1 (0.7)       20.1(0.6) 0.86 
   Pregnancy Outcome    
Systolic blood pressure (mmHg) 148 (15) 118 (10) <0.0001 
Diastolic blood pressure (mmHg) 95 (9) 70 (9) <0.0001 
Caesarean section 18 (36%) 9 (18%) 0.05 
Gestation at delivery (wks) 38.5 (1.6)   40.3 (1.0) <0.0001 
Birthweight (g)        3090 (616)   3609 (407) <0.0001 
Customised birthweight centile       40 (18, 66)    55 (40, 74) 0.02 
Small for gestational age                         
(<10th customised birthweight 
centile) 
 
    9 (18%)     0 (0%) 0.003 
Table 3-3. SCOPE study patient characteristics.  
 
Diagnosis of pre-eclampsia was  in keeping with the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) criteria (5); hypertension (systolic BP 
>140 or diastolic BP >90, on 2 occasions > 6 hours apart,) in association with 
proteinuria (defined as ≥ 300mg / 24 hrs or ++ on dipstick analysis). 
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3.2.3 Sample handling 
Study protocols are outlined in Chapter 2. In brief, urine samples (mid-stream, 
universal container) were taken at the morning out-patient clinic (PIP) or study 
interview (SCOPE), were anonymised, given a study code, and were stored in a 
refrigerator at 4°C for up to 4 hours. Samples were then transferred refrigerated 
to the research centre, separated and aliquoted. Samples were stored at -70°C, 
and thawed immediately prior to proteomic analysis.  
Capillary electrophoresis / mass spectrometry (CE/MS) proteomic analysis was 
performed as outlined in Chapter 2. To determine the urinary proteome in 
normal pregnancy, samples from 17 healthy pregnant women with 
uncomplicated pregnancies were compared to samples from 67 apparently 
healthy, non-pregnant female volunteers from Hannover medical school. In a 
“discovery phase” a training set of potential biomarkers was then developed 
using samples from 20 women who had gone on to develop pre-eclampsia and 20 
matched women who had uncomplicated pregnancies. In a validation phase the 
training set of discriminatory peptides was then analysed on a test set of a 
further 40 blinded samples from 20 cases and 20 controls.  
 
3.3 Results 
3.3.1 Urine proteome in healthy pregnancy 
As a proof of principle, the urinary proteome of healthy pregnant women (who 
did not develop pre-eclampsia, n=17) was compared to that of healthy non-
pregnant female volunteers (n=67). As shown in Figure 3.1, clear differences 
between these two cohorts were seen. On examination of the datasets, 284 
peptides that were significantly altered between the two groups were identified.  
The pregnancy-associated urinary peptides were then evaluated in a second set 
of independent samples; 248 urine samples from pregnant women that were 
included in the study and 141 healthy non-pregnant controls. Support vector 
machine (SVM) classification based on the 284 peptides revealed 98.6% 
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specificity and 98.4% sensitivity in the independent dataset. All pregnancy 
associated peptides are listed in Appendix XI.  
 
Figure 3-1.   Averaged urinary proteome in non-pregnant controls (a) and pregnant women 
at gestational week 12-16 (b). x-axis shows CE migration time (secs), y-axis molecular mass 
(Da), and z-axis signal intensity. Discriminatory peptides are shown between non-pregnant 
controls (c) and pregnant women at gestational week 12-16 (d)  
 
3.3.2 Biomarkers for prediction of pre-eclampsia at Week 28 
After having established clear differences in the urinary proteome between 
pregnant and non-pregnant women, further studies were performed to 
investigate whether biomarkers for the prediction of pre-eclampsia could be 
detected in the urinary proteome at gestational week 28. From the cohort of 
women with ≥2 risk factors for pre-eclampsia, 18 samples from women who 
subsequently developed pre-eclampsia (cases) and 17 samples from women who 
had normotensive pregnancies (controls) were examined (figure 3.2). After 
adjustment for multiple testing, the 10 biomarkers most significantly associated 
with pre-eclampsia were identified. A model containing these 10 biomarkers 
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differentiated between cases and controls (p<0.001).  A biomarker model was 
then generated which included an additional 40 peptides which were nominally 
significant between cases and controls. This more stable model enabled 
classification of the samples with 100% sensitivity and specificity, even when 
evaluated using complete take-one-out cross-validation. Based upon this model a 
classification factor was calculated as outlined in Chapter 2; classification factor 
was 1.032 ± 0.411 in women who subsequently developed pre-eclampsia (cases) 
compared to -1.038±0.432 (P<0.001, figure 3.3) in those whose pregnancy 
continued without developing pre-eclampsia.  
The peptides which were associated with pre-eclampsia include collagen 
fragments, fibrinogen and uromodulin. Full details of the peptides are shown in 
table 3.4.  
 
Figure 3-2 Averaged urinary proteome for pregnant controls at gestational week 28 (a) and 
women who subsequently developed pre-eclampsia (b). x-axis shows CE migration time 
(secs), y-axis molecular mass (Da), and z-axis signal intensity. Discriminatory peptides are 
shown for pregnant controls (c) and for women who subsequently developed pre-eclampsia 
(d).  
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Figure 3-3 Classification of pre-eclampsia specific urinary biomarkers. Translation of the 
pre-eclampsia specific urinary polypeptide signature (figure 3.2) into a classification factor 
demonstrates significant difference between women at gestational week 28 who 
subsequently developed pre-eclampsia (cases; open diamonds) and women who had 
normotensive pregnancies (controls; filled diamonds). Sensitivity and specificity were 100% 
with positive numbers predicting high risk for pre-eclampsia. 
 
This 50-marker panel was then examined to determine whether it could be used 
to detect pre-eclampsia at an earlier point in pregnancy. Using samples from the 
PIP study (gestational week 12-16) 45 women who subsequently developed pre-
eclampsia were matched for age and body mass index at booking to 86 controls 
who had normotensive pregnancies. Using the pre-eclampsia pattern generated 
from week 28, the model differentiated between those who went on to develop 
pre-eclampsia (classification factor -0.567±0.372) and those who had 
uncomplicated pregnancies (classification factor -0.721±0.439, P=0.048) (Figure 
3.4a).  
  
In a second step the classification factors were examined in samples from 
women with risk factors who had provided urine samples both at weeks 12-16 
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and 28. Classification factor decreased slightly from gestational week 12-16 to 
28 in those women who were sampled at both times and had a normal pregnancy 
(n=16; from -0.647±0.437 to -1.024±0.433, P=0.043; Figure 3.5a) whereas it 
markedly changed towards positive scores in those women who subsequently 
developed pre-eclampsia (n=16; from -0.392±0.383 to 1.070±0.383, P<0.001; 
Figure 3.5b). 
 In a third step, week 20 urine samples were analysed from 99 women (50 cases, 
49 controls) from the SCOPE study. In this cohort there was no significant 
difference between cases (classification factor, -0.755±0.533) and controls (-
0.724±0.418, P=0.73; Figure 3.4b), suggesting that the biomarkers identified at 
week 28 do not reliably predict pre-eclampsia when analysed earlier in 
pregnancy. Finally, the samples from gestational week 12-16 and 20 were 
analysed in order to find whether any other biomarker patterns could be used to 
accurately differentiate between cases and controls, and thereby to predict pre-
eclampsia, at an earlier time in pregnancy. No such early predictive biomarker 
patterns were identified.  
 
Figure 3-4 The classification factor was different between controls and women with future 
pre-eclampsia at gestational week 12-16 (PIP study; panel A) but not in an independent 
study cohort at gestational week 20 (SCOPE study; panel B). 
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Figure 3-5  Panel A shows changes in classification factor from gestational week 12-16 to 28 
in normotensive pregnancy (n=16; A) and in women who subsequently develop pre-
eclampsia (n=16; B). Horizontal lines indicate mean values.  
 
 
3.4 Discussion 
In this study CE-MS technology was used to examine the urinary proteome in 
pregnancy, and to attempt to identify a urinary proteomic signature that can be 
used in early and mid pregnancy to predict pre-eclampsia. At gestational week 
28, a urinary peptide pattern was identified, characterised by breakdown 
products of fibrinogen, collagen and uromodulin, which could differentiate 
women who subsequently developed pre-eclampsia. Given that the majority of 
women in this study were diagnosed with pre-eclampsia after 36 weeks’ 
gestation, this set of biomarkers may prove to be a helpful aid in the diagnosis of 
late-onset pre-eclampsia.  
Although the peptide pattern was used to differentiate between cases and 
controls at gestational week 12 to 16, it did not differentiate between cases and 
controls in an independent cohort of pregnant women at gestational week 20. 
The magnitude of overlap between cases and controls at 12 to 16 weeks, and the 
failure to replicate these findings in another cohort, preclude the use of this 
urinary peptide pattern as an early screening test. The different findings in the 2 
cohorts may result from differences in gestational age at sampling (20 weeks 
rather than 28 weeks) and study populations: SCOPE comprised healthy 
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nulliparous women, whereas PIP was a mixed-parity general obstetric 
population. 
The performance of this urinary peptide pattern at 28 weeks to discriminate 
women who subsequently developed pre-eclampsia from those with an 
uncomplicated pregnancy is similar to or better than that reported with serum 
FMS-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PGF) in the 
second trimester for early-onset pre-eclampsia (298-300). The discrimination 
seen with the urinary peptide pattern at 28 weeks is more in keeping with the 
diagnostic performance of the angiogenic biomarkers when measured in women 
after they have presented with symptoms or signs of pre-eclampsia (301).  
The failure of “classical” circulating biomarkers to accurately predict pre-
eclampsia (81), and the inconsistent results obtained from genetic studies (302) 
have led to an increase in recent years in “systems-medicine” based approaches 
such as proteomics. As discussed in chapter 1.7, previous proteomic research in 
pre-eclampsia has yielded mixed results. Amniotic fluid (240),  cerebro-spinal 
fluid (242) and placental tissue (303) have all been used for proteomic studies in 
pre-eclampsia, using samples taken from women undergoing amniocentesis, 
spinal anaesthesia, and Caesarean section respectively. All have reported 
peptide patterns that can accurately differentiate between women with pre-
eclampsia and women with normal pregnancies, but in keeping with most other 
studies in the field, samples were taken at the time of delivery rather than 
before it when such patterns may be clinically useful. Further, the invasive 
sampling required means that these media could never be applicable in large-
scale studies, nor in routine clinical practice.  
Plasma has been studied more extensively. Examining plasma from women at the 
time of diagnosis of pre-eclampsia, Blankley et al. (237) identified 
discriminatory peptides for pre-eclampsia included endoglin, pregnancy-
associated plasma protein A (PAPP-A) and sex hormone binding blobulin (SHBG), 
all of which have been reported to be altered in pre-eclampsia. In a separate 
study Blumenstein et al. (236) examined the plasma proteome at gestational 
week 20 in 39 women from the SCOPE cohort who subsequently developed pre-
eclampsia. They found 36 moderate-highly abundant proteins that were 
differentially expressed in women who went on to develop pre-eclampsia 
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compared to controls. Among these were proteins involved in lipid metabolism 
including Apolipoprotein A1, fragments of collagen and fibrinogen, and 
complement precursors.  
As discussed in section 1.6, the complexity of the plasma proteome, and the 
relatively high proteolytic activity of human blood mean that proteomic analysis 
of plasma and serum is potentially unreliable (218). To date, one other study has 
used urinary proteomics to identify disease-specific proteomic biomarkers for 
pre-eclampsia. As outlined in section 1.7.3, Buhimschi et al. (238) identified 
fragments of serpin peptidase inhibitor 1 (SERPINA-1) and albumin as biomarkers 
for pre-eclampsia. Although the peptide pattern allowed discrimination of 
severe from mild forms of pre-eclampsia, there was considerable overlap in 
peptide patterns with women with chronic hypertension. Further, patient 
numbers in their study were low, with only 19 women studied longitudinally 
during their pregnancy, of whom 3 developed pre-eclampsia. 
The differentially expressed polypeptide sequences between cases and controls 
identified in the current study are not only of potential clinical use but point 
towards biological processes that are altered during the development of pre-
eclampsia. Changes in extracellular matrix are a feature of all vascular diseases 
and are represented by a number of differentially expressed collagen fragments 
in the peptide pattern. These findings are not only in line with plasma proteome 
data by Blumenstein et al.(236), but also with previous studies of urinary 
proteomic markers of chronic kidney disease (304) and coronary artery disease 
(221,305). These conditions share some of the features of pre-eclampsia 
including endothelial dysfunction and inflammation and may therefore also be 
expected to share some of the characteristic proteomic markers with pre-
eclampsia. Fibrinogen leads to endothelial cell activation, which is another 
hallmark of the pathogenesis of pre-eclampsia and also features as a biomarker 
of pre-eclampsia in the study by Blumenstein et al. (236). Differential expression 
of uromodulin sequences in urine between cases and controls is not surprising 
since uromodulin, or Tamm-Horsfall protein, is the most abundant protein in 
normal urine and could therefore simply indicate non specific changes in the 
composition of urine in parallel to the disease process. The UMOD gene locus, 
however, has been found to be associated with glomerular filtration rate in 
genome-wide association studies (306) indicating a potential functional role of 
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uromodulin in the development of cardiovascular diseases. More recently, a 
genome-wide association study demonstrated that rs13333226 in the promoter 
region of UMOD is associated with hypertension, independently of renal function 
(307). These data on uromodulin, as a key player in renal disease and 
hypertension, could point towards subclinical vascular and renal damage in the 
early stage of pre-eclampsia that are indicated by differential urinary expression 
of uromodulin fragments and warrant further investigation. 
In this proteomic approach, analysis was restricted to peptides and proteins with 
a molecular mass >800 Da, whose concentrations were at least 2-fold different 
between cases and controls. Whereas typical pregnancy-related hormones such 
as oestrogen or progesterone and their respective metabolites can be detected 
in urine using mass spectrometry, the sample preparation and the data 
evaluation used in this study excluded these and many other smaller 
metabolites. This analytical approach should therefore be regarded as 
complementary to other approaches for the identification of diagnostic and 
predictive markers. The findings outlined here require validation in larger 
predictive and diagnostic studies to define their potential role in clinical care. 
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Mass CE_time Sequence Protein name 
Start 
AA 
Stop 
AA Swissprot name 
3657.665 40.71091      
3292.541 39.42096      
2841.256 24.53535 
ERGEAGIpGVpGAkGE
DGKDGSpGEpGANG 
Collagen alpha-
1 (III) chain 448 477 CO3A1_HUMAN 
2674.217 34.58338      
2658.271 19.47609 
DEAGSEADHEGTHST
KRGHAKSRPV 
Fibrinogen 
alpha chain 605 629 FIBA_HUMAN 
2587.195 21.09996      
2570.19 42.56018      
2196.993 33.68827      
2117.032 42.00351      
2048.927 24.46324      
2030.912 21.85225 
EGSpGRDGSpGAkGD
RGETGP 
Collagen alpha-
1 (I) chain 1021 1041 CO1A1_HUMAN 
2019.876 19.75444      
2014.898 21.90602 
EGSpGRDGSpGAKGD
RGETGP 
Collagen alpha-
1 (I) chain 1021 1041 CO1A1_HUMAN 
1968.9 25.96413      
1817.694 20.23435      
1812.786 24.13738      
1807.809 20.64857      
1795.793 24.99647      
1668.805 40.46556      
1652.698 20.12811      
1640.581 23.24178      
1594.762 40.21545 
pGpSGLPGLPGpPGPP
GP 
Collagen alpha-
3 (IX) chain 141 158 CO9A3_HUMAN 
1540.772 29.86551 SGSVIDQSRVLNLGP Uromodulin 589 603 UROM_HUMAN 
1495.684 23.3582      
1484.666 23.56837      
1482.666 22.46624      
1474.658 20.05341      
1417.635 20.02529      
1407.602 21.61461      
1405.635 20.13912 DGPpGRDGQpGHKG 
Collagen alpha-
2 (I) chain 933 946 CO1A2_HUMAN 
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1353.532 23.96295      
1319.584 20.88625      
1294.601 27.2447      
1270.503 38.0709      
1268.565 29.1139      
1263.543 22.72857      
1154.576 19.52543      
1138.586 19.50684      
1135.49 27.82094      
1101.537 27.61594      
1091.482 20.51256      
1071.494 21.43072      
1016.445 25.78512 ApGDKGESGPS 
Collagen alpha-
1 (I) chain 777 787 CO1A1_HUMAN 
949.219 34.33332      
945.4161 25.7221      
942.4489 20.46245      
906.1788 34.26189      
903.4102 21.58346      
858.3934 23.2367 SpGEAGRpG 
Collagen alpha-
1 (I) chain 522 530 CO1A1_HUMAN 
Table 3-4 List of peptides associated with pre-eclampsia at week 28
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4. Early pregnancy plasma biomarkers for the 
prediction of pre-eclampsia 
 
4.1 Introduction 
Pre-eclampsia has major implications for maternal and foetal health worldwide; 
despite decades of research it remains difficult to predict which women are 
likely to be affected. As discussed in section 1.1, several maternal 
characteristics including nulliparity, obesity, blood pressure and age at 
conception are associated with an increased risk of developing the condition, 
but no clinical or biochemical markers exist that can be used in early pregnancy 
to accurately risk-stratify women. Several biomarkers are reported to be 
elevated at the time of disease, but few have been shown to be elevated before 
diagnosis, a time-point when they could be clinically useful (308).  
 
Although the diagnosis of pre-eclampsia is usually made after 30 weeks of 
gestation, the underlying pathophysiology begins much earlier. The disease 
development is described as occurring in several stages: the early stages involve 
primarily the placenta, and only the final stages, characterised by hypertension 
and proteinuria, are clinically detectable (309). The search for predictive 
biomarkers has focused largely on placental factors, in particular anti-angiogenic 
peptides, which are released into the maternal circulation. As discussed in 
Chapter 1, elevated levels of soluble fms-like tyrosine kinase-1 (sFLT-1) and 
soluble endoglin (sENG) have been reported in women with pre-eclampsia, both 
at diagnosis (310) and, crucially, prior to the onset of clinically detectable 
disease (134,311,312). Neither these nor other biomarkers, however, have 
crossed the boundary to routine clinical practice. 
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The syndrome of pre-eclampsia is characterised by impaired placentation, 
maternal endothelial dysfunction and inflammation, arising from both the 
oxidatively stressed and ischaemic placenta, and from the excessive maternal 
systemic inflammatory response. This excessive response is thought to be 
predominantly Th1-cell mediated, in contrast to the largely Th-2 mediated 
response which is associated with normal pregnancy, and which may help to 
protect the foetus from the maternal immune system (313). Associations of 
several inflammatory markers with pre-eclampsia have been investigated: 
tumour necrosis factor alpha (TNF-α), interleukin 1-α and 1-β, interleukin-6 and 
interleukin-8 have all been reported to be elevated in the blood of women with 
pre-eclampsia (314). Adhesion molecules also play a key role in the 
inflammatory response, regulating the adherence of leucocytes to endothelial 
cells and the migration of leucocytes into perivascular tissue. Cellular forms of 
these molecules can be detected in the blood, and their levels are altered 
dramatically in conditions such as sepsis, acute coronary syndromes and 
rheumatoid arthritis (190). Circulating concentrations of the adhesion molecules 
P-Selectin (189,190), vascular cellular adhesion molecule-1 (VCAM-1; (191,315)), 
E-Selectin (189,190,316) and inter-cellular adhesion molecule-1 (ICAM-1; (190)) 
are reported to be elevated in women with established pre-eclampsia, indicating 
endothelial dysfunction. Few studies have examined these molecules in 
longitudinal studies throughout pregnancy. Inconsistent perturbations in their 
concentrations have been reported at 18-20 weeks of gestation among women 
who subsequently developed pre-eclampsia (194,278,317), while one study 
reported elevated P-Selectin concentrations at week 10-14 in 20 affected women 
(195). These hypothesis-generating findings require further study. 
 
In this study, therefore, a panel of circulating inflammatory cytokines and 
adhesion molecules were examined in the first trimester of pregnancy, and were 
screened for those that could be developed into clinically useful predictive 
markers for pre-eclampsia. 
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4.2 Methods 
4.2.1 Patient recruitment 
The Proteomics in Preeclampsia (PIP) study is described in detail in Chapter 2. At 
the time of this analysis delivery information was available on 2600 women who 
had been recruited at their initial antenatal hospital (booking) visit, of whom 49 
(1.9%) developed pre-eclampsia. These women were matched as closely as 
possible for age, body-mass index and gestational age at booking with 74 control 
women who had normotensive deliveries and delivered appropriately grown 
babies after 37 weeks’ gestation. Patient characteristics are shown in Table 4.1. 
 Cases (n=49) Controls (n=74) P-value 
Maternal age (yrs) 27.5±5.2 27.9±5.4 0.7 
Gestation at booking (weeks) 13.7±1.9 13.6±1.2 0.64 
BMI (kg/m²) 28.8±5.5 29.0±5.0 0.83 
SBP (mmHg) 120±12 114±11 0.01 
DBP (mmHg) 74±9 69±9 0.01 
Nulliparous  43 (88%) 54 (73%) 0.07 
Previous pre-eclampsia  1 (2%) 3 (4%) 1.00 
Family history of preeclampsia 7 (14%) 4 (5%) 0.11 
Twin pregnancy  2 (4%) 1 (1%) 0.56 
Smoker  6 (12%) 14 (19%) 0.45 
PlGF (pg/mL) 19.8 [10.4] 30.0 [20.2] <0.001 
sFLT-1 (pg/mL) 1766±609 1705±550 0.58 
sENG (ng/mL) 5.56 [3.9] 5.39 [2.3] 0.025 
Gestation at delivery (weeks) 37.8±2.5 39.9±2 <0.001 
Caesarean Section  26 (53%) 12 (16%) <0.001 
Birthweight (grams) 2938±734 3575±420 <0.001 
Table 4-1. Characteristics at booking of 49 women who developed pre-eclampsia (cases) 
and 74 women who had normotensive pregnancies (controls). Data are expressed as mean 
± standard deviation, or as n (percentage of total.) Non-normally distributed data are 
expressed as median [inter-quartile range].  
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As outlined in Chapter 2, women from the PIP study with 2 or more traditional 
risk factors for pre-eclampsia were invited for further sampling at gestational 
weeks 16 and 28. 180 women attended at gestational week 16 and 28; 17 (9.4%) 
of these women developed pre-eclampsia, 7 (3.9%) developed pregnancy-
induced hypertension, while the remainder had normotensive deliveries. For the 
this study, plasma samples of the first 11 cases and 39 women matched as 
closely as possible for age, BMI and parity who had normotensive deliveries 
(controls) were examined (table 4.2). Of these 50 women, 44 attended for 
further sampling 6-9 months post-natally (6 cases, 38 controls).  
 
 Cases (n=11) Controls (n=39) P-value 
Maternal age (yrs) 27.8±4.4 33.5±4.9 0.001 
BMI (kg/m²) 31.3±5.5 27.5±5.7 0.059 
SBP (mmHg) 127±9 123±14 0.469 
DBP (mmHg) 79±6 76±12 0.395 
Nulliparous n (%) 10 (91%) 14 (36%) 0.002 
Previous pre-eclampsia (n%) 1 (9%) 9 (23%) 0.423 
Family history of pre-
eclampsia n (%) 
5 (45%) 6 (15%) 0.005 
Twin pregnancy n (%) 1 (9%) 0 (0%) 0.22 
Smoker  1 (9%) 7 (18%) 0.67 
Gestation at delivery 
(weeks) 
39.1±1.8 40.3±1.3 0.018 
Caesarean Section n (%) 5 (45%) 5 (13%) 0.03 
Birthweight (g) 3284±469 3755±492 0.007 
Table 4-2. Characteristics at booking of women sampled at gestational week 16 and 28. Data 
are expressed as mean ± standard deviation, or as n (percentage of total.) Non-normally 
distributed data are expressed as median [inter-quartile range]. BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure.  
 
 
Having identified a potential biomarker in this study cohort, a further aim was to 
confirm the findings in an independent validation cohort. For this purpose, 
samples were made available from the Glasgow Outcome, Activated protein C 
resistance and Lipid (GOAL) study. This prospective pregnancy study, carried out 
in Glasgow between May 1997 and May 1999 was designed to examine the impact 
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of Factor V Leiden mutations on vascular complications of pregnancy. Over 4200 
pregnant women were included in the study; recruitment protocols have been 
described in detail elsewhere (318). Women were sampled at their first 
antenatal hospital visit (7-16 week gestation) and again in the third trimester 
(between 27 and 40 weeks of gestation). Patient characteristics were broadly 
similar to the PIP study, with a median maternal age of 29 (25-32) and an overall 
incidence of pre-eclampsia of 1.7% (318). Sixty-four first trimester (gestational 
week 7-16) plasma samples (33 cases and 31 controls matched for age and 
parity) and 58 third trimester (gestational week 27-34) plasma samples (28 
cases, 30 controls) were re-analysed for the current study. 
 
4.2.2 Circulating biomarkers 
Blood samples were obtained from the antecubital fossa into an EDTA tube (PIP) 
or sodium citrate tube (GOAL). Samples were stored at room temperature for 
less than one hour, transferred refrigerated to the research centre, and 
centrifuged at 3000 rpm for 10 minutes. The resultant plasma was stored at       
-70°C and defrosted immediately prior to analysis. 
Plasma levels of VCAM-1, ICAM-1, P-Selectin, E-Selectin and L-Selectin, 
Interleukins 1-α, 1-β, 2, 4, 6, 8 and 10, vascular endothelial growth factor 
(VEGF), tumour necrosis factor alpha (TNF-α), interferon-γ, monocyte 
chemotactic protein-1 (MCP-1) and epidermal growth factor (EGF) were 
determined by immunoassay using multi-analyte biochip array technology 
(Evidence Investigator, Randox Laboratories). Protocols and quality control 
procedures are described in Chapter 2.  
 
Soluble FMS-like tyrosine kinase-1 (sFLT-1), soluble endoglin (sENG), placental 
growth factor (PlGF) and E-selectin levels were measured using commercially 
available enzyme-linked immunosorbent assay (ELISA) kits (R+D Systems, 
Abingdon, UK) as outlined in Chapter 2. All samples were measured in duplicate, 
and mean values were used for statistical analysis. Intra-assay coefficients of 
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variation were 3.0%, 8.0%, 3.8%, 3.7% and 2.9% for sFLT-1, PlGF, sEng, E-selectin 
(PIP study) and E-selectin (GOAL study), respectively. 
 
4.2.3 Statistical analysis  
Statistical analysis was performed using SPSS (Version 15.0; SPSS Inc., Chicago 
IL, USA). Data are expressed as mean ± standard deviation or as number 
(percentage of total). The Kolmogorov-Smirnov test was used to evaluate the 
data distribution. Non-normally distributed data were log-transformed prior to 
analysis, and mean values were compared using the unpaired two tailed 
Student’s t-test. Variables that remained non-parametric after log-
transformation are expressed as median [inter-quartile range] and were 
compared using the Mann-Whitney U–test. A probability value of P<0.05 was 
considered significant. 
4.3 Results 
4.3.1 PIP booking visit samples: screening experiments 
Controls were similar to cases in respect of matched variables (Table 4.1). As 
expected, women who subsequently developed pre-eclampsia already had higher 
systolic and diastolic blood pressure at booking, going on to deliver babies of 
lower birthweight at an earlier gestation and with a higher rate of Caesarean 
delivery (Table 4.1). To further confirm that this study cohort was in keeping 
with other studies in the field, circulating concentrations of sENG, sFLT-1 and 
PIGF from the booking visit were measured in women who went on to develop 
pre-eclampsia and in women who remained normotensive. As expected, plasma 
levels of PIGF were significantly lower (P<0.001) in women who went on to 
develop pre-eclampsia, while levels of sENG were significantly higher (P=0.025) 
in affected women (figure 4.1). At booking, sFLT-1 levels were not different 
between the 2 groups; when sFLT-1 levels were measured at gestational week 
28, however, levels were higher in affected women (1979±1118 vs 1230±624 
pg/ml; P=0.003).  
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Figure 4-1 Levels of PlGF, sENG and sFLT-1 at the booking visit in the overall (low risk) 
population. Mean first trimester concentrations in women who developed preeclampsia 
(cases) and women who had normotensive pregnancies (controls) are displayed. 
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Multimarker assays of inflammatory markers and cytokines were then performed 
comparing the 49 cases and 74 controls (Table 4.1). E-Selectin levels were 
significantly higher (P=0.022) in women who went on to develop pre-eclampsia, 
compared to controls (figure 4.2).  There were no significant differences 
between cases and controls in levels of any of the other biochemical markers (all 
P>0.05, table 4.3). When analysed using a receiver operating characteristic 
(ROC) curve, the area under the curve (AUC) for E-Selectin was 0.653. Using the 
median E-Selectin level (12.5 ng/ml) as a cut-off, a sensitivity of 68% and a 
specificity of 58% for the detection of pre-eclampsia was determined. 
 
Figure 4-2 First trimester E-Selectin concentrations in the overall (low risk) population in 
women who developed preeclampsia (cases) and women who had normotensive 
pregnancies (controls). Boxplots indicate median, interquartile range and range. 
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 Cases (n=49) Controls (n=74) P-value 
VCAM-1 (ng/mL) 512±87 487±101 0.22 
ICAM-1 (ng/mL) 254±75 248±61 0.70 
E-Selectin (ng/mL) 15.1±4.9 12.9±4.5 0.02 
P-Selectin (ng/mL) 93.7±21 96.8±25 0.52 
L-Selectin (ng/mL) 1381±234 1318±288 0.27 
IL-2 (pg/mL)  1.27 [0.68] 1.18 [0.65] 0.75 
IL-4 (pg/mL) 1.58 [0.69] 1.55 [0.54] 0.59 
IL-6 (pg/mL) 0.84 [0.51] 0.86 [0.55] 0.89 
IL-8 (pg/mL) 2.09 [1.02] 2.13 [0.96] 0.48 
IL-10 (pg/mL) 0.76 [0.35] 0.69 [0.32] 0.25 
VEGF (pg/mL) 3.71 [1.28] 3.94 [1.08] 0.93 
Interferon-γ (pg/mL) 0.45 [0.3] 0.38 [0.5] 0.83 
TNF-α (pg/mL) 1.82 [0.61] 1.69 [0.53] 0.33 
IL-1 α (pg/mL) 0.08 [0.06] 0.09 [0.07] 0.27 
IL-1 β (pg/mL) 0.92 [0.78] 0.79 [0.77] 0.33 
MCP-1 (pg/mL) 81.8 [55.9] 96.9 [46.3] 0.41 
EGF (pg/mL) 5.43 [9.52] 9.4 [13.7] 0.12 
Table 4-3 Comparison of circulating levels of adhesion molecules and inflammatory 
cytokines at gestational week 12-16 in cases and controls. Normally distributed data are 
expressed as mean ± standard deviation, non-normally distributed data are expressed as 
median [inter-quantile range].  
 
 
4.3.2 PIP longitudinal study 
In order to investigate the consistency of E-selectin as a marker of risk of pre-
eclampsia throughout pregnancy, further cytokine and growth factor assays were 
measured in the women with risk factors for pre-eclampsia who had been 
sampled longitudinally throughout pregnancy. Plasma samples from gestational 
weeks 16 and 28 (11 cases and 39 controls) and from 6-9 months post-natally (6 
cases and 38 controls) were examined. In keeping with the findings from the 
booking samples, E-Selectin levels were elevated at both time-points (week 16: 
13.6±5.4 vs 10.6±3.3 ng/mL, P=0.032; week 28: 14.4±5.6 vs 10.7±3.5 ng/mL, 
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P=0.010), while there was no difference between cases and controls when 
measured post-natally (11.6±3.9 vs 12.5±3.8 ng/mL, P=0.596; figure 4.3). None 
of the other inflammatory markers were significantly different between cases 
and controls at gestational weeks 16 or 28, or post-natally (table 4.4) 
 
Figure 4-3 E-Selectin concentrations in the risk factor (high risk) population at (a) 
gestational week 16, (b) week 28, and at (c) 6 months post-natally in women who developed 
pre-eclampsia (cases) and women who had normotensive pregnancies (controls). Boxplots 
indicate median, interquartile range and range. 
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4.3.3 Replication using a singleplex ELISA  
In order to minimise any limitations in sensitivity that are inherent from 
multiplex detection assays, these findings were replicated using a commercial E-
Selectin specific ELISA. Samples from gestational week 12-16 that had already 
been measured with the multi-analyte biochip array were reanalysed with the 
ELISA. There was a strong correlation between data from both methods (r=0.715, 
P<0.001) although ELISA data were 4.1-fold lower than multi-analyte biochip 
array data. ELISA data were therefore corrected by multiplying levels by 4.1 and 
the agreement between the two assays subsequent to this adjustment is 
demonstrated in a scatterplot and a Bland-Altman plot (Figure 4.4) 
 
Figure 4-4 Left: Scatterplot showing correlation of E-Selectin measured using Randox assay 
(x-axis) and ELISA assay (y-axis.) There was a strong correlation between data from both 
methods (r=0.715, P<0.001) Right: Bland-Altman plot demonstrating the agreement between 
E-Selectin concentrations when measured using the 2 techniques. 
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4.3.4 GOAL: Validation in an independent study cohort  
Findings from the PIP plasma samples were then validated in an independent 
study cohort. Using the GOAL study cohort, first trimester samples from 33 cases 
and 31 controls, and third trimester samples from 28 cases and 30 controls were 
analysed using the E-Selectin specific ELISA. When measured in the first 
trimester, plasma E-Selectin levels were not different in women who went on to 
develop pre-eclampsia compared to controls (3.0±1.0 vs 2.7±1.3 ng/mL, 
P=0.371; Figure 4.5a). When measured in the third trimester, E-Selectin levels 
were higher in the women who were subsequently affected compared to controls 
(3.9±1.9 vs 3.0±1.6 ng/mL, P=0.048; Figure 4.5 b). 
 
Figure 4-5 : E-Selectin concentrations in the GOAL (mixed risk factor status) study cohort in 
(a) first and (b) third gestation samples, in women who developed preeclampsia (cases) and 
women who had normotensive pregnancies (controls). Boxplots indicate median, 
interquartile range and range. 
 
4.4 Discussion 
Given that pre-eclampsia is a condition characterised by widespread 
inflammation (319), the hypothesis for this study was that screening for a large 
number of inflammatory and adhesion markers using a multi-analyte biochip 
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array would lead to identification of the markers with the strongest association 
with pre-eclampsia. Despite this, circulating concentrations of all inflammatory 
cytokines and growth factors, and the majority of soluble cell adhesion 
molecules in early pregnancy were not different at booking between affected 
and unaffected women. The multiplex assays did, however, demonstrate that 
levels of E-Selectin were significantly higher in women who went on to develop 
pre-eclampsia compared to controls. These findings were confirmed by re-
analysing using an ELISA technique, although multiplex assays were 4.1 fold 
higher than ELISA levels. This difference is perhaps explained by the fact that 
there is no international standard for quantifying E-selectin concentrations, and 
so different manufacturers will have different in-house processes and will use 
different standards for calibrating their assay method. This in itself is not a 
problem when comparing assays as long as they have good agreement, as well as 
good correlation as outlined by Bland & Altman (320). The strong agreement 
observed further suggests that the antibodies used by the manufacturers are 
likely to be recognising similar antigens and not distinct isoforms of the soluble 
E-selectin fragment. Further verification of the elevated E-selectin levels in pre-
eclampsia was provided using samples from the same cohort of women at later 
time points during pregnancy, and from third trimester (but not first trimester) 
samples from an independent cohort. 
E-Selectin is an 11 kD cell-surface glycoprotein, and is a member of the selectin 
family involved in mediating the interaction of circulating leucocytes with the 
vascular endothelium. It is expressed exclusively on endothelial cells, in 
response to cytokines including TNF-α and Interleukin-1 (189). Elevated soluble 
E-Selectin levels are indicative of endothelial cell activation and damage, and 
given that endothelial dysfunction can explain many of the clinical 
characteristics of the condition (321), it is perhaps not surprising that elevated 
soluble E-Selectin levels are associated with pre-eclampsia. E-Selectin 
concentrations have been previously reported to be elevated at the time of 
delivery in women with both mild and severe pre-eclampsia (189), and to be 
elevated at week 20 in women who went on to develop the condition (194). This 
study has demonstrated that elevated E-selectin is detectable at an earlier point 
in pregnancy, possibly as early as the end of the first trimester. This may suggest 
an aetiological role, or that expression and cleavage of the molecule reflects 
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early pathophysiological changes leading to pre-eclampsia. It is clear, however,  
that E-Selectin levels alone would not be a useful predictor of pre-eclampsia; 
the area under the ROC curve for E-Selectin was inferior to that recently 
demonstrated using a model of clinical risk factors for predicting pre-eclampsia 
in the SCOPE cohort described in Chapter 3 (3).  
Strengths and limitations of this study should be considered. Many of the studies 
designed to find biomarkers for predicting pre-eclampsia in early pregnancy have 
rigid protocols where women attend at certain time-points during pregnancy. In 
reality, women attend their healthcare professional at a variety of time-points, 
depending on the regularity of their normal menstrual cycle, on local protocols, 
and on pressures upon midwifery and ultrasound services. One advantage of the 
PIP study is that the “real-life” situation of antenatal care has been reflected, 
by including all women up to 18 weeks of gestation.  
In keeping with the literature, elevated circulating levels of sENG (134) and 
reduced circulating PlGF levels (311) were seen in women who went on to 
develop pre-eclampsia compared to controls. sFLT-1 levels (310) were not 
different between the 2 groups at booking, but when measured in third 
trimester samples were higher in affected women. These results suggest that PIP 
is an externally comparable cohort to test predictive markers for pre-eclampsia. 
A potential limitation of this paper is that both the PIP and the GOAL studies 
were performed in Glasgow, a city which has some of the highest rates of 
cardiovascular disease in Europe. E-Selectin polymorphisms have been reported 
to be associated with essential hypertension (322) and coronary artery disease 
(323), while E-Selectin levels are also associated with a variety of risk factors for 
cardiovascular disease (324). It is possible therefore that increased E-selectin 
levels do not specifically explain the pathophysiology of pre-eclampsia in these 
cohorts but rather lead to higher blood pressures and thereby trigger the 
initiation of a process that eventually causes pre-eclampsia. In this study as in 
many other studies (12), both systolic and diastolic blood pressures were already 
slightly but significantly higher at booking in women who subsequently 
developed pre-eclampsia compared to those with uncomplicated pregnancies.  
 
169 
How best to diagnose pre-eclampsia, and how to define severe forms of the 
disease remain a matter of debate. The majority of women in this study had 
late-onset, milder variants of pre-eclampsia, with only 9 having more severe, 
early onset (diagnosed at <37 weeks’ gestation) disease. Previous studies have 
reported that levels of angiogenic factors correlate with severity of disease 
(325), and one might expect the same of E-Selectin levels. Bretelle et al. (326) 
reported that E-Selectin levels at term were elevated in normotensive women 
with small for gestational age (SGA) babies, as well as in those with pre-
eclampsia. Further studies, comparing E-Selectin levels in women with early and 
late-onset disease, and in women with pre-eclampsia with SGA babies would be 
beneficial.   
A further limitation is the first trimester findings from the PIP study were not 
replicated in first trimester samples from the GOAL study. There are a number 
of factors which could account for this: first trimester samples from the GOAL 
study were taken as early as gestational week 7, which is earlier than in PIP and 
the majority of other studies, and may be before the early pathophysiological 
changes of pre-eclampsia can be detected. Another factor may be that quality of 
GOAL samples was suboptimal due to a storage time of up to 13 years. 
Finally, out of the many biomarkers analysed with the multi-analyte biochip 
array only E-selectin levels were different between cases and controls. This may 
be because this method of measurement was not sensitive enough to detect 
differences between cases and controls, or because there is truly no difference 
in levels at this early stage in pregnancy. The fact that the findings were 
confirmed both in later stages of pregnancy, and in an independent study 
cohort, suggest that the elevated E-Selectin levels in affected women were not a 
false positive finding related to multiple testing. These data highlight a potential 
functional role of soluble E-Selectin in the development of pre-eclampsia, or 
reflect E-selectin being a biomarker of underlying pathophysiological processes. 
Further epidemiological and basic science studies are required to confirm and 
expand on these findings. 
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 Week 16 Week 28 Post-natal 
 Cases 
(n=11) 
Controls 
(n=39) 
P Cases 
(n=11) 
Controls 
(n=39) 
P Cases 
(n=6) 
Controls 
(n=38) 
p 
VCAM-1 (ng/mL) 471±69 491±110 0.58 505±82 476±97 0.38 558±98 507±105 0.27 
ICAM-1 (ng/mL) 214±78 239±50 0.21 235±93 239±52 0385 180±41 230±60 0.06 
E-Selectin (ng/mL) 13.6±5.4 10.6±3.3 0.03 14.4±5.6 10.7±3.5 0.01 11.6±3.9 12.5±3.8 0.60 
P-Selectin (ng/mL) 115±33 112±44 0.85 123±38 123±38 0.99 116±33 124±55 0.75 
L-Selectin (ng/mL) 1166±131 1158±177 0.89 993±127 966±133 0.55 1255±81 1257±175 0.98 
IL-2 (pg/mL)  2.73 [2.84] 1.54 [1.29] 0.35 1.34 [0.27] 1.34 [0.69] 0.89 1.6 [5.5] 1.89 [2.6] 0.79 
IL-4 (pg/mL) 1.54 [0.7] 1.62 [0.89] 0.45 1.67 [1.26] 1.49 [0.46] 0.68 2.1 [2.1] 1.71 [1] 0.16 
IL-6 (pg/mL) 0.69 [0.29] 0.82 [1.04] 0.5 1.15 [0.48] 1.1 [1.21] 0.89 1.39 [0.73] 0.93 [0.81] 0.17 
IL-8 (pg/mL) 2.38 [2.08] 2.38 [1.24] 0.75 2.28 [0.99] 2.46 [1.75] 0.36 3.39 [1.98] 4.5 [3.0] 0.16 
IL-10 (pg/mL) 0.81 [0.72] 0.78 [0.42] 0.91 0.7 [0.18] 0.7 [0.34] 0.3 0.68 [0.21] 0.79 [0.46] 0.32 
VEGF (pg/mL) 5.08 [4.13] 4.42 [1.83] 0.98 4.89 [4.18] 5.17 [3.3] 0.48 24.5 [24] 22 [19] 0.81 
IFN-γ (pg/mL) 0.55 [0.43] 0.58 [0.63] 0.83 0.62 [0.4] 0.59 [0.8] 0.99 0.54 [2.4] 0.88 [1.1] 0.66 
TNF-α (pg/mL) 1.43 [0.61] 1.61 [0.83] 0.27 1.6 [0.6] 1.73 [0.6] 0.64 2.3 [0.48] 2.23 [0.8] 0.42 
IL-1 α (pg/mL) 0.12 [0.04] 0.1 [0.1] 0.61 0.13 [0.2] 0.11 [0.1] 0.49 0.15 [0.19] 0.17 [0.14] 0.96 
IL-1 β (pg/mL) 0.7 [1.62] 0.86 [1.0] 0.86 0.77 [0.77] 0.95 [0.99] 0.39 1.17 [1.12] 1.1 [1.3] 0.89 
MCP-1 (pg/mL) 89.6 [45] 84.3 [41.6] 0.56 68.3 [30.8] 71.6 [34] 0.84 120 [31] 130 [99] 0.43 
EGF (pg/mL) 18.6 [29.6] 12.7 [21.2] 0.45 12.2 [17.5] 21 [25] 0.57 15.2 [21] 20.1 [44] 0.61 
Table 4-4 Circulating concentrations of adhesion molecules and inflammatory cytokines in women studied longitudinally throughout pregnancy. Normally 
distributed data are expressed as mean ± standard deviation, non-normally distributed data are expressed as median [inter-quantile range].
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5. A study of peripheral arterial tonometry (PAT) for 
the assessment of endothelial function in 
pregnancy 
 
5.1 Introduction 
Pregnancy is associated with a number of physiological vascular changes, 
including an increase in cardiac output and a reduction in peripheral resistance 
and blood pressure (106). These changes, which are evident as early as 5 weeks 
gestation (90), are reported to be largely governed by the vascular endothelium. 
Long considered to be an inert barrier to elements contained within the blood, 
the endothelium is now known to have a number of physiological roles, acting as 
a biological interface between blood and the tissues, and modulating growth, 
haemostasis, vascular tone and inflammation throughout the circulatory system.  
Although pre-eclampsia is recognised as having its origins in the placenta (327), 
it is thought that many of the clinical manifestations of the condition including 
hypertension, proteinuria and oedema are caused by dysfunction and mal-
regulation of the maternal endothelium (265). Detection of endothelial 
dysfunction could therefore represent a potential area for the early prediction 
of pre-eclampsia, which could in turn lead to earlier diagnosis, closer monitoring 
of affected women, and intervention where indicated.  
Several studies have demonstrated the relationship between endothelial 
dysfunction and pre-eclampsia (89,90,265,328), but the majority have been 
restricted to in-vitro experiments involving endothelial cells or vessels from 
maternal or foetal tissues. These and other techniques for assessment of the 
endothelium involving infusion of vasoactive substances are clearly too invasive 
to be used either in large studies of pregnant women, or in routine clinical 
practice.  
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A non-invasive technique for the measurement of endothelial function, 
ultrasonic measurement of flow-mediated dilatation (FMD) at the brachial 
artery, has been reported extensively. As discussed in section 1.3, previous 
studies have shown enhanced FMD as normal pregnancy progresses (86), with the 
highest dilatation in the third trimester (329). FMD measurement using this 
technique has been reported to be significantly reduced, suggesting endothelial 
dysfunction, in women with pre-eclampsia compared to women with 
normotensive pregnancies (88).  
The use of ultrasound to measure FMD, however, requires specific training, and 
is dependent upon the skill of the operator, which may preclude its use in 
widespread clinical practice. An alternative technique for assessment of 
endothelial function which has emerged in recent years is the assessment of 
peripheral arterial tone (PAT). This technique assesses peripheral microvascular 
endothelial function by measuring changes in digital pulse volume during 
reactive hyperaemia. The reactive hyperaemia index (RHI) generated is highly 
correlated with ultrasound-based FMD (330), and also with coronary artery 
endothelial function on angiography following infusion of acetylcholine (288). 
Data from the Framingham cohort have demonstrated an independent 
relationship between RHI and multiple traditional and metabolic cardiovascular 
risk factors (331). In contrast to ultrasound based techniques the assessment of 
endothelial function by PAT requires minimal specific training, and therefore 
may be applicable in large clinical studies (332).  
The aim of this study was to evaluate endothelial function as assessed by PAT at 
different time-points during pregnancy. I assessed the ability of PAT studies in 
early pregnancy to predict hypertensive disorders in later pregnancy, and 
examined the relationship between RHI and risk factors for pre-eclampsia. 
Further, I examined how endothelial function scores derived from PAT correlate 
with those derived from flow-mediated dilatation, and examined whether 
abnormalities persisted after pregnancy.  
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5.2 Methods 
5.2.1 Patient recruitment 
The overall Proteomics in Pre-eclampsia (PIP) study is described in detail in 
Chapter 2. A subset of 180 pregnant women with ≥2 risk factors for pre-
eclampsia were invited to attend for study visits at gestational weeks 16 and 28, 
and at 6-9 months post-partum for further sampling and vascular function 
studies. Of this subset, 17 (9.4%) women developed pre-eclampsia, 7 (3.9%) 
developed pregnancy-induced hypertension (PIH) without significant proteinuria, 
and 156 (87%) remained normotensive throughout pregnancy. Demographics of 
the women in the vascular function study are shown in table 5.1, those of the 
overall study cohort are described in Chapter 2.  
 Pre-eclampsia 
or PIH (n=24) 
Normotensive 
(n=156) 
p-
value 
Age (years) 30.7±5.1 33.1±5.2 0.03 
BMI at booking(kg/m²) 30.3±5.8 27.8±5.6 0.04 
SBP at booking (mmHg) 126±10 120±12.6 0.06 
DBP at booking (mmHg) 79±7 74±9.3 0.007 
Smoking n(%) 1 (4%) 12 (7.6%) 1.0 
Nulliparous n(%) 20 (83%) 67 (43%) <0.001 
Ethnicity (% non-Caucasian) 2 (8.3%) 9 (5.8%) 0.64 
Pre-eclampsia in previous 
pregnancy n (%) 
2 (8.3%) 33 (21%) 0.17 
Family history of pre-
eclampsia n (%)  
9 (37.5%) 21 (13.5%) 0.007 
Gestation at delivery (wks) 39.3±2 39.9±1.6 0.098 
Birthweight (grams) 3295±520 3601±509 0.007 
Table 5-1. Demographics of women studied at gestational week 16 and 28. Data are 
expressed as mean ± standard deviation, or as number (% of total).  
 
5.2.2 Post delivery studies 
Of the 180 women studied at gestational weeks 16 and 28, 80 attended again at 
6-9 months post-natally, of whom 8 had developed pre-eclampsia, 4 had 
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developed PIH, and 68 had remained normotensive throughout. A further 15 
women, who had been recruited to the study at booking and went on to develop 
pre-eclampsia, but who had not attended for vascular function studies during 
pregnancy, also attended at 6-9 months post-natally. There was therefore post-
natal data available on 96 women, 23 of whom had developed pre-eclampsia, 4 
of whom had developed PIH, and 69 who had remained normotensive. 
Demographics of the women studied post-natally are shown in table 5.2. 
 Pre-eclampsia 
or PIH (n=27) 
Normotensive 
(n=69) 
p-value 
Age (yrs) 31.2±4.5 35.6±4.9 <0.001 
BMI (kg/m²) 28.8±7.4 27.5±5.5 0.346 
SBP (mmHg) 127±13 124±13 0.385 
DBP (mmHg) 83±10 78±11 0.074 
Smoking (%) 1 (3.7%) 6 (8.7%) 0.67 
Ethnicity (% non-Caucasian) 1 (3.7%) 4 (5.8%) 1.0 
Family history of pre-
eclampsia (%) 
8 (29.6%) 9 (13%) 0.074 
Table 5-2 Demographics of women studied post-natally. Data are expressed as mean ± 
standard deviation, or as number (% of total). 
  
Pre-eclampsia and pregnancy-induced hypertension (PIH) were defined in 
keeping with the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) criteria (5) as described in section 1.1.   
5.2.3 PAT recording 
Peripheral arterial tone (PAT) was recorded using the EndoPAT 2000 device 
(Itamar Medical, Caesarea, Israel) as described in Chapter 2. In brief, the system 
comprises pneumatic finger probes which assess digital volume changes 
accompanying pulse waves. A blood pressure cuff was placed on the dominant 
arm (study arm) while the other arm acted as a control. PAT probes were placed 
on the index fingers of each hand for continuous recording of the PAT signal. 
After a 10 minute acclimatisation period, the blood pressure cuff was inflated to 
suprasystolic pressures for 5 minutes, then released, while PAT recording 
continued for a further 5 minutes.  
176 
PAT data were analysed using proprietary software in an operator-independent 
manner. Reactive hyperaemia index (RHI) was calculated as described in Chapter 
2. All recordings were performed in the same temperature-controlled room by 
myself or by a research nurse trained by myself.  
5.2.4 Brachial artery flow-mediated dilatation 
Brachial artery ultrasound was used to measure flow-mediated dilatation as 
outlined in Chapter 2. 16 consecutive women attending for vascular function 
studies at week 16 and 28 were examined on the same day as PAT assessment. 
Of them, one woman developed pre-eclampsia and one developed pregnancy-
induced hypertension; the remaining 14 remained normotensive. In brief, after 
baseline brachial artery recordings for 5 minutes, a blood pressure cuff was 
inflated on the forearm distal to the artery. The cuff was released after 5 
minutes and the artery was then scanned for a further 5 minutes to record the 
effects of reactive hyperaemia. The study was recorded and analysed offline 
using proprietary software. Flow-mediated dilatation (FMD) was expressed as the 
percentage change in the arterial diameter pre and post cuff occlusion, relative 
to the baseline diameter. All FMD recordings were performed by the same 
experienced investigator, Miss Lesley Anderson.  
 
5.2.5 Statistical analysis 
The Kolmogorov-Smirnov test was used to assess the normality of data 
distribution. Normally distributed data are expressed as mean ± standard 
deviation, non-normally distributed data are expressed as median [IQR]. Data 
were compared using the Students t-test for normally distributed data, the 
Mann-Whitney U-test for non-normally distributed data and Fisher’s exact test 
for categorical variables. Univariate correlations were performed using Pearson’s 
correlation. A p-value of <0.05 was considered significant. Statistical analysis 
was performed using the statistical package SPSS version 15.0 (SPSS inc., 
Chicago, Illinois, USA).   
Since EndoPAT 2000 has only rarely been reported for use in pregnancy, it was 
not possible to perform a formal power calculation prior to the study. The 
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original aim was to examine 200 pregnant women with ≥ 2 risk factors at both 
gestational weeks 16 and 28, with an expected “drop-out” rate of 10%. 
Recruitment for the vascular function sub-study therefore continued until 180 
women had been examined at both week 16 and 28. Based upon the sample size, 
the standard deviations, and an anticipated 10% incidence of pre-eclampsia or 
PIH in this cohort, the study was 80% powered to detect a difference of 0.43 in 
RHI between women who would go on to develop hypertensive disorders and 
those who would remain normotensive.  
5.3 Results 
5.3.1 Cases vs controls 
Women who went on to develop PIH or pre-eclampsia (cases) were younger than 
those with normotensive deliveries (controls). Although systolic blood pressure 
was not significantly different between the two groups at booking, cases already 
had a higher diastolic blood pressure (79±7 vs 74±9 mmHg, p=0.007) at week 16 
than controls (table 5.1).  
In a first step, reactive hyperaemia index (RHI) was compared between women 
who went on to develop pre-eclampsia or PIH and women who remained 
normotensive. No significant difference was seen between the two groups at 
either gestational week 16 (1.78 [0.59] vs 1.81 [0.94], p=0.69) or week 28 (1.46 
[0.32] vs 1.52 [0.29], p=0.27) (table 5.3).  
There was no relationship between RHI and either birth weight or gestation at 
delivery when examined at either week 16 or week 28. 
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 Week 16 Week 28 
 Cases 
(n=24) 
Controls 
(n=156) 
p-
value 
Cases 
(n=24) 
Controls 
(n=156) 
p-
value 
RHI 1.78 
[0.59] 
1.81 
[0.94] 
0.69 1.46 
[0.32] 
1.52 
[0.29] 
0.27 
Baseline pulse 
amplitude (AU) 
occluded arm 
547 
±333 
579 ±376 0.69 981±470 1040±426 0.53 
Baseline pulse 
amplitude (AU) 
control arm 
491±306 535±355 0.57 902±425 963±422 0.51 
Table 5-3. PAT recordings at gestational week 16 and 28. Data are expressed as mean ±SD 
(normally distributed data) and median [inter-quartile range] (non-normally distributed data). 
AU = arbitrary units.   
 
 
5.3.2 Relationship between RHI and maternal risk factors 
5.3.2.1 Week 16 
There was no relationship between RHI at week 16 and maternal age, BMI, 
systolic blood pressure, parity, smoking status, or total number of risk factors 
for pre-eclampsia. There was, however, a significant inverse correlation 
between diastolic blood pressure and RHI (r=-0.165, p=0.02) (figure 5.1). 
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Figure 5.1. Scatterplot depicting the relationship between RHI and diastolic blood pressure 
at gestational week 16.  
 
Baseline pulse amplitude was not related to maternal age, BMI, smoking status, 
diastolic blood pressure, parity or total number of risk factors, but was higher in 
women with a higher systolic blood pressure (r=0.142, p=0.049) (figure 5.2). 
 
Figure 5.2. Scatterplot depicting relationship between baseline pulse amplitude and systolic 
blood pressure at gestational week 16.  
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Pregnant women with a history of pre-eclampsia in a previous pregnancy were 
then examined to determine whether vascular function was altered in their 
subsequent pregnancy. When compared to pregnant women without a history of 
the condition no difference was seen in RHI or baseline pulse amplitude between 
the two groups.  
 
5.3.2.2 Week 28 
At gestational week 28, there was no relationship between RHI and maternal 
age, BMI, systolic BP, diastolic BP, smoking status, parity or total number of risk 
factors.  
Baseline pulse amplitude was higher in women with a higher BMI (r=0.188, 
p=0.009) (figure 5.3), and in women with a higher systolic blood pressure 
(r=0.187, p=0.009) (figure 5.4), but was not related to age, smoking, parity, 
diastolic blood pressure or total number of risk factors.  
 
Figure 5.3 Scatterplot depicting relationship between baseline pulse amplitude and BMI at 
gestational week 28.  
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Figure 5.4 Scatterplot depicting relationship between baseline pulse amplitude and systolic 
blood pressure at gestational week 28.  
 
5.3.3 Relationship between RHI and baseline pulse amplitude 
In the study cohort overall, RHI at gestational week 28 was significantly lower 
when compared to week 16 (1.51 [0.32] vs 1.78 [0.89], p<0.001, figure 5.5a) 
suggesting an apparent deterioration in endothelial function with advanced 
pregnancy. This deterioration occurred both in women who went on to develop 
pre-eclampsia or PIH (1.46 [0.32] week 28 vs 1.78 [0.59] week 16, p=0.028) and 
in women who had normotensive pregnancies (1.52 [0.29] week 28 vs 1.81 [0.94] 
week 16, p<0.001).  
Further analysis revealed that the baseline pulse amplitude was significantly 
higher in both arms, indicative of vasodilatation at week 28 compared to week 
16 (1009±434 AU week 28 vs 570±364 AU week 16 study arm, 934±422 AU week 
28 vs 526±342 AU week 16 control arm, p<0.001, figure 5.5b). 
Baseline pulse amplitude was then compared with RHI. There was a significant 
inverse correlation between RHI and baseline pulse amplitude, with lower RHI in 
women with higher blood flow at baseline. This was true both at gestational 
week 16 (r=-0.326, p<0.001) and at week 28 (r=-0.329, p<0.001).   
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5.3.4 Comparison with FMD 
In order to determine whether the reduction in endothelial function score in 
later pregnancy was restricted to the PAT device, FMD scores using brachial 
artery ultrasound were compared between 16 pregnant women at gestational 
week 16 and 28. In keeping with the findings using PAT there was a significantly 
lower percentage change in artery diameter at gestational week 28 compared to 
gestational week 16 (7.46% ±1.83% vs 9.42% ±2.22%, p=0.009; figure 5.5c). In 
addition, baseline brachial artery diameter was higher at week 28 compared to 
week 16 (3.73mm ±0.17mm vs 3.30mm ±0.29mm, p<0.001; figure 5.5d), 
indicating vasodilatation with advanced pregnancy. RHI measured using PAT and 
FMD measured using brachial artery ultrasound were correlated at gestational 
week 28 (r=0.49, p=0.03), but not significantly at week 16 (r=0.47, p=0.085).   
 
Figure 5.5 (a) Comparison of RHI between gestational weeks 16 and 28 in overall study 
cohort. (b) Comparison of baseline pulse amplitude between gestational weeks 16 and 28 in 
overall study cohort. (c) Comparison of FMD percentage between gestational weeks 16 and 
28 in 16 pregnant women. (d) Comparison of brachial artery diameter at baseline in 16 
women.
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5.3.5 Post-natal data 
Endothelial function was then examined at 6-9 months following pregnancy. 27 
women who had developed pre-eclampsia or PIH were compared with 69 women 
who had normotensive, uncomplicated pregnancies. RHI at 6-9 months post-
natally was not different between cases and controls (2.09 [0.76] vs 1.92 [1.07], 
p=0.28) (Figure 5.6a). Baseline pulse wave amplitude, however, was significantly 
higher in controls compared to cases (583±333 AU vs 411±248 AU, p=0.017 study 
arm, 535±297 vs 404±229, p=0.042 control arm) (Figure 5.6b).  
 
 Pre-eclampsia 
or PIH (n=27) 
Normotensive 
(n=69) 
p-value 
RHI 2.09 [0.76] 1.92 [1.07] 0.297 
Pulse amplitude (AU) study 
arm 
411±248 583±333 0.007 
Pulse amplitude (AU) control 
arm 
404±229 535±297 0.042 
Table 5-4. PAT recordings in women studied post-natally. Data expressed as mean ± 
standard deviation (normally distributed data) and median [inter-quartile range] (non-
normally distributed data). 
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Figure 5.6 [a] RHI at 6-9 months post-natally in women with recent pre-eclampsia (cases) 
and women with normotensive pregnancies (controls). [b] Baseline pulse amplitude post-
natally in cases and controls.  
 
5.4 Discussion 
In this study PAT was used to examine endothelial function during and after 
pregnancy in a cohort of women with risk factors for pre-eclampsia. At both 
gestational week 16 and 28, there was no difference in reactive hyperaemia 
index between women who would go on to develop hypertensive disorders, and 
those who would go on to have normotensive pregnancies. Previous studies using 
brachial artery ultrasound have reported increased FMD in pregnancy compared 
to non-pregnant controls, a finding which is thought to be secondary to 
increased nitric oxide (NO) production (333). It is less certain what happens to 
FMD in later pregnancy: although some studies have reported increased FMD 
after 30 weeks gestation (329,334), others have reported a reduction in the final 
few weeks of pregnancy (87). Using PAT an apparent deterioration in endothelial 
function was seen between gestational week 16 and 28, both in women who 
went on to develop pre-eclampsia or PIH and in those who remained 
normotensive. RHI at all stages of pregnancy was lower than in healthy non-
pregnant women studied as part of the Framingham cohort. When the data were 
evaluated further there was a marked increase in baseline pulse amplitude in 
keeping with vasodilatation, suggesting that in later pregnancy, women were 
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less able to further vasodilate from baseline. Similar data using the more 
established brachial artery ultrasound technique suggest that this is a common 
feature with techniques which analyse flow-mediated dilatation, and not limited 
to the EndoPAT system.  
There was not a clear correlation between PAT and FMD recordings. While this 
may be due to the relatively small number of women (16) studied using both 
techniques, it may also be the case that the 2 techniques are measuring 
different parameters; FMD measures shear-mediated changes in large artery 
(brachial) function, while PAT measures hyperaemic response in small vessels. 
The position of the cuff may also be of importance; with FMD the cuff is placed 
distal to the vessel being studied, whereas with PAT studies the cuff is proximal 
to the vessels being studied, and the fingertips are “downstream” of the local 
tissue injury caused by cuff inflation.  
FMD has been reported to be reduced in women at the time of diagnosis of pre-
eclampsia compared to normotensive women (88), but it is unclear whether this 
is a cause or a consequence of the disease. Few longitudinal studies have 
examined ability of brachial artery FMD during pregnancy to predict future pre-
eclampsia. One study in which 506 women were examined at mean gestational 
week 22 reported that those who went on to develop pre-eclampsia (n=14) had a 
lower FMD than those with normal pregnancies (89). Only one study has been 
reported in the literature using PAT to examine endothelial function in women 
with pre-eclampsia. Yinon et al. (335) examined 17 women at the time of 
diagnosis or pre-eclampsia (mean gestation 32 weeks) and compared them with 
25 women with normotensive pregnancies.  The group reported reduced RHI in 
women with pre-eclampsia compared to controls, and a positive correlation 
between RHI and birthweight. Women with pre-eclampsia were, however, 
studied at a later point in pregnancy than women with normal pregnancies, a 
factor that I have shown may have influenced their capacity for further 
vasodilatation from baseline, and may have confounded results.  
A growing body of evidence has emerged in recent years that women with pre-
eclampsia are at increased risk of future development of hypertension, renal 
disease and coronary artery disease (252). One potential mechanism that links 
pre-eclampsia and cardiovascular disease in later life is maternal endothelial 
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dysfunction. In keeping with this theory, a number of studies have reported the 
use of brachial artery ultrasound to demonstrate impaired endothelial function 
in women with a history of pre-eclampsia. One study, examining women with a 
history of pre-eclampsia at 3 years post-partum reported reduced flow-mediated 
dilatation compared to women with a history of normotensive pregnancy, 
findings that were not explained by the presence of maternal risk factors (265). 
Further studies using this technique have reported ongoing endothelial 
dysfunction when measured at 6-12 months (266) and at one year (267) after a 
pre-eclamptic pregnancy.  In the present study, using PAT to examine 
endothelial function at 6-9 months after pregnancy, there was no difference in 
RHI between those who had pre-eclampsia or PIH and those who had 
normotensive pregnancies. Women with a history of pre-eclampsia or PIH did, 
however, have reduced baseline pulse amplitude during baseline recordings. This 
feature, suggesting reduced vasodilatation after an affected pregnancy, may 
represent an early change in vascular function, and merits further investigation.   
In this study both women with pre-eclampsia and women with PIH without 
significant proteinuria were included together in the analysis. As is discussed in 
section 1.1, how best to diagnose pre-eclampsia and how to differentiate 
between the different forms of the disease is a matter of significant debate. 
When women with PIH alone were excluded from the analysis results were not 
affected. Many diagnostic criteria do not require significant proteinuria for 
diagnosis of pre-eclampsia (3). Further, in a recent study examining predictors 
of adverse foetal and maternal outcomes in women with pre-eclampsia it was 
reported that altering the diagnostic criteria to include women without 
significant proteinuria made no difference to analysis (336). 
In conclusion, RHI measured using PAT during pregnancy did not identify which 
women were at risk of going on to develop pre-eclampsia or PIH. I found that 
PAT and brachial artery ultrasound FMD, methods which rely upon flow-mediated 
dilatation to assess endothelial function, are less likely to be reliable when used 
in later pregnancy when women are more vasodilated. Women with a history of 
pre-eclampsia are at increased risk of future cardiovascular disease (7); further 
studies using these techniques may aid in explaining the mechanisms underlying 
this risk. 
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6. Pulse wave analysis: assessment of a novel 
technique for the prediction of pre-eclampsia 
 
6.1 Introduction 
The importance of blood pressure measurement during pregnancy has been 
firmly established, but blood pressure alone is not sensitive enough when 
measured in early pregnancy to be of value in the prediction of pre-eclampsia. 
Current medical practice relies upon the measurement of peripheral systolic and 
diastolic blood pressure; it may be that analysis of other components of the 
pulse wave and estimation of central pressures can provide further 
understanding of cardiac and vascular physiology. Pulse wave analysis (PWA) is 
one such technique, and can be used to estimate central pressures and 
augmentation index (AIx), an estimate of arterial stiffness. Pulse wave analysis 
with applanation tonometry has been used extensively in non-pregnant 
populations to demonstrate arterial stiffness in patients with hypertension, 
diabetes mellitus and hyperlipidaemia (106).  Further, increased AIx using PWA 
has been shown to be a strong independent risk factor for premature cardiac 
disease (99).  
Normal pregnancy is associated with a number of important changes to the 
maternal vasculature, including a rise in heart rate, intravascular volume and 
cardiac output, and a corresponding reduction in vascular resistance. Studies 
using PWA to examine maternal wave reflections and arterial stiffness in 
pregnancy have reported lower central systolic and diastolic blood pressures, 
and lower AIx compared to the non-pregnant state (106,107). These changes are 
evident from the first trimester, reach their nadir in mid-pregnancy, and rise to 
pre-pregnancy levels in the third trimester.  
Pre-eclampsia is thought to be characterised by an aberrant maternal 
cardiovascular adaptation to pregnancy (337), and a small number of studies 
have used applanation tonometry to examine arterial stiffness in women with 
pre-eclampsia. Compared to women with normotensive pregnancies, women 
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with pre-eclampsia have been reported to have significantly elevated AIx, 
indicating arterial stiffness, when examined at the time of diagnosis of pre-
eclampsia (91,109,110,338). Results, however, have not been consistent, with 
one more recent study demonstrating no significant difference in AIx between 
women with pre-eclampsia and those with normotensive pregnancies (337).   
In keeping with many other methods for the prediction of pre-eclampsia, in 
order to be clinically useful the alterations in pulse wave characteristics would 
have to be evident prior to the onset of clinically detectable disease. Further, to 
justify the increased expense, training and time associated with the studies, 
they would have to supply additional information on top of the maternal risk 
factor profile. One longitudinal study has been reported, using applanation 
tonometry to examine 210 pregnant women at 11-14 weeks gestation. The 
authors reported increased augmentation pressure (AP) and AIx in women who 
subsequently developed pre-eclampsia compared to those who had normotensive 
pregnancies, and that both AP and AIx corrected for heart rate (AIx 75) were 
significantly negatively correlated with birth weight and with gestation at 
delivery (95). 
In this longitudinal prospective study, PWA was used to examine characteristics 
of the pulse waveform in a cohort of pregnant women both during and after 
pregnancy. These women had been selected from the overall study cohort 
because of the presence of ≥ 2 traditional risk factors for pre-eclampsia. 
Further, to examine the effects of pregnancy itself, characteristics of the pulse 
waveform of pregnant women were compared with non-pregnant women.  
 
6.2 Methods 
6.2.1 Recruitment 
Pregnant women were recruited at their initial antenatal hospital appointment, 
as described in Chapter 2. Women with 2 or more traditional risk factors for pre-
eclampsia (12) were invited for vascular function studies at gestational weeks 
16, 28 and at 6-9 months post-natally. Women with chronic hypertension, 
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diabetes, and renal disease were not included in the study. A total of 180 
pregnant women were studied at gestational week 16 and 28; 17 (9.4%) 
developed pre-eclampsia, 7 (3.9%) developed pregnancy induced hypertension 
without significant documented proteinuria (PIH) and 156 women had 
normotensive pregnancies. Characteristics of the women studied longitudinally 
throughout pregnancy are shown in table 6.1.  
 Pre- 
eclampsia or 
PIH (n=24) 
Normotensive 
(n=156) 
p-
value 
Age (years) 30.7±5.1 33.1±5.2 0.03 
BMI at booking(kg/m²) 30.3±5.8 27.8±5.6 0.04 
SBP at booking (mmHg) 126±10 120±12.6 0.06 
DBP at booking (mmHg) 79±7 74±9.3 0.007 
Smoking (%) 1 (4%) 12 (7.6%) 1.0 
Nulliparous (%) 20 (83%) 67 (43%) <0.001 
Ethnicity (% non-Caucasian) 2 (8.3%) 9 (5.8%) 0.64 
Pre-eclampsia in previous 
pregnancy (%) 
2 (8.3%) 33 (21%) 0.17 
Family history of pre-
eclampsia (%)  
9 (37.5%) 21 (13.5%) 0.007 
Gestation at delivery (wks) 39.3±2 39.9±1.6 0.098 
Birthweight (grams) 3295±520 3601±509 0.007 
Table 6-1. Demographics of women studied at gestational week 16 and 28. Data are 
expressed as mean ± standard deviation, or as number (% of total).  
 
 
Of the women who attended at weeks 16 and 28, 81 attended at 6-9 months 
post-natally, of whom 8 had developed pre-eclampsia, 4 had developed 
pregnancy-induced hypertension without proteinuria, and 69 had remained 
normotensive. A further 15 women, who had been recruited to the original study 
at booking and had developed pre-eclampsia, but who had not attended for 
vascular function studies during pregnancy, were also seen at 6-9 months post-
natally. Demographics of women studied post-natally are shown in table 6.2. 30 
health nulliparous non-pregnant women, recruited using advertising posters in 
the University of Glasgow, were examined using the same protocols.  
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 Pre-eclampsia 
or PIH (n=27) 
Normotensive 
(n=69) 
p-value 
Age (yrs) 31.2±4.5 35.6±4.9 <0.001 
BMI (kg/m²) 28.8±7.4 27.5±5.5 0.346 
SBP (mmHg) 127±13 124±13 0.385 
DBP (mmHg) 83±10 78±11 0.074 
Smoking (%) 1 (3.7%) 6 (8.7%) 0.67 
Ethnicity (% non-Caucasian) 1 (3.7%) 4 (5.8%) 1.0 
Family history of pre-
eclampsia (%) 
8 (29.6%) 9 (13%) 0.074 
Table 6-2 Demographics of women studied post-natally. Data are expressed as mean ± 
standard deviation, or as number (% of total).  
 
 
Pre-eclampsia definition was in keeping with the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) criteria (5); systolic blood pressure ≥ 
140 mmHg and diastolic blood pressure ≥ 90 mmHg on 2 occasions >6 hours 
apart, in association with proteinuria (≥ 300 mg/24 hrs, protein : creatinine ratio 
≥ 30 mg/mmol, or if neither were available, ++ or more on dipstick 
measurement). Pregnancy-induced hypertension (PIH) was defined using the 
same blood pressure criteria, but without significant documented proteinuria. 
Delivery information was obtained from labour ward databases; casenotes for all 
women who developed pre-eclampsia or gestational hypertension were reviewed 
by myself. All women gave written informed consent, and the study was 
approved by the West Glasgow Research Ethics Committee.  
 
6.2.2 Pulse wave analysis 
Pulse wave analysis was performed using the SphygmoCor device (Atcor medical, 
West Ryde, Australia), as described in Chapter 2. In brief the radial artery was 
gently compressed with the tip of a pencil-shaped tonometer at the site of 
maximal pulsation. The tonometer contains a micro-manometer which provides 
an accurate recording of the pressure within the radial artery. The aortic 
pressure waveform was derived from the peripheral waveform using a validated 
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generalised transfer function. The augmentation index (AIx), a composite 
measure of systemic arterial stiffness and wave reflection amplitude, central 
systolic, diastolic and pulse pressures, and augmentation pressure (AP) were 
calculated using the integrated software.  Since AIx is influenced by heart rate 
(109), AIx was standardised to a heart rate of 75 beats per minute (AIx-75). 
Waveforms over an 8 second period were recorded, and the SphygmoCor 
software created an average arterial waveform which was used for the analysis. 
The system has an internal quality control index, and readings were discarded if 
amplitude was too low or if variability between waveforms was too high. All 
studies were performed by myself until three satisfactory waveforms were 
produced; mean values were used in the subsequent analysis.  
 
6.3 Results 
6.3.1 Comparison between non-pregnant women and pregnant 
women at gestational week 16 
Non-pregnant controls were younger, and had a lower BMI than pregnant women 
at gestational week 16 (table 6.3). In keeping with the vascular changes 
expected in pregnancy, pregnant women had a higher resting heart rate than 
non-pregnant controls (77±9 bpm vs 66±12 bpm, p<0.001). Brachial systolic and 
diastolic blood pressure was not different between the 2 groups. Peripheral and 
central AIx, AP and central systolic and diastolic pressures were not significantly 
different between pregnant women at gestational week 16 and non-pregnant 
women.   
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 Non-
pregnant 
(n=30) 
Gestational 
week 16 
(n=180) 
p-value 
Age (years) 28.3±5.9 32.6±5.3 <0.001 
BMI (kg/m2 23.9±3.5 28±5.6 <0.001 
SBP (mmHg) 120±10 121±12 0.542 
DBP (mmHg) 77±7 75±10 0.284 
Heart rate (bpm) 66±12 77±9 <0.001 
Peripheral AIx (%) 55.9±11.8 52.9±15 0.305 
Central SBP (mmHg) 105±9 106±13 0.722 
Central DBP (mmHg) 78±8 76±9 0.394 
Central PP (mmHg) 27.7±5.4 30.1±8.9 0.154 
Central AP 2.38±3.1 2.25±3.8 0.863 
Central AIx (%) 8.3±10 6.7±12 0.463 
Central AIx-75 (%) 4.5±12 7.8±12 0.159 
Table 6-3 Comparison of PWA characteristics between non-pregnant controls and pregnant 
women at gestational week 16.  
 
6.3.2 Comparison between Sphygmocor and EndoPAT- derived 
augmentation index 
There was a significant correlation between AIx derived from EndoPAT (as 
described in Chapter 5) and AIx derived from Sphygmocor, both at gestational 
week 16 (r=0.523, p<0.001) and week 28 (r=0.629, p<0.001). Bland Altman plots 
demonstrating the relationship between the 2 methods of assessment of 
augmentation index are shown in figure 6.1.   
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Figure 6.1. Bland Altman plots demonstrating the relationship between augmentation index 
as measured by EndoPAT and SphygmoCor at gestational week 16 (left) and 28 (right).  
 
6.3.3 Correlation of PWA parameters with maternal risk factors 
At gestational week 16, AIx-75 was significantly correlated with both brachial 
systolic (r=0.226, p=0.002) and diastolic (r=0.373, p<0.001) blood pressures, 
maternal age (r=0.366, p<0.001) and maternal BMI (r=0.169, p=0.021) (figures 
6.2, 6.3).  AIx-75 was not related to smoking status (8.4±12.6 smokers vs 
7.4±11.5 non-smokers, p=0.8) or ethnicity (8.9±9.2 non-Caucasian vs 7.8±11.8 
Caucasian, p=0.76), but was lower in nulliparous women (3.77±11.2 nulliparous 
vs 11.88±10.8 parous, p<0.001), reflecting their younger age.  
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Figure 6.2 Scatterplots demonstrating relationship between AIx-75 and systolic blood 
pressure (left) and diastolic blood pressure (right).  
 
 
Figure 6.3 Scatterplots demonstrating relationship between AIx-75 and maternal age (left) 
and body mass index (right). 
 
 
At gestational week 16, women with a history of pre-eclampsia in a previous 
pregnancy had a higher AP (3.5±2.7 vs 1.9±3.9, p=0.008), PAIx (59.5±13 vs 
51.4±15, p=0.003) and central AIx 75 (11.3±11.1 vs 7.0±11.7, p=0.046) compared 
to those without a history of the condition. Systolic blood pressure was not 
different, but diastolic blood pressure was higher (78±10 vs 74±9, p=0.03) in 
women with a history of previous pre-eclampsia.  
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At gestational week 28, women with a history of previous pre-eclampsia again 
had a higher AP (2.94±3.4 vs 0.96±3.6, p=0.003), PAIx (59.0±16 vs 47.8±17, 
p<0.001) and central AIx 75 (13.8±11 vs 6.9±11.6, p=0.001). These findings were 
independent of maternal age, maternal BMI and maternal systolic and diastolic 
blood pressure, which were not different between the two groups.  
 
 
6.3.4 Comparison of women who developed pre-eclampsia or PIH 
and controls 
6.3.4.1 Overall study cohort 
As expected, heart rate rose from week 16 to 28 in both cases and controls 
(table 6.4). At gestational week 16, women who went on to develop pre-
eclampsia or PIH had a higher brachial DBP than those who remained 
normotensive (table 6.4). Central DBP was also higher in cases at week 16, but 
there was no difference in central SBP, central pulse pressure, augmentation 
pressure, nor in peripheral or central AIx between cases and controls.  
At gestational week 28, brachial systolic and diastolic pressures were 
significantly higher in women who went on to develop pre-eclampsia or PIH, but 
there was no difference in central systolic, diastolic or pulse pressure, 
augmentation pressure, or peripheral or central augmentation index between 
cases and controls.  
When the longitudinal changes from gestational week 16 to 28 were compared 
between cases and controls, there was a significant difference in systolic blood 
pressure change, (p=0.02), but not in any determinants of pulse wave analysis 
(table 6.4).  
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 Week 16 Week 28 
 Cases 
(n=24) 
Controls 
(n=156) 
p-value Cases   
(n=24) 
Controls   
(n=156) 
p-value 
Brachial  SBP (mmHg) 126±10 120±13 0.061 131±10 † 120±12 <0.001 
Brachial DBP (mmHg) 79±7 74±10 0.007 80±7.4 72±8.5 <0.001 
Heart rate (bpm) 79±8 77±9 0.492 82±21 84±12 0.546 
Aortic SBP (mmHg) 110±9 106±13 0.119 108±25 103±15 0.178 
Aortic DBP (mmHg) 81±7 75±9 0.007 79±18 74±11 0.052 
Aortic PP (mmHg) 29±6 30.1±9 0.588 28.8±8.5 29.1±9.7 0.901 
Augmentation Pressure 2.65±3.1 2.25±3.9 0.639 1.45±3.2 1.37±3.8 0.853 
Peripheral AIx (%) 54.7±13 52.8±15 0.568 49.7±17 49.8±17 0.987 
Central AIx (%) 8.17±10 6.56±12 0.544 3.26±9.7 3.81±12.1 0.837 
Central AIx-75 (%) 10.0±9.2 7.7±12.1 0.390 9.14±9.3 8.35±12 0.936 
Table 6-4. Comparison of PWA parameters between cases and controls at gestational week 16 and 28. † represents a significant difference between cases 
and controls in longitudinal changes from week 16 to 28.    
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6.3.4.2 Women studied at week 16, 28 and post-natally 
Of the women who were studied both during and after pregnancy, 12 developed 
pre-eclampsia or PIH, and 69 remained normotensive throughout. There was no 
significant difference in PAIx, CAP or CAIx-75 between week 16 and week 28 in 
either cases or controls. When women were examined post-natally, however, 
compared to week 28 there was a significant elevation in AP (5.67±3.1 vs 
1.83±3.8, p=0.001 cases , 6.82±4.3 vs 1.44±3.4, p<0.001 controls), in PAIx 
(66.6±9 vs 53.8±14.6, p=0.003 cases, 71.7±15 vs 52.6±14.9, p<0.001 controls) 
and in AIx-75 (14.3±10.5 vs 8.8±11.3, p=0.043 cases, 16.95±10.7 vs 9.2±12.2, 
p<0.001 controls), figure 6.4.  
 
Figure 6.4 Comparison of augmentation index corrected for heart rate (AIx-75) in cases (left) 
and controls (right) at week 16, week 28 and post-natally.  
 
6.3.5 Correlation with birth outcomes 
Women who developed pre-eclampsia or PIH delivered babies of smaller 
birthweight with a higher rate of operative delivery than those who remained 
normotensive (table 6.1). It has previously been reported that both 
augmentation index and augmentation pressure correlate with birthweight and 
gestation at delivery (95). In this cohort there was a significant negative 
correlation between AIx 75 at week 16 and gestation at delivery (P=-0.163, 
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p=0.033), with higher augmentation index in women who delivered at an earlier 
gestation. There was, however, no relationship between any of the other 
parameters of PWA and either birthweight or gestation at delivery, when 
recorded at either week 16 or week 28.  
 
6.3.6 Post-natal data 
27 women who had developed pre-eclampsia or PIH were then compared with 69 
women who had normotensive deliveries at 6-9 months post-natally. Women who 
had developed pre-eclampsia or PIH were younger, with a trend towards a higher 
post-natal diastolic blood pressure than those who had normotensive deliveries 
(table 6.5). There was no difference between the 2 groups in central systolic 
diastolic pressure, AP, or peripheral or central augmentation index.  
 
 Pre-
eclampsia 
or PIH 
(n=27) 
Normotensive 
(n=69) 
p-
value 
Age (yrs) 31.2±4.5 35.6±4.9 <0.001 
BMI (kg/m²) 28.8±7.4 27.5±5.5 0.35 
SBP (mmHg) 127±13 124±13 0.39 
DBP (mmHg) 83±10 78±11 0.07 
Central SBP (mmHg) 114±12 112±13 0.46 
Central DBP (mmHg) 83±8.7 79±10.3 0.07 
Central PP (mmHg) 31.1±8.3 33.2±7.6 0.26 
Augmentation 
Pressure 
5.7±3.6 6.8±4.2 0.24 
Peripheral AIx (%) 67.9±12.6 71.7±14.9 0.25 
Central AIx (%) 18.1±8.7 19.7±10.5 0.47 
Central AIx (%) HR 75 15.4±8.7 16.9±10.5 0.50 
Table 6-5 Comparison of PWA parameters at 6-9 months post-natally between women who 
had pre-eclampsia or PIH (cases) and women who had normotensive pregnancies 
(controls).  
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6.4 Discussion 
Understanding the relationship between arterial stiffness and pre-eclampsia may 
help to improve our understanding of the pathogenesis of this important 
condition. In this study, pulse wave analysis was examined longitudinally 
throughout pregnancy, at 6-9 months post-natally, and in healthy non-pregnant 
controls. Pregnant women were pre-selected on the basis of risk factors for pre-
eclampsia because any technique used to predict pre-eclampsia in early 
pregnancy would have to be capable of differentiation in such a “high-risk” 
population group. Further, pre-selecting women on the basis of risk factors is 
perhaps more realistic for clinical practice, since it would not be feasible 
logistically or financially to carry out testing such as PWA in all pregnant women. 
Previous studies have reported reduced augmentation pressure and 
augmentation index throughout normal pregnancy (106-108), with changes 
evident from the first trimester. In this study, there were no differences in any 
of the components of pulse wave analysis when comparing pregnant women at 
gestational week 16 with non-pregnant controls. This discrepancy is likely to be 
in part because the non-pregnant women in this study were significantly younger 
and had a lower BMI - even allowing for the expected weight gain during 
pregnancy (339)- than the pregnant women. A further potential factor affecting 
pulse wave characteristics is the phase of the menstrual cycle. This was not 
recorded in the non-pregnant controls nor the women studied post-natally; it has 
been previously reported that the menstrual cycle has a significant effect on 
pulse wave analysis, with lower AIx in the luteal phase (105). When women who 
had been examined during pregnancy were examined again post-natally, 
augmentation pressure and both peripheral and central AIx were higher than 
during pregnancy.  
It has long been generally accepted that blood pressure falls in normal 
pregnancy, beginning from 12-14 weeks, reaching a trough at around 24 weeks, 
and rising in the third trimester. These findings, based on large observational 
studies dating back to the 1960s (340) have been the basis for clinical guidelines 
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and for classification of hypertensive disorders (341), and as reported in Chapter 
1 have led to the theory that a lack of “drop” in mid-trimester blood pressure is 
an independent risk factor for pre-eclampsia. In this study there was no 
significant alteration in blood pressure between gestational week 16 and week 
28 in either cases or controls, other than a rise in systolic blood pressure in the 
women who went on to develop pre-eclampsia. In keeping with this observation, 
a recent study performed in pregnant Caucasian women with singleton 
uncomplicated pregnancies in fact reported a significant rise in both systolic and 
diastolic blood pressures during pregnancy, with no mid-trimester dip (342). The 
authors speculated that these findings may have been because women in the 
Western world are generally more obese than in the past, and are having 
children at a later age than previously. It may be that “normal” ranges for blood 
pressure during pregnancy need to be revised, and this area merits further 
investigation.  
A further aim of this study was to examine the ability of pulse wave analysis to 
predict pre-eclampsia in early pregnancy. Khalil et al. (95) examined pregnant 
women at gestational week 11-14, and using applanation tonometry, 
demonstrated elevated augmentation pressure and augmentation index at this 
early stage in women who went on to develop pre-eclampsia. In the current 
study, at week 16, women who went on to develop pre-eclampsia or PIH already 
had a higher, but within normal limits, brachial blood pressure compared to 
those who had normotensive pregnancies. In contrast to the findings of Khalil et 
al., there was no difference in AP or AIx between cases and controls at this early 
time-point. Further studies at gestational week 28 again did not differentiate 
women destined to develop pre-eclampsia or gestational hypertension from 
controls. The reason for this difference is not clear; the study of Khalil et al. had 
a particularly high incidence of pre-eclampsia (6.7% compared to 2.3% in the 
overall PIP study population) which in turn was felt by the authors to be related 
to the high Afro-Caribbean population studied. Previous studies which 
demonstrated elevated AIx in women with pre-eclampsia were not fully adjusted 
for maternal age, BMI and brachial blood pressure (337), all factors which I have 
here shown to have a significant effect on AIx, and which may contribute to the 
discrepancy seen. 
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Women with pre-eclampsia are at increased risk of future development of 
cardiovascular disease (252). Since endothelial dysfunction has been reported in 
women after a pre-eclamptic pregnancy, and since arterial stiffness is associated 
with cardiovascular disease, it seems plausible that increased arterial stiffness 
would be seen in women after a pre-eclamptic pregnancy. In keeping with this 
theory, AIx at 7 weeks post-partum has been reported to be elevated in women 
with pre-eclamptic pregnancies, despite a normalisation in blood pressure (105). 
Whether the differences in AIx are longer lasting remains uncertain; one study in 
which women were examined at a mean of 5 years post delivery did not report 
any difference in any measurement of pulse wave analysis between women who 
had pre-eclampsia and those who had normotensive pregnancies (109). In the 
current study, in which women were examined at 6-9 months after delivery, 
there was similarly no difference between affected and unaffected women.  
One potential limitation of this technique in the assessment of pregnant women 
is the use of a generalised transfer factor to calculate central pressures. 
Although the transfer factor has been validated in a wide range of different 
patient groups, ages, diseases and drugs, it has not been specifically validated 
for use in pregnancy. Further studies, examining normal values for different 
stages in pregnancy, and assessing the applicability of the generalised transfer 
factor during pregnancy are indicated. A further potential limitation of the 
current study is that pulse wave velocity (PWV) was not examined. Further 
information about arterial wave reflection can be gained from examining aortic 
(carotid to femoral) and brachial (carotid to brachial) pulse wave velocity, and 
this technique has previously been used to demonstrate increased pulse wave 
velocity in women with established pre-eclampsia compared to controls (337). 
Studying PWV is, however, more time consuming, more invasive, and requires 
further training and expertise than PWA alone, and so may not be applicable in 
large scale studies for screening for pregnancy complications.  
As in Chapter 5, in this PWA study both women with pre-eclampsia and women 
with PIH without significant proteinuria were included together in the analysis. 
When women with PIH alone were excluded from the analysis results were not 
affected.  
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In summary, in this study of women with risk factors for pre-eclampsia, pulse 
wave analysis did not provide additional information beyond brachial blood 
pressure and maternal risk factor profile about risk of future development of 
pre-eclampsia, whether analysed at gestational week 16 or 28. There was no 
significant difference in blood pressure or in pulse wave analysis characteristics 
between week 16 and week 28. In contrast to other literature in the field, 
significant differences were not seen between pregnant women at gestational 
week 16 and non-pregnant controls, nor was there any difference post-natally 
between cases and controls.  
Although PWA did not help to differentiate between cases and controls during 
pregnancy, it is uncertain whether it could be used to aid the early detection of 
severe disease, early onset disease, or adverse foetal or maternal outcomes. 
Further longitudinal studies examining its role in predicting long-term 
cardiovascular disease in affected women are also merited.  
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7. General discussion & conclusions 
7.1 Introduction 
It is clear that rather than just being proteinuric gestational hypertension, pre-
eclampsia is a complex multi-system disease characterised by exaggerated 
systemic inflammation and endothelial dysfunction. The condition remains a 
challenge for doctors, midwives, expectant mothers and scientists alike. The 
only known cure for pre-eclampsia is delivery; in women who develop pre-
eclampsia before term the only options available to obstetricians are supportive 
and temporising measures until delivery is safe (336). The maternal and foetal 
short and long-term outcomes for such management, however, remain 
uncertain, with few evidence-based guidelines available. It is evident, therefore, 
that any method which could improve early detection of the disease, and which 
could help to predict adverse foetal and maternal outcomes, would have the 
potential to be of enormous clinical benefit. 
The overall aim of the work described in this thesis was to attempt to identify 
clinical and biochemical markers that could lead to an improvement in our 
ability to predict pre-eclampsia in early pregnancy. To do this I designed and set 
up a large prospective study, in which women were recruited in the first 
trimester, and were followed longitudinally throughout their pregnancy. To 
attempt to examine what happens to these markers throughout pregnancy, I 
recruited a cohort of women with established risk factors such as nulliparity, 
obesity and a family history of pre-eclampsia, to carry out further sampling and 
vascular function studies throughout their pregnancy. Finally, since women with 
a history of pre-eclampsia are known to be at increased risk of future 
cardiovascular disease, I examined these women after their pregnancy to 
determine whether they had detectable vascular dysfunction that might 
contribute to their increased long-term cardiovascular risk.  
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7.1.1 Proteomic studies 
Given the multi-factorial nature of the disease, and the key role that the kidney 
plays in its pathogenesis, urinary proteomics was felt to represent a promising 
area for identification of novel predictive biomarkers. As outlined in Chapter 3, 
capillary electrophoresis / mass spectrometry techniques were used to 
successfully define, for the first time, the human urinary proteome in 
pregnancy. In addition, this work led to the identification of a pattern of 
peptides that were altered at gestational week 28 in women who subsequently 
developed pre-eclampsia. It was disappointing not to be able to identify a 
proteome pattern that could be used to predict the condition at an earlier point 
in pregnancy, since such a “late” biomarker may be of limited benefit in clinical 
practice. I was able to demonstrate, however, that the pre-eclampsia related 
peptides identified at week 28 were not present at an earlier point in 
pregnancy. Further, I demonstrated that their levels are dynamic, with a clear 
elevation in their urinary concentration between week 12-16 and week 28 in 
affected women, and no real difference in women who were unaffected. These 
dynamic changes suggest that such peptide patterns do not exist, or at least 
cannot be detected using these methods at earlier stages in pregnancy.  
The potential clinical relevance of the predictive biomarker pattern at week 28 
should not be overestimated, since these data have yet to be validated in 
further cohorts of pregnant women. Proteomic analysis was only carried out in 
samples from the first 2500 women recruited to the PIP study; it may be possible 
to validate findings in the subsequent 1500 women in the study. Further studies 
using independent study cohorts, and complementary techniques such as 
metabolomics (248), and transcriptomics (343), may help with future research in 
this area.  
7.1.2 Plasma biomarkers 
A second main focus of this study was to attempt to identify plasma biomarkers 
that could improve early prediction of pre-eclampsia. Much of the work 
performed in this field in recent years has focussed on anti-angiogenic peptides, 
in particular soluble FMS-like tyrosine kinase 1 (sFLT-1) and soluble Endoglin 
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(sENG), and the role that they play in disease development. I was able to 
demonstrate that at booking, women who went on to develop pre-eclampsia 
already had altered circulating concentrations of the anti-angiogenic peptide 
sENG, and PGF, the factor that it inhibits. Circulating concentrations of sFLT-1, 
the peptide most studied in the recent literature, were not different between 
cases and controls at booking, but were significantly higher at week 28 in 
affected women. One advantage of this study is that, in keeping with the real 
life situation, women were sampled at their initial antenatal hospital visit which 
was at any point between 10 and 18 weeks of gestation, rather than at a fixed 
gestational time-point as in the majority of other studies. Despite this, the 
alterations in concentrations remained consistent, and may further help to 
identify at-risk women.   
Inflammation, arising from both the developing placenta and the maternal 
vasculature, is known to play a key role in the pathogenesis of pre-eclampsia. In 
view of this I also used early pregnancy plasma samples to examine a panel of 
adhesion molecules and inflammatory markers, to determine whether any could 
be utilised as pre-eclampsia biomarkers, in order to improve early prediction. Of 
the inflammatory biomarkers studied, I was able to show that E-Selectin levels 
were significantly elevated at booking in women who went on to develop pre-
eclampsia. To ensure that this was not a chance finding related to multiple 
testing, I also showed that circulating E-Selectin levels were elevated in affected 
women both at week 16 and at week 28. When tested in an independent study 
cohort, levels were again shown to be elevated at a gestational time-point well 
before the onset of clinically detectable disease. E-Selectin is released 
exclusively from endothelial cells, and since endothelial dysfunction is known to 
be an important step in disease development, this work suggests a novel role for 
E-Selectin in pre-eclampsia pathogenesis.  
 
7.1.3 Vascular function studies 
A further focus of the PIP study was to examine the ability of non-invasive 
vascular function phenotyping to predict future pre-eclampsia. Using peripheral 
arterial tonometry (PAT) at gestational weeks 16 and 28, I was unable to detect 
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any difference in endothelial function between women who would go on to 
develop pre-eclampsia and those who would have normotensive pregnancies. I 
was able to show that PAT score was negatively correlated with fingertip blood 
flow during baseline recordings, which suggests that PAT and other similar 
techniques may be of limited utility in pregnancy, when women are more 
vasodilated. I also used pulse wave analysis to examine augmentation index, a 
marker of arterial stiffness as a predictor of future pre-eclampsia. Although a 
previous study had shown increased augmentation index in early pregnancy in 
women who went on to develop pre-eclampsia (95), this study had been 
performed in a cohort of women with particularly high rates of pre-eclampsia. In 
the PIP cohort, with a disease incidence of around 2.3%, I was able to 
demonstrate that there was no significant difference between affected and 
unaffected pregnancies, suggesting that this is unlikely to be a useful test for 
pre-eclampsia detection in the first and second trimesters.  
 
7.2 Diagnostic criteria discussion 
7.2.1 Blood pressure thresholds 
A recurring theme throughout this thesis is that definitions of pre-eclampsia 
have varied throughout the years and continue to be different in different 
studies and in different parts of the world. Historically, emphasis was placed 
upon diastolic blood pressure rather than systolic, and so was over-represented 
in classifications of hypertension both during and outwith pregnancy. The initial 
international classification and definition of the hypertensive disorders of 
pregnancy compiled by Davey et al. in 1988 (344) reflected this, requiring a 
diastolic blood pressure of 90 mmHg on two occasions, or a single diastolic blood 
pressure of 110 mmHg to make the diagnosis. Further complicating the 
classification of hypertensive disorders in pregnancy is the fact that pregnant 
women are mainly looked after by obstetricians rather than general physicians, 
whose classifications of hypertension can often be different. “Normal” blood 
pressure levels vary significantly at different time-points throughout pregnancy, 
causing further uncertainty. Some pre-eclampsia classifications have therefore 
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suggested that changes in blood pressure levels between the first and third 
trimesters, with or without proteinuria, rather than absolute blood pressure 
levels are more important for determining maternal and foetal outcomes (345). 
7.2.2 Proteinuria thresholds 
The level of proteinuria required to define pre-eclampsia is another area which 
has differed in different classifications of the disease. Traditional diagnostic 
criteria relied upon 24 hour urinary collections, which were well adhered to 
since the majority of affected women were in-patients in hospital. In the out-
patient or community setting where most women are now looked after, 
however, compliance with 24 hour urinary collection is poor. The International 
Society for Study of Hypertension in Pregnancy (ISSHP) guidelines require a 
protein : creatinine ratio of ≥30 mg/mmol or a Dipstick analysis of at least + 
proteinuria, in the absence of infection. Some classifications, however, do not 
require any proteinuria for diagnosing pre-eclampsia. The SCOPE study, an 
ongoing international prospective study which is outlined in Chapter 3 uses the 
Australasian criteria which consist of pregnancy-induced hypertension (as 
defined above), plus a multisystem complication, which can be significant 
proteinuria, or renal insufficiency, liver test abnormalities, neurological 
complications or haematological complications.  
 
The presence of proteinuria, however, does appear to be significant in terms of 
foetal and maternal outcomes. One recent Australasian study compared 
outcomes in proteinuric and non-proteinuric pre-eclampsia over an 18 year 
period (6). They reported that proteinuric pre-eclampsia was associated with a 
higher incidence of perinatal mortality, preterm delivery and severe 
hypertension than non-proteinuric pre-eclampsia. There are a number of women 
who develop gestational hypertension with liver failure, renal failure or foetal 
growth restriction, but do not have significant proteinuria. What diagnosis should 
be given to these women, and how they should be classified, remains uncertain.   
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7.2.3 Disease severity thresholds 
How to define severe pre-eclampsia is a further area in which classifications vary 
worldwide. Early onset disease is often considered to be a criterion for severe 
disease, which is in turn defined as disease detected at <34 weeks’ gestation in 
Canada and <35 weeks in the USA (8). Other features which appear in diagnostic 
classifications for disease severity include heavy proteinuria (3-5 grams per day 
or >1g / litre), signs of maternal end-organ dysfunction, abnormal maternal 
laboratory testing (including HELLP syndrome), elevated uric acid levels, and 
foetal morbidity or mortality. Definitions of severe hypertension also differ, with 
systolic blood pressure over 160 mmHg in UK and Australasian classifications, 
over 170 mmHg in American and Canadian studies, and diastolic blood pressures 
over 110 mmHg being defined as severe.  
One of the reasons for the lack of agreement is that none of the classification 
systems have been independently assessed for their ability to identify which 
women and foetuses are at highest risk of adverse outcomes. One recent study 
was designed to do this, and described the development and validation of an 
outcome and prediction model fullPIERS (Pre-eclampsia Integrated Estimate of 
RiSk) (336). In this study, a number of variables assessed at the time of 
admission to hospital with pre-eclampsia were examined for their ability to 
predict fatal or life-threatening maternal outcomes. In a collaborative 
international study over 2000 women with pre-eclampsia were included, of 
whom 13% developed associated adverse maternal or foetal outcomes. Of the 
variables assessed, early gestational age at diagnosis, the presence of hypoxia, 
chest pain or dyspnoea, and elevations in serum creatinine and liver enzymes 
were all associated with adverse outcomes, both within 48 hours of admission, 
and within 7 days of admission. Interestingly, blood pressure levels themselves 
did not appear to predict adverse maternal or foetal outcomes.  
7.2.4 Treatment thresholds 
The management of pre-eclampsia revolves around close observation of affected 
women, delivery of the foetus when possible, and therapeutic strategies to 
attempt to reduce foetal and maternal complications. Which women should be 
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treated with blood pressure lowering medications, and how they should be 
treated also remains uncertain. Management guidelines tend to be based on 
practice patterns which have been established over the years, rather than 
clinical trials with clearly-defined end-points. There are many systematic 
reviews of the subject, but as discussed above the different diagnostic criteria, 
different methods for measuring blood pressure, and the presence or absence of 
underlying conditions such as chronic hypertension limit their usefulness. 
Since prescription of anti-hypertensive therapies do not appear to affect the 
underlying disease process (which is initiated in the placenta), and since blood 
pressure levels do not appear to influence foetal or maternal outcomes (336), 
the main indication for treating high blood pressure in pregnancy is to help to 
prevent stroke. A systolic blood pressure above 160 mmHg is associated with a 
significantly increased risk of cerebral haemorrhage (346), and as a result many 
clinicians advocate treatment above this level. In a recent Confidential Enquiry 
into Maternal and Child Health (CEMACH) report, intracranial haemorrhage 
accounted for 12 of the 18 deaths associated with pre-eclampsia (42).  
Reflecting the inconsistency in treatment throughout the UK, the Vitamins in 
Pregnancy (VIP) trial of high risk women described in section 1.2.4 reported that 
a third of women with recorded sustained systolic hypertension >160 mmHg had 
received no anti-hypertensive treatment (42).  
Although most would advocate treatment in women with associated symptoms 
such as cardiac or neurological decompensation, it is unclear whether women 
with “moderate” hypertension or those with isolated diastolic hypertension 
should be treated. To further explore this, a Cochrane systematic review 
examined the use of anti-hypertensive therapies in women with mild-moderate 
hypertension in pregnancy, which was in turn defined as systolic blood pressure 
of 140-169 mmHg or diastolic blood pressure of 90 to 109 mmHg, with or without 
significant proteinuria (347). Examining 46 trials of over 4200 affected women, 
the authors reported that use of antihypertensive therapy was associated with a 
significant reduction in development of severe hypertension, (RR 0.5, 95% CI 
0.41 to 0.61), but that there was no significant effect on rates of development 
of pre-eclampsia. One of the concerns of treating women with mild-moderate 
hypertension is the potential to compromise foetal wellbeing, since lowering 
systemic blood pressure could in theory reduce placental blood flow. The 
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Cochrane meta-analysis did not reveal any effect on foetal or neonatal death 
rates, nor on rates of small for gestational age (SGA) babies, or preterm 
deliveries. The target to which blood pressure should be lowered, and how 
rapidly the blood pressure should be reduced remains uncertain. 
 
7.3 Disease pathogenesis 
As outlined in Section 1.1 there are two main phases in the development of pre-
eclampsia: the “placental” phase characterised by impaired placental 
development, placental ischaemia and oxidative stress, and the “maternal” 
phase characterised by maternal endothelial dysfunction and inflammation. 
Factors released by the placenta, including the anti-angiogenic peptides and 
syncytiotrophoblastic debris, appear to provide a link between the two main 
phases. 
The strength of association between the 2 main stages of pre-eclampsia, 
however, may be different between different individuals. Whether pre-
eclampsia is of early or late onset appears in turn to depend upon whether or 
not the placenta is small and under-developed (8). Although thought to be 
crucial to the development of pre-eclampsia, not all women with impaired 
placental development will develop hypertensive problems. Similarly, women 
with normally developed placentas can develop pre-eclampsia. In these women 
it is likely that underlying maternal cardiovascular and metabolic factors 
contribute to set off a cascade of maternal and placental inflammation and 
oxidative stress, resulting in late-onset pre-eclampsia (8). In this study, largely 
because of the numbers involved, I included all women with pre-eclampsia in the 
analysis whether their disease was of early or late onset, or whether they had 
growth-restricted babies or not. It may in fact be the case that early onset 
(placental) and late onset (maternal) pre-eclampsia are 2 different conditions. 
Further research will determine whether or not methods for reducing the 
excessive inflammatory and oxidative stress (for example with statins or 
metformin) and improving endothelial function can improve foetal and maternal 
outcomes.  
213 
 
7.4 PIP study 
Pre-eclampsia is said to affect between 3-8% of all pregnancies in the Western 
world, and around 5% of all first-time mothers. One of the surprising aspects of 
this study was that the incidence was lower, at 2.3% overall. A number of 
reasons may account for this discrepancy. First, as outlined in Section 1.1 the 
diagnostic criteria used in this study are more stringent than those used in some 
other studies, requiring sustained blood pressure recordings over 140 mmHg 
systolic and 90 mmHg diastolic on at least 2 occasions, with significant 
proteinuria, occurring after 20 weeks’ gestation. Further, in this study only a 
small number of women with chronic hypertension, diabetes and renal disease 
were included, since they were usually already attending dedicated “high-risk” 
antenatal clinics. The main theme underlying the PIP study was to identify which 
women were at increased risk of going on to develop pre-eclampsia, with the 
implication being that these women would be more closely monitored 
throughout their pregnancy. Women with diabetes, pre-existing hypertension 
and renal disease are already known to be at high risk of pre-eclampsia; as a 
result they are already closely monitored throughout, and a marker identifying 
them as high-risk would not add to their management.  
Another reason behind the relatively low incidence seen may be that the 
population of the study was largely Caucasian, with a low number of black 
women, who as discussed in Chapter 1 are at increased risk of the condition. 
Rates of ethnicity varied in this study: in the Southern General Hospital 13% of 
women were non-Caucasian (of whom the majority were of South Asian 
ethnicity) whilst in Ayrshire only 1 woman included in the study was non-
Caucasian. Cigarette smoking was another potentially important factor; smokers 
are known to be at lower risk of developing pre-eclampsia compared to non-
smokers (59), and it may be that the relatively high rates of smoking (albeit self-
reported and potentially inaccurate) in this study were partially protective 
against the development of hypertensive problems.  
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Despite this, the incidence of pre-eclampsia was similar to that reported in the 
Glasgow Outcome APCR and Lipid (GOAL) study, described in Chapter 4. This 
study, carried out in the same city and with broadly similar patient 
demographics and disease definitions, reported an incidence of pre-eclampsia of 
1.7%. This again highlights the importance of definitions of pre-eclampsia that 
are agreed internationally, allowing accurate comparison of different studies.  
 
7.5 Future cardiovascular health  
An emerging concept in pre-eclampsia, as outlined in Chapters 1, 5 and 6, is the 
associated risk of future maternal hypertension, ischaemic heart disease, stroke, 
diabetes and renal disease. The studies describing this long-term risk are, 
however, largely observational, employing linkage analysis of birth records with 
morbidity and mortality databases. The mechanisms determining the increased 
cardiovascular risk remain poorly understood. As part of this study I examined 
vascular function in women at 6-9 months after pregnancy. I was unable to 
detect a difference in endothelial function or arterial stiffness between women 
whose pregnancies had been complicated by pre-eclampsia, and those who had 
normotensive pregnancies. While the peripheral arterial tonometry (PAT) 
technique and its reliance on baseline pulse amplitude may help to explain this, 
it is of interest that other more established techniques for determining 
cardiovascular risk including carotid ultrasound measurement of intima media 
thickness (IMT) have also not been shown to be different between affected and 
unaffected women (274). There remain other unanswered questions. Nearly all 
the studies describing the relationship between pre-eclampsia and future 
cardiovascular disease have been performed in Northern Europe, in largely 
Caucasian populations. Pre-eclampsia is more common in other racial groups 
(31), and in particular in the developing world (4), and whether these women 
are also at increased risk of future cardiovascular disease is not yet known. It is 
also uncertain whether pregnancy induced hypertension without significant 
proteinuria is associated with the same risk of future cardiovascular disease.   
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The longer term implications of pre-eclampsia do not appear to be restricted to 
mothers; previous observational studies have reported elevated systolic and / or 
diastolic blood pressures in the offspring of affected women when examined in 
childhood and adolescence. A recent prospective study looked at this 
relationship in more detail, and examined the offspring of 205 women who had 
pre-eclampsia, 1118 who had pregnancy-induced hypertension and 5345 
normotensive mothers at 9 years of age (348). Offspring of women with a history 
of pre-eclampsia or gestational hypertension had an increased SBP and DBP 
compared to offspring of normotensive women, a finding which was independent 
of obesity or other lifestyle factors. The association of pre-eclampsia with 
elevated offspring blood pressure was felt to be at least partly related to the 
association with low birth weight and preterm delivery.  
7.5.1 Opportunities for intervention 
Rather than being a discrete condition, pre-eclampsia appears to represent the 
extreme end of a maternal systemic response engendered by pregnancy itself 
(349) and has been described as the “metabolic syndrome” of pregnancy (23). As 
a risk factor for future cardiovascular disease it is largely ignored by clinicians - 
mainly because of poor understanding of the long-term implications, and 
because of poor communication between obstetric and primary care teams 
(350).  
The importance of a history of pre-eclampsia has, however, been recognised by 
its inclusion alongside traditional risk factors such as smoking and family history 
in the 2011 American Heart Association guidelines for prevention of 
cardiovascular disease in women (351). Although the short-term cardiovascular 
risk for women with pre-eclampsia is low, it has been suggested that affected 
women should be closely monitored after pregnancy, starting as early as 12 
months post partum (352). It is important that these women avoid obesity and 
smoking, and that lipids, blood pressure and glucose are monitored, with early 
intervention where indicated. For many women, pregnancy will be the only time 
they seek medical attention between childhood and retirement; it is important 
that clinicians make the most of the information about future health that can be 
gained at this time. 
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7.5.2 Recurrence in subsequent pregnancies 
Many of the modern methods for risk-stratifying pregnant women rely on 
“secondary prevention” of pre-eclampsia: women who have previously had the 
disease are closely monitored throughout pregnancy. It is clear, however, that 
using a history of previous pre-eclampsia to identify high-risk women is 
inadequate. In the PIP study, 83% of the women who developed pre-eclampsia 
were nulliparous; of the 35 women with a history of pre-eclampsia in a previous 
pregnancy who were considered “high-risk” and invited for further vascular 
function studies, pre-eclampsia recurred in only 2 (5.7%). In this study, however, 
it was not possible to check case records from previous pregnancies for accuracy 
of diagnosis, and since the gestation at which pre-eclampsia had developed in 
previous pregnancies was not always available this information was not included 
in the overall analysis. The risk of recurrence of pre-eclampsia is known to be 
lower in women with pre-eclampsia who delivered at term compared to those 
who had required early delivery (353), so this information may have been 
relevant. Population database studies have reported recurrence rates of pre-
eclampsia of around 15% (354) but again these do not include gestation at 
diagnosis, and rely on routinely collected delivery data which can often be 
inaccurate.  
The Vitamins in Pre-eclampsia (VIP) study mentioned in section 1.2.4 recruited 
women who were at high-risk of developing pre-eclampsia, and as part of this 
separately examined 500 women who had developed pre-eclampsia (in the 
pregnancy immediately preceding the index pregnancy) and had required 
delivery before 37 completed weeks’ gestation (355). In these women pre-
eclampsia recurred in 23%; risk of recurrence was highest in those who had 
required delivery at less than 34 weeks’ gestation, in non-Caucasian women, 
those with higher blood pressure at booking, and in those with detectable 
proteinuria at booking. Even in women who remained normotensive in the 
subsequent pregnancy, those with a history of previous pre-eclampsia had a 
higher risk of delivering smaller babies at an earlier gestation than those without 
a history of previous pre-eclampsia. The risks of recurrent pre-eclampsia are not 
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confined to pregnancy; women who have had pre-eclampsia in more than one 
pregnancy appear to be at higher cardiovascular risk, and have been shown to be 
at higher risk of future development of hypertension (356), and of end-stage 
renal disease (254) than those with single episodes.  
7.6 Conclusions 
The work described in this thesis reports on a number of studies designed to 
improve early prediction of pre-eclampsia. Despite the huge amount of research 
done in the field, it remains difficult to predict the condition early, and the vast 
majority of women are only diagnosed when all the manifestations of the 
condition are evident, by which time treatment options are limited.  
In routine clinical practice we currently screen for several conditions in early 
pregnancy such as syphilis, HIV and Rhesus iso-immunisation that have a far 
lower incidence than pre-eclampsia. It could be argued that screening for 
hypertensive disorders should be given a higher priority, and is the single most 
important aspect of antenatal care (357). Why has our ability to predict pre-
eclampsia not improved? As medical students we are taught that pre-eclampsia 
has one cause (pregnancy) and one cure (delivery) and it may be that some 
clinicians see pre-eclampsia prediction as a futile and pointless exercise.  
The reports of confidential enquiries into maternal deaths over the years have 
consistently identified deficiencies in care related to pre-eclampsia: in 46% of 
maternal deaths and 65% of foetal deaths, different management could 
reasonably have expected to alter the outcome (357). Many of the problems 
relate to community based care, in particular inadequate checking of blood 
pressure and proteinuria, and inadequate communication with hospital-based 
staff. If the care of pregnant women is to continue to be moved into the 
community setting, it is clear that the identification of at-risk women will have 
to improve. 
Although proteomics based, and other laboratory biomarkers are not yet 
sensitive or specific enough to accurately predict the condition, there are many 
maternal risk factors that can easily be assessed in early pregnancy. A predictive 
model based upon these risk factors was recently shown to be associated with an 
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area under the ROC curve of 0.71 for disease prediction (3), but in current 
clinical practice much of the information about risk factors is collected and 
documented but not acted upon.  
Education of pregnant women also has to take a prominent role. Mothers and 
midwives often take a healthy pregnancy outcome for granted, and do not 
understand the potential for pregnancy related problems. Many pregnant women 
do not understand why they are having their blood pressure taken (357), while 
80% of affected women have no idea of the “danger” signs associated with the 
condition (358). Further work in pre-eclampsia research must establish 
generalised guidelines for diagnosis and classification of severity, to improve 
early prediction and to allow the development of proper evidence based 
guidelines for treatment and prevention.  Pre-eclampsia is a potentially 
devastating condition, and it is hoped that future research and resources will 
help to improve the care of affected women.  
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Appendix I; Main study invitation letter 
BHF Glasgow Cardiovascular Research Centre 
PIP Study Team 
 
 
 
 
Dear Madam, 
 
 
We would like to tell you about a research project we are carrying out at Glasgow 
University. The aim of the research project is to find out more information about a 
condition called pre-eclampsia - in which pregnant women can develop high blood 
pressure. In particular we hope, as a result of the research project, to be able to predict 
easier which women are at risk of developing the condition.  
 
We will be asking all pregnant women to donate samples of urine and blood that may be 
analysed later to help us with our research. These samples will be taken at your booking 
visit, as well as the routine blood and urine tests that the midwives take. Please take the 
time to read the enclosed Patient Information Leaflets and consent form, and if you have 
any further questions do not hesitate to contact us.  
 
Best wishes, 
 
PIP (Proteomics In Pre-eclampsia) Study Team  
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Appendix II; Main patient information sheet  
Invitation 
You are being invited to take part in a research study (Proteomics In Pre-eclampsia, PIP study.) 
Before you decide it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and discuss it with others 
if you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
Pre-eclampsia is a condition in which pregnant women can develop high blood pressure. It affects 
approximately 5% of all pregnancies, and in rare cases can cause problems for the mother or baby. 
Although it is a fairly common condition, doctors do not yet fully understand the causes of the 
condition. In this study we aim to do detailed analysis of the urine and blood of pregnant women, 
looking especially at the patterns of proteins (proteomics). It is hoped that this information will 
help us to work out which women are at risk of developing pre-eclampsia, and to find out more 
about the condition.  
 
Why have I been chosen to take part? 
 
All pregnant women who have decided to have their baby at the Queen Mothers Hospital, Southern 
General Hospital, and Princess Royal Maternity Hospital will be invited to take part in this study. 
The study will run for one year.  
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part: participation is completely voluntary. If 
you do decide to take part you will be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
What will be involved if I decide to take part? 
 
At your booking visit the midwife will be taking samples of blood. If you decide to take part in the 
study we will take an extra sample of blood from you (about 1 teaspoonful), which will be stored, 
and may be analysed at a later date. You will also give a sample of urine to your midwife at your 
booking visit. We will take a small sample of this urine which will be stored in our laboratory, and 
we may use the sample at a later date to look at the proteins in the urine. 
In some women we would like to carry out further tests on the blood vessels, and we may invite 
you to visit the clinical investigations unit at the BHF Glasgow Cardiovascular Research Centre for 
these tests. These tests are simply a research tool, and do not give us any further information about 
your pregnancy. They can, however, tell us more about how the blood vessels work in pregnancy, 
and we hope this will increase our understanding of pre-eclampsia. We will only be able to carry 
out these additional tests in a small number of women, and we will contact you by telephone to 
arrange the tests if we think you could take part.  
What are the risks of taking part in this research? 
 
Blood and urine samples are taken for clinical purposes at your booking visit so that there is no 
extra risk associated with this research. The amount of blood taken does not place you at any risk. 
This study will not affect your health, travel, life or any other insurance cover. 
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What are the benefits of taking part? 
 
There is no benefit to you in taking part in this study, as we will simply be taking samples of your 
blood and urine. It is hoped, however, that the information that we get from this study will help us 
to find out more about pre-eclampsia, and will help with the care of pregnant women in the future.  
 
Will my taking part in this study be kept confidential? 
 
Your personal information will be kept on a file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre. All samples will be labelled with a code and not with any 
personal details so that all analyses will be carried out anonymously. All information which is 
collected about you during the course of the research will be kept strictly confidential. Any 
information about you which leaves the hospital or the Clinical Investigation Unit will have your 
name and address removed so that you cannot be recognised from it. 
 
What will happen to any samples I give? 
 
You will donate blood and urine samples for research purposes. Some examinations on these 
samples will be done straight away. Other examinations will be done at a later stage when we 
collect more samples from other patients. We will also store some of the samples in our laboratory, 
so that we can perform additional tests in the future if required. This is why we enclose another 
information sheet and consent form allowing us to look a t a wider range of pregnancy-related 
conditions in the future. The samples are treated as "gift"; this means you will not be entitled to any 
future financial reimbursement related to this study and related research. 
 
Genetic testing 
 
We know that the risk of pre-eclampsia also depends on the genetic makeup. We will therefore 
examine the genes that may be related to pre-eclampsia. The genetic tests are for research only and 
do not look at specific changes of your genetic makeup. These tests do not have any immediate 
clinical relevance. In addition, like all other tests in this study, this is done after removing your 
name from the sample so that researchers cannot race the results back to you. 
 
What will happen to the results of the research study? 
 
The results of the research study will be stored on a computer database and are likely to be 
published in medical journals. Reports or publications resulting from the study will not contain any 
personal details. The research doctor will provide a copy of the results on request. 
 
Who is organising and funding the research? 
 
The research is organised by the BHF Glasgow Cardiovascular Research Centre, University of 
Glasgow, in collaboration with Obstetric Units at the Queen Mother's Hospital, Southern General 
Hospital, and Princess Royal Maternity Hospital. The study is funded by charities and the Scottish 
Government and researchers will not receive any payment for conducting this research.  
 
Contact for Further Information 
 
Should you have any further questions please feel free to call Dr David Carty, Dr Christian Delles 
or Prof. Anna Dominiczak at the BHF Glasgow Cardiovascular Research Centre, telephone 0141 
330 4565 or 0141 330 5420. 
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Appendix III; Main PIP study consent 
form. 
 
 
 
 
Title of Project:  
Proteomics in Pre-eclampsia study (PIP)  
 
Name of Researcher: 
Prof. Anna F. Dominiczak 
 
Reference: 07/S0709/79 
Version: 1.1 
Date: 03/10/2007 
 
 
Patient Identification Code for this Study:  -      -  
 
 
I agree to take part in the above project. 
 
 
• I confirm that I have read and understand the information sheet 
dated 03/10/2007 for the above study. I have had the opportunity 
to consider the information, ask questions and have had these 
answered satisfactorily. 
 
• I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
• I understand that sections of any of my medical notes and data 
collected during the study, may be looked at by members of the 
research team, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records. 
 
• I agree to donate samples of blood and urine, for the purposes of 
the research project. I understand that samples will be examined 
for genes and proteins that may be related to pre-eclampsia or 
other pregnancy-related conditions. 
 
• I agree to my GP being informed of my taking part in this study.  
 
 
____________________________ ____________ _____________________ 
Name of Patient Date Signature 
 
____________________________ ____________ _____________________ 
Name of Person taking consent  Date Signature 
 
 
 
1 for participant; 1 for researcher
 
Please initial 
box 
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Appendix IV; PIP Study Data Collection Form 
 
Patient Name: Date: Nurse Initials: 
Study 
Number 
 
Parity: 
Hospital 
Number 
 
Gestation at Booking: 
 
EDD: 
 
Height: 
 
Weight: 
Address 
 
 
 
 
 
 
Currently Smoking:  
Yes           No  
Mobile/Home 
Phone 
 
Blood sample obtained: 
Yes           No  
DOB 
 
Urine sample obtained: 
Yes           No  
 
Agree to sub-study contact?  Yes     No  
 
Primigravida…………………………………………………..  
Age ≥ 40…………………………………………………….....  
BMI > 25……………………………………………………....  
Previous pre-eclampsia………………………………………...  
10 years or more since last pregnancy………………………...  
Multiple pregnancy…………………………………………....  
BP at booking - > 130 systolic or > 80 diastolic……………...  
Diabetes………………………………………………………  
Kidney disease………………………………………………..  
Antiphospholipid syndrome…………………………………..  
Autoimmune disease………………………………………….  
Proteinuria at booking………………………………………...  
Family history of pre-eclampsia (mother or sister)…………...  
History of hypertension………………………………………. 
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Appendix V; PIP sub-study data 
collection form                                                   
 
 
Patient Demographics 
 
Study Code  
Date of Birth  
Patient Initials  
Number of Weeks Gestation  
Examination Date  
 
Consent Obtained   
 
Clinical Examination 
 
Height (cm)  
Weight (kg)  
BMI  
Blood Pressure (seated) using OMRON 
machine 
 
Heart Rate  
 
Blood Samples         Urine Samples 
 
Type of Sample Required Obtained 
5mls in purple top  
7mls in orange top  
5mls in green top  
 
Endothelial Function test using Endo-pat 2000 
 
RHI  
AI  
HR  
 
Pulse Wave Analysis carried out         ECG carried out 
 
If relevant, arrange time for next visit 
 
Please attach: 
 
 Completed consent form   ECG trace 
 PWA printout     Endo-pat 2000 printout 
 
 
Sample obtained for 
proteomics 
 
Dipstick test Comment: 
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Appendix VI; Invitation letter for sub-study 
BHF Glasgow Cardiovascular Research Centre 
PIP Study Team 
 
 
###Name### 
###Address Line 1### 
###Address Line 2### 
###Address Line 3### 
###Address Line 4### 
 
###Post Code### 
 
 
 
Dear Ms ###Name###, 
 
 
Further to our telephone conversation, thank you for agreeing to participate in the second 
stage of our research project. We would like you to come on:-  
 
DATE: 
TIME: 
 
Enclosed you will find a flier, with a map that has details of how to get to our research 
centre, and an information leaflet that has further details about the tests. We will provide 
you with refreshments if needed. The tests will take around one hour in total. Please 
contact us if you have any questions about the tests. 
Best wishes, 
 
Proteomics in Pre-eclampsia (PIP) Study Team. 
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Appendix VII; Consent form for 
vascular function substudy 
 
Title of Project:  
Proteomics in Pre-eclampsia study (PIP)  
 
Name of Researcher: 
Prof. Anna F. Dominiczak 
 
Reference: AB/115252/1 
Version: PIP-VF.1.0 
Date: 30/08/2007 
 
 
Patient Identification Code for this Study:  -      -  
 
 
 
I agree to take part in the above project. 
 
 
• I confirm that I have read and understand the information sheet 
dated 30/08/2007 for the above study. I have had the opportunity 
to consider the information, ask questions and have had these 
answered satisfactorily. 
 
• I understand that this is a substudy of the PIP Study and that all of 
my rights as outlined in the main study also apply to the substudy. 
My consent to participating in the main study will be attached to this 
form. 
 
• I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
• I understand that sections of any of my medical notes and data 
collected during the study, may be looked at by members of the 
research team, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records. 
 
• I agree to donate samples of blood and urine, for the purposes of 
the research project und to undergo tests to look at the function of 
my blood vessels. I understand that samples will be examined for 
genes and proteins that may be related to pre-eclampsia. 
 
 
 
____________________________ ____________ _____________________ 
Name of Patient Date Signature 
 
____________________________ ____________ _____________________ 
Name of Person taking consent  Date Signature 
 
Please initial 
box 
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Appendix VIII; Patient information sheet for 
vascular function substudy 
Invitation 
 
You are being invited to take part in the second part (substudy) of our research study. Before you 
decide it is important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
The purpose of our study is to find markers in blood and urine that will help us to work out which 
women are at risk for developing pre-eclampsia. You have already given us a blood and urine 
sample at your booking visit. We have chosen a subset of women from the booking visit to carry 
out a few more tests. These tests will help us to further narrow down the markers that we hope to 
find in blood and urine. They will also tell us how meaningful these markers are  
 
Why have I been chosen to take part? 
 
Pre-eclampsia has many causes, many of which we do not yet fully understand, and it can be very 
difficult to predict which women will get it. There are certain factors which can make pregnant 
women slightly more likely than average to get pre-eclampsia. These factors include women who 
are having their first baby, women who are over 35 years old, women with a family history of the 
condition, and women who have certain medical conditions such as high blood pressure. When you 
booked in at the hospital you gave the midwife information about your medical and family history, 
and it is from this information that you have been chosen to take part in the study.  
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do decide to take part you will be 
asked again to sign a consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
 
What will be involved if I decide to take part? 
 
If you decide to take part, we will invite you to come to our research centre for a 45 minutes 
appointment. We will invite you to come twice - one visit shortly after your booking visit, and 
again when you are around 28 weeks pregnant. On each occasion we will carry out the following 
tests: 
 
• We would like to measure your blood pressure, using a machine which is similar to ones 
used at your GP practice. 
• We would like to take another sample of urine, which will be stored in our lab, and may be 
analysed along with the urine sample you gave at the booking visit.  
• We would like to take a sample of blood (about 1½ tablespoonful) which will be stored in 
our lab. 
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• We would like to examine the blood vessels in your wrist. This examination involves 
assessment of your pulse with a pencil-like probe. It is carried out at the artery at your wrist 
and takes 1 to 2 minutes. We can then look at the pulse waveform, which gives us useful 
information about the blood vessels in pregnant women.  
• We would like to attach a small probe to your index finger, which measures the blood flow. 
We will then inflate a blood pressure cuff for 5 minutes, and then deflate it and continue to 
monitor the blood flow to the finger. This test takes about 20 minutes, and can give us 
useful information about the endothelium, which is the inner layer of blood vessels.  
 
What are the risks of taking part? 
 
We will take blood from the vein in your arm which in rare cases results in a small bruise. The 
amount of blood taken for this research does not place you at any risk. The other tests are "non-
invasive", that is that probes are only attached to your skin. Assessment of your pulse waveform 
has no specific risks or side-effects. Measurement of blood flow in your finger may lead to some 
numbness in your arm during the test, which will disappear when the cuff is deflated. A small 
bruise at your forearm may result from the cuff but will disappear within one or two days. 
 
What are the benefits of taking part? 
 
There is no benefit to you in taking part in this study, as we will simply be taking samples of your 
blood and urine. The blood vessel tests which we will do are research investigations, and do not tell 
us whether or not you are likely to get pre-eclampsia, or any other pregnancy-related problems. It is 
hoped, however, that the information that we get from this study will help us to find out more about 
pre-eclampsia, and will help with the care of pregnant women in the future.  
 
Will my taking part in this study be kept confidential? 
 
Your personal information will be kept on a file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre. All samples will be labelled with a code and not with any 
personal details so that all analyses will be carried out anonymously. All information which is 
collected about you during the course of the research will be kept strictly confidential. Any 
information about you which leaves the hospital or the Clinical Investigation Unit will have your 
name and address removed so that you cannot be recognised from it. 
 
What will happen to any samples I give? 
 
You will donate blood and urine samples for research purposes. Some examinations on these 
samples will be done straight away. Other examinations will be done at a later stage when we 
collect more samples from other patients. We will also store some of your samples for up to 10 
years to perform additional tests if required. The samples are treated as "gift"; this means you will 
not be entitled to any future financial reimbursement related to this study and related research. 
 
Contact for Further Information 
 
Should you have any further questions please feel free to call Dr David Carty, Dr Christian Delles 
or Prof. Anna Dominiczak at the BHF Glasgow Cardiovascular Research Centre, telephone 0141 
330 4565 or 0141 330 5420. 
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Appendix IX; Patient information sheet for non-
pregnant control group 
Invitation 
 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
What is the purpose of the study? 
 
The purpose of our study is to improve our ability to predict which women are at risk of developing 
pre-eclampsia. As part of this study we have been studying the function of the inner layer of blood 
vessels (endothelium) in pregnant women at different time-periods in their pregnancy. We are also 
carrying out these studies in women who are not pregnant, to examine how the function of blood 
vessels differs between pregnant and non-pregnant women.  
 
Why have I been chosen to take part? 
 
We are inviting women are not pregnant, who are aged between 18 and 45 years to take part in the 
study.  
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do decide to take part you will be 
asked again to sign a consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
 
What will be involved if I decide to take part? 
 
If you decide to take part, we will invite you to come to our research centre for a 45 minutes 
appointment. We will carry out the following tests: 
 
• We would like to measure your blood pressure, using a machine which is similar to ones 
used at your GP practice. 
• We would like to take a sample of urine, which will be stored in our lab. 
• We would like to take a sample of blood (about 1½ tablespoonful) which will be stored in 
our lab. 
• We would like to examine the blood vessels in your wrist. This examination involves 
assessment of your pulse with a pencil-like probe. It is carried out at the artery at your wrist 
and takes 1 to 2 minutes. We can then look at the pulse waveform, which gives us useful 
information about the blood vessels.  
• We would like to attach small probes to your index finger, which measure the blood flow. 
We will then inflate a blood pressure cuff around one arm for 5 minutes, and then deflate it 
and continue to monitor the blood flow to the finger. This test takes about 20 minutes, and 
can give us useful information about the endothelium, which is the inner layer of blood 
vessels.  
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What are the risks of taking part? 
 
We will take blood from the vein in your arm which in rare cases results in a small bruise. The 
amount of blood taken for this research does not place you at any risk. The other tests are "non-
invasive", that is that probes are only attached to your skin. Assessment of your pulse waveform 
has no specific risks or side-effects. Measurement of blood flow in your finger may lead to some 
numbness in your arm during the test, which will disappear when the cuff is deflated. A small 
bruise at your forearm may result from the cuff but will disappear within one or two days. 
 
What are the benefits of taking part? 
 
There is no benefit to you in taking part in this study, as we will simply be taking samples of your 
blood and urine. The blood vessel tests which we will do are research investigations, and do not tell 
us whether or not you are likely to develop problems if you were to become pregnant. It is hoped, 
however, that the information that we get from this study will help us to find out more about pre-
eclampsia, and will help with the care of pregnant women in the future.  
 
Will my taking part in this study be kept confidential? 
 
Your personal information will be kept on a file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre. All samples will be labelled with a code and not with any 
personal details so that all analyses will be carried out anonymously. All information which is 
collected about you during the course of the research will be kept strictly confidential. Any 
information about you which leaves the hospital or the Clinical Investigation Unit will have your 
name and address removed so that you cannot be recognised from it. 
 
What will happen to any samples I give? 
 
You will donate blood and urine samples for research purposes. Some examinations on these 
samples will be done straight away. Other examinations will be done at a later stage when we 
collect more samples from other patients. We will also store some of your samples for up to 10 
years to perform additional tests if required. The samples are treated as "gift"; this means you will 
not be entitled to any future financial reimbursement related to this study and related research. 
 
Contact for further Information 
 
Should you have any further questions please feel free to call Dr David Carty, Dr Christian Delles 
or Prof. Anna Dominiczak at the BHF Glasgow Cardiovascular Research Centre, telephone 0141 
330 4565 or 0141 330 5420. 
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Appendix X; Further information sent to substudy 
participants 
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Appendix XI. List of pregnancy-associated peptides.  
protID Mass CE_t Sequence Protein name Swissprot name 
4845 900.2692 43.6572       
5675 911.4349 25.87627 DGKTGPpGPA Collagen alpha-1 (I) chain   CO1A1_HUMAN 
11282 980.4996 22.40554       
11413 981.5851 24.79552 VLNLGPITR Uromodulin  UROM_HUMAN 
14478 1040.475 25.05015 SpGPDGKTGPp Collagen alpha-1 (I) chain  CO1A1_HUMAN 
14906 1050.477 26.92478 MGPRGPpGPpG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
16915 1083.504 21.67677       
18448 1108.534 20.38335       
20457 1138.586 19.50684       
20749 1141.511 26.05729       
21294 1153.399 36.63236       
21365 1154.512 25.64497 PpGEAGKpGEQG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
21637 1155.454 36.9503       
21747 1157.537 37.44405 GPPGPpGppGPPS  Collagen alpha-1 (I) chain  CO1A1_HUMAN 
21893 1159.577 20.64463       
23356 1179.52 37.4916       
23467 1181.485 36.99772       
23968 1191.517 36.17672       
24168 1195.479 37.50522       
24442 1199.473 37.69087       
24510 1200.538 24.14255       
25429 1217.529 35.78057       
25893 1223.571 19.39261       
25932 1223.57 20.18306       
26092 1224.711 24.76768       
26326 1229.476 36.56928       
26431 1231.488 39.56649       
26630 1234.563 27.37202 ApGDRGEPGPpGP Collagen alpha-1 (I) chain CO1A1_HUMAN 
27229 1245.551 21.62387       
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27340 1247.482 39.60707       
28103 1257.443 33.9189       
28306 1260.605 27.4268       
28839 1270.503 38.0709       
29279 1276.398 35.92331       
30263 1294.488 39.46778       
30575 1297.582 27.36504 
SpGSpGPDGKTGP
p Collagen alpha-1 (I) chain  CO1A1_HUMAN 
30593 1297.591 22.08441 
ApGKNGERGGpGG
p Collagen alpha-1 (III) chain CO3A1_HUMAN 
31626 1314.348 36.15068       
33209 1339.602 27.48587 
SpGERGETGPpGP
A Collagen alpha-1 (III) chain   CO3A1_HUMAN 
33840 1352.779 24.60145       
33973 1353.656 25.63162       
34186 1358.38 36.46108       
34432 1363.428 36.33749       
34724 1366.622 27.4376 
pPGEAGKpGEQGV
p Collagen alpha-1 (I) chain  CO1A1_HUMAN 
34766 1367.643 38.88257 
PpGPpGPpGPPGTP
V Collagen alpha-1 (XVIII) chain COIA1_HUMAN 
35201 1375.572 38.27861       
35204 1375.605 23.245       
35424 1380.639 23.83049       
35912 1389.601 39.02101       
35979 1390.442 36.94585       
36156 1392.623 21.75213       
36566 1401.384 36.55667       
36759 1405.606 39.03535       
36965 1408.62 28.99544       
36988 1408.66 39.13381 
GPPGppGPpGPPG
PPS Collagen alpha-1 (I) chain   CO1A1_HUMAN 
37650 1422.545 37.5732       
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37785 1423.638 20.16397       
37903 1424.662 39.29955 
GLPGPpGPpGSFLS
N Collagen alpha-1 (XVII) chain  COHA1_HUMAN 
37949 1425.587 22.31776       
38021 1426.667 38.94155 
GLpGLPGPpGPpGp
PG Collagen alpha-3 (IX) chain CO9A3_HUMAN 
38174 1428.391 36.74784       
38605 1435.659 28.83627 
SpGSPGPDGKTGP
pGP Collagen alpha-1 (I) chain  CO1A1_HUMAN 
38752 1438.449 36.76394       
38798 1438.667 27.87549 
GLpGTGGPpGENG
KpG Collagen alpha-1 (III) chain CO3A1_HUMAN 
38910 1440.562 24.30044 
DEAGSEADHEGTH
S Fibrinogen alpha chain  FIBA_HUMAN 
39275 1445.618 37.35901       
39322 1446.636 39.42789       
40091 1449.641 21.85606       
40737 1462.616 39.42141       
41431 1466.659 21.8713       
41514 1467.807 24.68522       
41972 1478.614 39.30267       
42304 1485.674 23.76807 
DGQpGAKGEpGDA
GAK Collagen alpha-1 (I) chain  CO1A1_HUMAN 
43442 1507.738 40.02385 
VGPpGPpGPpGPP
GPPS Collagen alpha-1 (I) chain CO1A1_HUMAN 
43642 1510.565 39.0518       
43678 1510.676 19.51616       
43691 1510.682 20.16625       
44633 1523.841 29.75377 VIDQSRVLNLGPIT Uromodulin  UROM_HUMAN 
44718 1525.479 37.16451       
45857 1549.687 20.21417       
45980 1552.498 37.21467       
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46542 1561.448 36.95663       
46554 1561.686 40.62815       
46880 1567.702 20.19208 
GSEADHEGTHSTK
RG Fibrinogen alpha chain   FIBA_HUMAN 
46961 1569.654 39.31398       
47367 1576.6 26.37432       
47855 1576.743 19.50785 YKRKANDESNEHS Osteopontin   OSTP_HUMAN 
48008 1577.687 40.084       
48162 1580.886 24.84996       
48176 1580.879 23.8674 IDQSRVLNLGPITR Uromodulin UROM_HUMAN 
48540 1587.656 39.46728       
48580 1588.706 30.15033 
TGLSMDGGGSPKG
DVDP 
Sodium/potassium-transporting ATPase 
gamma chain  ATNG_HUMAN 
48651 1590.442 37.39939       
49248 1593.75 39.57015       
50075 1611.695 29.4784       
50212 1613.819 23.98601 
VGGGEQPPPAPAP
RRE Xylosyltransferase 1 XYLT1_HUMAN 
50633 1620.671 29.49355       
50904 1624.546 37.72626       
51328 1632.709 40.14696       
51678 1633.757 19.52845       
51804 1634.799 29.71747 
SpGNIGPAGKEGPV
GLpG Collagen alpha-2 (I) chain  CO1A2_HUMAN 
51875 1635.786 40.44105 
VGPpGPpGPpGPP
GPPSAG Collagen alpha-1 (I) chain CO1A1_HUMAN 
52096 1638.736 19.60149       
52100 1638.728 20.22988 
AGSEADHEGTHST
KRG Fibrinogen alpha chain  FIBA_HUMAN 
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52189 1640.581 23.24178       
52507 1646.795 21.88543       
52609 1648.727 22.82574       
52769 1649.727 22.64299       
53216 1654.782 23.12638 
SpGEAGRpGEAGLp
GAKG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
53957 1669.689 21.46473 
DEAGSEADHEGTH
STK Fibrinogen alpha chain  FIBA_HUMAN 
54525 1680.752 30.02747 
GLpGTGGPpGENG
KpGEp Collagen alpha-1 (III) chain CO3A1_HUMAN 
54687 1684.666 31.75269       
54688 1684.671 30.65638       
54846 1687.536 37.78593       
54976 1689.742 40.60201       
55756 1700.721 29.93699 
GmpGSpGGpGSDG
KpGPpG Collagen alpha-1 (III) chain CO3A1_HUMAN 
56011 1705.731 40.43673       
56325 1712.771 30.99943       
58222 1752.783 19.61447       
59056 1767.781 19.81004       
59100 1768.826 20.77489       
59430 1776.855 21.4446       
60975 1812.786 24.13738       
61039 1813.715 31.69499       
61048 1813.778 40.65807       
61221 1817.694 20.23435       
61573 1825.786 20.13497 
DEAGSEADHEGTH
STKR Fibrinogen alpha chain  FIBA_HUMAN 
61753 1829.752 40.83957       
61899 1833.844 27.08198       
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62044 1836.791 31.14372       
62226 1840.836 41.17953       
63391 1864.807 20.42988       
64170 1880.895 43.9095       
64431 1885.651 38.81996       
65368 1901.823 43.82548       
66161 1916.768 20.32244       
66240 1917.938 31.77883       
66656 1927.914 19.51821 
DkGETGEQGDRGIk
GHRG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
67951 1950.851 35.76881       
69769 1991.941 22.04607       
69979 1996.786 20.9757       
70361 2006.857 33.43506       
70413 2007.945 22.10222 
DGESGRpGRpGER
GLpGPpG Collagen alpha-1 (III) chain CO3A1_HUMAN 
70485 2009.879 32.29178       
70999 2021.903 33.23276       
73177 2062.933 26.57903 
DAGApGAPGGKGD
AGApGERGPpG Collagen alpha-1 (III) chain CO3A1_HUMAN 
73246 2063.932 21.94861 
NGDDGEAGKpGRp
GERGPpGP Collagen alpha-1 (I) chain  CO1A1_HUMAN 
73434 2067.818 20.62077       
73628 2070.022 19.3539       
75410 2100.013 19.48241 
PpGKAGEDGHpGK
PGRpGERG Collagen alpha-2 (I) chain CO1A2_HUMAN 
76423 2117.96 27.7093 
DGQPGAKGEPGDA
GAKGDAGPPGp Collagen alpha-1 (I) chain CO1A1_HUMAN 
77679 2148.015 25.28724 
QGLpGTGGPpGEN
GKpGEPGpKG Collagen alpha-1 (III) chain CO3A1_HUMAN 
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79737 2187.987 27.17073       
79786 2188.999 26.88501 
ADGQPGAKGEPGD
AGAKGDAGPpGP Collagen alpha-1 (I) chain CO1A1_HUMAN 
81196 2210.954 33.60553 
NGApGNDGAKGDA
GApGApGSQGApG Collagen alpha-1 (I) chain CO1A1_HUMAN 
81457 2216.03 33.83058 
IGPpGPAGApGDKG
ESGPSGPAGPTG Collagen alpha-1 (I) chain CO1A1_HUMAN 
81607 2219.007 19.65068 
DEAGSEADHEGTH
STKRGHAK Fibrinogen alpha chain   FIBA_HUMAN 
82026 2226.992 26.27752 
GNSGEpGApGSKG
DTGAKGEpGPVG Collagen alpha-1 (I) chain CO1A1_HUMAN 
83107 2244.066 19.49733       
83441 2248.968 33.69466       
84126 2256.973 33.5541       
84164 2257.869 35.92739       
84363 2261.995 27.12127 
GADGQpGAKGEPG
DAGAKGDAGPpGP Collagen alpha-1 (I) chain  CO1A1_HUMAN 
85020 2276.023 27.23118 
ADGQPGAKGEpGD
AGAKGDAGPpGPA Collagen alpha-1 (I) chain CO1A1_HUMAN 
85503 2286.115 19.41889       
85761 2292.019 27.28272 
ADGQpGAKGEpGD
AGAKGDAGPpGPA Collagen alpha-1 (I) chain CO1A1_HUMAN 
85896 2294.983 33.51783       
86426 2306.034 19.53317 
DEAGSEADHEGTH
STKRGHAKS Fibrinogen alpha chain FIBA_HUMAN 
86677 2308.017 27.33705 
ADGQpGAKGEpGD
AGAKGDAGppGPA Collagen alpha-1 (I) chain  CO1A1_HUMAN 
86951 2314.012 33.65553       
240 
87012 2315.102 19.41716       
87341 2319.995 34.29261       
87619 2325.995 33.76476       
88052 2334.985 33.6041       
88282 2339 34.00721       
88622 2343.131 19.45944       
90651 2385.054 33.94877       
91542 2407.092 27.67152 
LDGAKGDAGPAGP
KGEpGSpGENGAp
G Collagen alpha-1 (I) chain CO1A1_HUMAN 
91855 2414.154 19.57439       
92350 2423.02 34.02705       
92841 2430.098 28.32809 
ADGQPGAKGEpGD
AGAKGDAGPpGPA
GP Collagen alpha-1 (I) chain  CO1A1_HUMAN 
93227 2442.074 34.09673       
93361 2445.098 28.23779 
mASDASHALEAALE
QMDGIIAGTK Liprin-beta-2; N-term.   LIPB2_HUMAN 
93417 2446.092 28.37261 
ADGQpGAKGEpGD
AGAKGDAGpPGPA
GP  Collagen alpha-1 (I) chain  CO1A1_HUMAN 
94308 2471.155 34.77354 
TGPIGPpGPAGApG
DKGESGPSGPAGP
TG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
94674 2480.06 34.12281       
94807 2483.121 27.56515 
AGQDGRpGPpGpp
GARGQAGVmGFpG Collagen alpha-1 (I) chain CO1A1_HUMAN 
94948 2487.125 28.27413 
GADGQPGAKGEpG
DAGAKGDAGPpGP
AGP Collagen alpha-1 (I) chain CO1A1_HUMAN 
97257 2539.1 34.45086       
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97463 2544.128 28.25992       
97506 2545.12 28.20161 
GPpGADGQpGAKG
EpGDAGAKGDAGp
PGP Collagen alpha-1 (I) chain  CO1A1_HUMAN 
97653 2548.286 35.15708       
97736 2551.152 34.71513       
98089 2559.18 19.40742 
DEAGSEADHEGTH
STKRGHAKSRP Fibrinogen alpha chain   FIBA_HUMAN 
98596 2563.147 21.21006       
98660 2564.15 22.97496 
GApGQNGEpGGKG
ERGApGEKGEGGP
pG Collagen alpha-1 (III) chain CO3A1_HUMAN 
99021 2570.19 42.56018       
100255 2596.233 34.89552       
100767 2608.127 42.23556       
102725 2642.214 27.69602 
QGpPGPSGEEGKR
GPNGEAGSAGPPG
ppG Collagen alpha-2 (I) chain  CO1A2_HUMAN 
102924 2647.199 23.46703 
NRGERGSEGSPGH
PGQPGPpGPpGAp
GP Collagen alpha-1 (III) chain CO3A1_HUMAN 
103080 2650.173 34.95789       
104307 2666.176 35.03149       
104376 2668.25 41.97426       
104786 2679.197 23.52889 
NRGERGSEGSPGH
pGQpGppGpPGAP
GP Collagen alpha-1 (III) chain CO3A1_HUMAN 
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104954 2682.143 22.49183       
105352 2695.198 23.52252 
NRGERGSEGSpGH
pGQpGppGPPGAP
Gp Collagen alpha-1 (III) chain CO3A1_HUMAN 
105744 2705.16 35.12898       
106667 2726.283 42.93932       
108119 2756.268 35.24034       
108327 2761.315 21.49226 
ERGSPGpAGPKGS
pGEAGRpGEAGLp
GAKG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
108574 2764.214 42.62656       
109164 2777.316 21.5225 
ERGSpGPAGpKGS
pGEAGRpGEAGLp
GAKG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
110052 2799.085 25.06936       
110468 2811.256 23.84819       
110680 2817.256 35.10447       
112106 2854.363 34.86364       
114230 2912.168 25.55697       
114795 2925.314 35.67595       
115312 2939.149 33.76711       
117658 2999.447 36.05018       
118163 3011.387 29.74951 
LTGSpGSpGpDGKT
GPPGPAGQDGRP
GPpGppG Collagen alpha-1 (I) chain  CO1A1_HUMAN 
118224 3013.292 22.2946 
ESGREGApGAEGS
pGRDGSpGAKGDR
GETGPA Collagen alpha-1 (I) chain  CO1A1_HUMAN 
118694 3023.356 24.55931       
243 
119292 3035.191 42.02093       
119385 3037.409 36.00759       
119538 3041.375 29.98314       
120367 3063.444 30.09824 
RTGEVGAVGpPGF
AGEKGPSGEAGTA
GpPGTpGP Collagen alpha-2 (I) chain  CO1A2_HUMAN 
120693 3069.376 36.00438       
121337 3079.413 30.07032 
RTGEVGAVGpPGF
AGEkGPSGEAGTA
GpPGTpGP Collagen alpha-2 (I) chain CO1A2_HUMAN 
121772 3092.439 36.29566 
TGEVGAVGPpGFA
GEKGPSGEAGTAG
PpGTpGPQG Collagen alpha-2 (I) chain CO1A2_HUMAN 
121775 3092.464 31.24934 
ADGQPGAkGEPGD
AGAKGDAGPPGPA
GpAGpPGPIG  Collagen alpha-1 (I) chain   CO1A1_HUMAN 
121940 3098.436 30.05541 
LTGNpGVQGPEGK
LGPLGApGEDGRp
GpPGSIG Collagen alpha-2 (V) chain CO5A2_HUMAN 
121989 3100.42 29.96433       
122520 3112.365 22.62618       
123565 3145.459 38.89295       
123643 3148.458 31.26646       
123671 3149.46 31.24549 GADGQPGAKGEpG Collagen alpha-1 (I) chain CO1A1_HUMAN 
244 
DAGAKGDAGPpGP
AGpAGPPGPIG 
123969 3158.439 29.71371 
GERGSpGGpGAAG
FpGARGLpGpPGSN
GNPGPpGp Collagen alpha-1 (III) chain CO3A1_HUMAN 
124172 3165.462 31.32057       
124268 3168.357 24.70453 
GEpGRDGVpGGpG
MRGmpGSpGGpGS
DGKpGPpG Collagen alpha-1 (III) chain CO3A1_HUMAN 
124688 3185.465 25.4677       
125529 3215.396 19.99446       
126699 3248.529 30.66041 
RTGEVGAVGpPGF
AGEKGPSGEAGTA
GPPGTpGpQG Collagen alpha-2 (I) chain  CO1A2_HUMAN 
127351 3264.556 25.75167 
AAGEPGkAGERGV
pGPpGAVGPAGKD
GEAGAQGPPGP Collagen alpha-1 (I) chain CO1A1_HUMAN 
127402 3265.431 36.08731       
127852 3280.556 25.81551       
127899 3281.434 36.0914       
128086 3286.555 30.92069       
128140 3287.479 30.97061       
128689 3303.412 36.0889       
128908 3310.493 36.57161       
129019 3314.431 20.14047       
129131 3318.546 30.99198       
129150 3319.382 36.08194       
130482 3350.549 31.01736       
245 
130504 3351.545 36.38531       
130747 3359.578 31.89787       
131294 3375.574 31.91691       
131589 3385.547 25.48872       
131879 3397.56 31.84766       
132057 3401.66 23.49281       
132411 3406.568 31.24378       
132504 3409.617 31.93033 
NTGApGSPGVSGP
KGDAGQPGEkGSp
GAQGPPGAPGPLG Collagen alpha-1 (III) chain CO3A1_HUMAN 
132834 3421.555 25.99412       
132950 3425.605 31.27027 
ASHTSDSDVPSGV
TEVVVKLFDSDPIT
VTVPVE Clusterin CLUS_HUMAN 
133430 3441.609 31.38498 
NTGAPGSpGVSGp
KGDAGQpGEKGSp
GAQGpPGAPGPLG Collagen alpha-1 (III) chain CO3A1_HUMAN 
134470 3473.596 31.47644 
NTGApGSpGVSGp
KGDAGQpGEKGSp
GAQGpPGAPGpLG Collagen alpha-1 (III) chain CO3A1_HUMAN 
135047 3495.56 31.9667       
141672 3718.721 32.4816       
142080 3734.721 32.49717       
143372 3775.616 37.25807       
144635 3831.81 28.48446       
145456 3870.814 33.49116       
145889 3891.752 24.52856       
146624 3927.821 33.59714       
246 
146936 3943.83 33.62845       
148557 4002.618 20.65664       
148640 4005.81 33.05918       
149717 4043.806 33.12202       
156445 4305.937 28.82961 
ARGNDGARGSDG
QpGpPGPpGTAGFp
GSpGAKGEVGpAG
SpGSNGApG Collagen alpha-1 (III) chain CO3A1_HUMAN 
162922 4549.146 26.55078       
179138 6688.901 20.81745       
190524 14109.54 21.93083       
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